Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,7815675,absorption,"For the patient group as a whole, 26Mg absorption was low but was not different for the two supplements (23.5% vs 22.8% for magnesium chelate and MgO, respectively).",Bioavailability of magnesium diglycinate vs magnesium oxide in patients with ileal resection. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7815675/),%,23.5,1072,DB00145,Glycine
,7815675,absorption,"For the patient group as a whole, 26Mg absorption was low but was not different for the two supplements (23.5% vs 22.8% for magnesium chelate and MgO, respectively).",Bioavailability of magnesium diglycinate vs magnesium oxide in patients with ileal resection. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7815675/),%,22.8,1073,DB00145,Glycine
,29976060,bioavailability,Pharmacokinetic studies in rats showed an increase in the bioavailability of peptide 12 > 70-fold (from 0.58 ± 0.11% to 43.8 ± 14.9%) after applying the LPCM method to peptide 12 and converting it to the prodrug 12P.,Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29976060/),%,0.58,1759,DB00145,Glycine
,29976060,bioavailability,Pharmacokinetic studies in rats showed an increase in the bioavailability of peptide 12 > 70-fold (from 0.58 ± 0.11% to 43.8 ± 14.9%) after applying the LPCM method to peptide 12 and converting it to the prodrug 12P.,Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29976060/),%,43.8,1760,DB00145,Glycine
,17993748,distribution (t(1/2alpha)),"After i.v. administration of NFLXGA, the distribution (t(1/2alpha)) and elimination half-life (t(1/2beta)) were 0.36 +/- 0.07 h and 7.42 +/- 3.55 h, respectively.",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and oral administration in pigs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993748/),h,0.36,3063,DB00145,Glycine
,17993748,elimination half-life (t(1/2beta)),"After i.v. administration of NFLXGA, the distribution (t(1/2alpha)) and elimination half-life (t(1/2beta)) were 0.36 +/- 0.07 h and 7.42 +/- 3.55 h, respectively.",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and oral administration in pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993748/),h,7.42,3064,DB00145,Glycine
,17993748,volume of distribution of NFLXGA at steady state (Vd(ss)),The volume of distribution of NFLXGA at steady state (Vd(ss)) was 4.66 +/- 1.39 l/kg.,Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and oral administration in pigs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993748/),[l] / [kg],4.66,3065,DB00145,Glycine
,17993748,maximal absorption concentration (C(max)),"After p.o. administration of NFLXGA, the maximal absorption concentration (C(max)) was 0.43 +/- 0.06 microg/ ml at 1.36 +/- 0.39 h (T(max)).",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and oral administration in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993748/),[μg] / [ml],0.43,3066,DB00145,Glycine
,17993748,T(max),"After p.o. administration of NFLXGA, the maximal absorption concentration (C(max)) was 0.43 +/- 0.06 microg/ ml at 1.36 +/- 0.39 h (T(max)).",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and oral administration in pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993748/),,1,3067,DB00145,Glycine
,17993748,absorption (t(1/2ka)),"The mean absorption (t(1/2ka)) and elimination half-life (t(1/2beta)) of NFLXGA were 0.78 +/- 0.27 h and 7.13 +/- 1.41 h, respectively.",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and oral administration in pigs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993748/),h,0.78,3068,DB00145,Glycine
,17993748,elimination half-life (t(1/2beta)),"The mean absorption (t(1/2ka)) and elimination half-life (t(1/2beta)) of NFLXGA were 0.78 +/- 0.27 h and 7.13 +/- 1.41 h, respectively.",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and oral administration in pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993748/),h,7.13,3069,DB00145,Glycine
,17993748,systemic bioavailability (F),The mean systemic bioavailability (F) after p.o. administration was 31.10 +/- 15.16%.,Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and oral administration in pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993748/),%,31.10,3070,DB00145,Glycine
,9044241,recovery,"The recovery of ASA, SA and SUA was between 90-105%.","A highly sensitive HPLC method for the simultaneous determination of acetylsalicylic, salicylic and salicyluric acids in biologic fluids: pharmacokinetic, metabolic and monitoring implications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9044241/),%,90-105,5501,DB00145,Glycine
,3705620,excretion,"The excretion of salicylic acid was found to be highly variable within the study panel (1.3-31% of dose in 12 h), and was related to both urine volume and pH.",The metabolism of aspirin in man: a population study. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705620/),%,1.3-31,6997,DB00145,Glycine
,3705620,excretion,"The excretion of the two salicyl glucuronides was highly variable, ranging from 0.8 to 42% of the dose.",The metabolism of aspirin in man: a population study. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705620/),%,0.8 to 42,6998,DB00145,Glycine
,10972478,specific activity,"In an in vivo study female Sprague Dawley rats were pretreated with 100 mg/kg of dexrazoxane by intravenous injection 1 h before the injection of 14C-doxorubicin (specific activity 0.4 microCi/mg, 10 mg/kg).",Interaction of dexrazoxane with red blood cells and hemoglobin alters pharmacokinetics of doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972478/),[μci] / [mg],0.4,8782,DB00145,Glycine
,8405034,long terminal half-life,"Cmax was reached after 3-6 h, and after a shorter beta-phase a long terminal half-life of 53 h of total tiopronin was found.",Pharmacokinetics of oral tiopronin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405034/),h,53,8998,DB00145,Glycine
,8405034,t1/2,"Tiopronin measured as unbound (non-protein-bound) drug disappeared more rapidly from plasma, with a calculated t1/2 of 1.8 h.",Pharmacokinetics of oral tiopronin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405034/),h,1.8,8999,DB00145,Glycine
,8405034,Mean residence time,"Mean residence time was higher (58 h) when calculated as total tiopronin than as unbound tiopronin (6 h), and this was also the case for the volume of distribution (V lambda = 455 l vs V lambda,u = 41 l).",Pharmacokinetics of oral tiopronin. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405034/),h,58,9000,DB00145,Glycine
,8405034,Mean residence time,"Mean residence time was higher (58 h) when calculated as total tiopronin than as unbound tiopronin (6 h), and this was also the case for the volume of distribution (V lambda = 455 l vs V lambda,u = 41 l).",Pharmacokinetics of oral tiopronin. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405034/),h,6,9001,DB00145,Glycine
,8405034,volume of distribution (V lambda,"Mean residence time was higher (58 h) when calculated as total tiopronin than as unbound tiopronin (6 h), and this was also the case for the volume of distribution (V lambda = 455 l vs V lambda,u = 41 l).",Pharmacokinetics of oral tiopronin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405034/),l,455,9002,DB00145,Glycine
,8405034,"V lambda,u","Mean residence time was higher (58 h) when calculated as total tiopronin than as unbound tiopronin (6 h), and this was also the case for the volume of distribution (V lambda = 455 l vs V lambda,u = 41 l).",Pharmacokinetics of oral tiopronin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405034/),l,41,9003,DB00145,Glycine
,8405034,Absolute bioavailability (f),"Absolute bioavailability (f) was 63%, and bioavailability calculated from urinary excretion was 47%, which are well correlated with each other.",Pharmacokinetics of oral tiopronin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405034/),%,63,9004,DB00145,Glycine
,8405034,bioavailability,"Absolute bioavailability (f) was 63%, and bioavailability calculated from urinary excretion was 47%, which are well correlated with each other.",Pharmacokinetics of oral tiopronin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405034/),%,47,9005,DB00145,Glycine
,12743672,bioavailability,"The mean (+/- standard deviation) bioavailability of melagatran was 22.2+/-4.3% and 17.4+/-2.8% after single and repeated dosings, respectively.","Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12743672/),%,22.2,9413,DB00145,Glycine
,12743672,bioavailability,"The mean (+/- standard deviation) bioavailability of melagatran was 22.2+/-4.3% and 17.4+/-2.8% after single and repeated dosings, respectively.","Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12743672/),%,17.4,9414,DB00145,Glycine
,16026008,t(1/2),"The lipophilic camptothecin prodrug, camptothecin-(O20)-succinimidoglycinate, was released from the conjugate with t(1/2) = 2.2 +/- 0.1 h in rodent plasma.",Synthesis of a macromolecular camptothecin conjugate with dual phase drug release. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026008/),h,2.2,10974,DB00145,Glycine
,16026008,t(1/2),"The blood clearance in a rodent model as measured by CPT was release limited, t(1/2) = 2.1 +/- 0.2 h, while the conjugate half-life was 14.2 +/- 1.7 h.",Synthesis of a macromolecular camptothecin conjugate with dual phase drug release. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026008/),h,2.1,10975,DB00145,Glycine
,16026008,half-life,"The blood clearance in a rodent model as measured by CPT was release limited, t(1/2) = 2.1 +/- 0.2 h, while the conjugate half-life was 14.2 +/- 1.7 h.",Synthesis of a macromolecular camptothecin conjugate with dual phase drug release. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026008/),h,14.2,10976,DB00145,Glycine
,19439489,IC(50),"IC(50) values of YM-252124 for 1-methyl-4-phenylpyridinium uptake via hOCT2 and rOct2 were 93.9 and 1700 microM, respectively, suggesting that this metabolite is secreted into urine via hOCT2/rOct2 and that the large difference in the inhibitory potentials between hOCT2 and rOct2 explains the species difference in the urinary excretion ratio of the radioactivity.","Identification of human metabolites of (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a novel If channel inhibitor, and investigation of the transporter-mediated renal and hepatic excretion of these metabolites. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19439489/),μM,93.9,11157,DB00145,Glycine
,19439489,IC(50),"IC(50) values of YM-252124 for 1-methyl-4-phenylpyridinium uptake via hOCT2 and rOct2 were 93.9 and 1700 microM, respectively, suggesting that this metabolite is secreted into urine via hOCT2/rOct2 and that the large difference in the inhibitory potentials between hOCT2 and rOct2 explains the species difference in the urinary excretion ratio of the radioactivity.","Identification of human metabolites of (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a novel If channel inhibitor, and investigation of the transporter-mediated renal and hepatic excretion of these metabolites. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19439489/),μM,1700,11158,DB00145,Glycine
,933069,urine volume,"The urine volume was thus in the normal range, 0-1-0-3ml./min.",The effect of a meal of meat on glomerular filtration rate in dogs at normal urine flows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/933069/),[ml] / [min],0-1-0-3,12056,DB00145,Glycine
,933069,clearance,"2. Under these conditions, the exogenous creatine clearance of fourteen dogs, measured 17 hr after a meal, was 2-74 ml./min kg-1+/-0-54 (s.d.).",The effect of a meal of meat on glomerular filtration rate in dogs at normal urine flows. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/933069/),[ml] / [kg·min],2-74,12057,DB00145,Glycine
,6437805,biological half-time,The biological half-time was 9.9 +/- 1.5 hr for the ethoxy-labeled compound and 12.5 +/- 1.9 hr for the ethanol label.,Metabolism and excretion of 2-ethoxyethanol in the adult male rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437805/),h,9.9,13015,DB00145,Glycine
,6437805,biological half-time,The biological half-time was 9.9 +/- 1.5 hr for the ethoxy-labeled compound and 12.5 +/- 1.9 hr for the ethanol label.,Metabolism and excretion of 2-ethoxyethanol in the adult male rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437805/),h,12.5,13016,DB00145,Glycine
,8760119,Extra,"Extraction of glycine-extended gastrin-17 was measured in the kidney (36%), hindlimb (31%, P < 0.001), head (26%), and the gut (16%, P < 0.01), but not in the liver or the lungs.",Pharmacokinetics and organ metabolism of carboxyamidated and glycine-extended gastrins in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760119/),,31,15522,DB00145,Glycine
,8760119,half-life,"The half-life, metabolic clearance rate, and apparent volume of distribution for amidated gastrin-17 were 3.5 +/- 0.4 min, 15.5 +/- 1.1 ml.kg-1.min-1, and 76.5 +/- 9.9 ml/kg, respectively, and for glycine-extended gastrin-17 were 4.3 +/- 0.6 min, 17.4 +/- 0.9 ml.kg-1.min-1, and 104.7 +/- 11.9 ml/kg, respectively.",Pharmacokinetics and organ metabolism of carboxyamidated and glycine-extended gastrins in pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760119/),min,3.5,15523,DB00145,Glycine
,8760119,metabolic clearance rate,"The half-life, metabolic clearance rate, and apparent volume of distribution for amidated gastrin-17 were 3.5 +/- 0.4 min, 15.5 +/- 1.1 ml.kg-1.min-1, and 76.5 +/- 9.9 ml/kg, respectively, and for glycine-extended gastrin-17 were 4.3 +/- 0.6 min, 17.4 +/- 0.9 ml.kg-1.min-1, and 104.7 +/- 11.9 ml/kg, respectively.",Pharmacokinetics and organ metabolism of carboxyamidated and glycine-extended gastrins in pigs. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760119/),[ml] / [kg·min],15.5,15524,DB00145,Glycine
,8760119,metabolic clearance rate,"The half-life, metabolic clearance rate, and apparent volume of distribution for amidated gastrin-17 were 3.5 +/- 0.4 min, 15.5 +/- 1.1 ml.kg-1.min-1, and 76.5 +/- 9.9 ml/kg, respectively, and for glycine-extended gastrin-17 were 4.3 +/- 0.6 min, 17.4 +/- 0.9 ml.kg-1.min-1, and 104.7 +/- 11.9 ml/kg, respectively.",Pharmacokinetics and organ metabolism of carboxyamidated and glycine-extended gastrins in pigs. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760119/),min,4.3,15525,DB00145,Glycine
,8760119,apparent volume of distribution,"The half-life, metabolic clearance rate, and apparent volume of distribution for amidated gastrin-17 were 3.5 +/- 0.4 min, 15.5 +/- 1.1 ml.kg-1.min-1, and 76.5 +/- 9.9 ml/kg, respectively, and for glycine-extended gastrin-17 were 4.3 +/- 0.6 min, 17.4 +/- 0.9 ml.kg-1.min-1, and 104.7 +/- 11.9 ml/kg, respectively.",Pharmacokinetics and organ metabolism of carboxyamidated and glycine-extended gastrins in pigs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760119/),[ml] / [kg],76.5,15526,DB00145,Glycine
,8760119,apparent volume of distribution,"The half-life, metabolic clearance rate, and apparent volume of distribution for amidated gastrin-17 were 3.5 +/- 0.4 min, 15.5 +/- 1.1 ml.kg-1.min-1, and 76.5 +/- 9.9 ml/kg, respectively, and for glycine-extended gastrin-17 were 4.3 +/- 0.6 min, 17.4 +/- 0.9 ml.kg-1.min-1, and 104.7 +/- 11.9 ml/kg, respectively.",Pharmacokinetics and organ metabolism of carboxyamidated and glycine-extended gastrins in pigs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760119/),[ml] / [kg],104.7,15527,DB00145,Glycine
,12955372,t1/2,"The geometric means of the t1/2 for melagatran were 4.0 h and 4.2 h for the first and last doses, respectively, in patients, and 3.5 h and 3.7 h, respectively, in controls.",Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955372/),h,4.0,16525,DB00145,Glycine
,12955372,t1/2,"The geometric means of the t1/2 for melagatran were 4.0 h and 4.2 h for the first and last doses, respectively, in patients, and 3.5 h and 3.7 h, respectively, in controls.",Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955372/),h,4.2,16526,DB00145,Glycine
,12955372,t1/2,"The geometric means of the t1/2 for melagatran were 4.0 h and 4.2 h for the first and last doses, respectively, in patients, and 3.5 h and 3.7 h, respectively, in controls.",Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955372/),h,3.5,16527,DB00145,Glycine
,12955372,t1/2,"The geometric means of the t1/2 for melagatran were 4.0 h and 4.2 h for the first and last doses, respectively, in patients, and 3.5 h and 3.7 h, respectively, in controls.",Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955372/),h,3.7,16528,DB00145,Glycine
,12955372,F,"Geometric means of F of melagatran following oral administration of ximelagatran were 22% and 24% for the first and last doses, respectively, in patients and 21% and 23%, respectively, in controls.",Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955372/),%,22,16529,DB00145,Glycine
,12955372,F,"Geometric means of F of melagatran following oral administration of ximelagatran were 22% and 24% for the first and last doses, respectively, in patients and 21% and 23%, respectively, in controls.",Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955372/),%,24,16530,DB00145,Glycine
,12955372,F,"Geometric means of F of melagatran following oral administration of ximelagatran were 22% and 24% for the first and last doses, respectively, in patients and 21% and 23%, respectively, in controls.",Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955372/),%,21,16531,DB00145,Glycine
,12955372,F,"Geometric means of F of melagatran following oral administration of ximelagatran were 22% and 24% for the first and last doses, respectively, in patients and 21% and 23%, respectively, in controls.",Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955372/),%,23,16532,DB00145,Glycine
,27230928,C,"Five cohorts (C1-C5) of 3 patients received variable molar doses of TF2 and approximately 150 MBq of 68Ga-IMP288 after different pretargeting time intervals (C1: 120 nmol TF2, 6 nmol IMP288, 24 h; C2: 120 nmol TF2, 6 nmol IMP288, 30 h; C3: 120 nmol TF2, 6 nmol IMP288, 42 h; C4: 120 nmol TF2, 3 nmol IMP288, 30 h; and C5: 60 nmol TF2, 3 nmol IMP288, 30 h).",Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27230928/),h,30,17774,DB00145,Glycine
,27230928,T/MBP,"In C1, T-SUVmax and T/MBP ranged from 4.09 to 8.93 and 1.39 to 3.72 at 60 min and 5.14 to 11.25 and 2.73 to 5.38 at 120 min, respectively.",Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27230928/),,1.39 to 3.72,17775,DB00145,Glycine
,27230928,mole ratio,"In C4, the TF2-to-peptide mole ratio was increased to 40 (delay 30 h), resulting in high T-SUVmax but with higher MBP than in C2.",Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27230928/),,40,17776,DB00145,Glycine
greater,15328250,oral bioavailability,"In all species examined, cinacalcet was well absorbed, with greater than 74% oral bioavailability of cinacalcet-derived radioactivity in monkeys and humans.",Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15328250/),%,74,20502,DB00145,Glycine
,18819478,flow-rate,"The analytes were separated on a Kromasil C18 column (250 mm x 4.6 mm, 5 microm) using 0.2% glacial acetic acid aqueous solution including 0.015 mol x L(-1) KH2PO4 and acetonitrile (56:44) as a mobile phase at a flow-rate of 0.8 mL x min(-1), and fluorescence detection wavelength were set at lamda(e x) = 340 nm and lamda(e m) = 375 nm, the column temperature was 30 degrees C.",[Determination of tiopronin in rat plasma by HPLC following fluorescent derivatization]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18819478/),[ml] / [min],0.8,21241,DB00145,Glycine
,18819478,percentage of absolute recovery,The percentage of absolute recovery ranged from 73.7% to 79.7%.,[Determination of tiopronin in rat plasma by HPLC following fluorescent derivatization]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18819478/),%,73.7,21242,DB00145,Glycine
,18819478,percentage of absolute recovery,The percentage of absolute recovery ranged from 73.7% to 79.7%.,[Determination of tiopronin in rat plasma by HPLC following fluorescent derivatization]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18819478/),%,79.7,21243,DB00145,Glycine
,7945530,elimination half-life,"After the fourth injection, the plasma radioactivity concentration reached a steady state and the elimination half-life was determined to be 11.2 days.","Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. Second communication: distribution and elimination of the new monoclonal antibody, regavirumab after repeated administration in rats, and placental transfer and milk-passage study after single administration to pregnant and lactating rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945530/),d,11.2,22763,DB00145,Glycine
,7945530,minimum steady state concentration (Css-min),The plasma concentration curve after repeated administration corresponded with that simulated by the pharmacokinetic parameters obtained previously and the minimum steady state concentration (Css-min) at 168 h after repeated administration was about 33 micrograms eq. of MCA C23/ml.,"Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. Second communication: distribution and elimination of the new monoclonal antibody, regavirumab after repeated administration in rats, and placental transfer and milk-passage study after single administration to pregnant and lactating rats. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945530/),eq·μg,33,22764,DB00145,Glycine
,7945530,ratio of milk to plasma radioactivity,"In lactating rats, some radioactivity was secreted into the milk and the ratio of milk to plasma radioactivity reached 0.28 after a single administration of 125I-TI-23.","Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. Second communication: distribution and elimination of the new monoclonal antibody, regavirumab after repeated administration in rats, and placental transfer and milk-passage study after single administration to pregnant and lactating rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945530/),,0.28,22765,DB00145,Glycine
,30822797,oral bioavailability,The oral bioavailability was 48%.,"Quantitation of Ivosidenib, A Novel Mutant IDH1 Inhibitoron Mice DBS: Application to a Pharmacokinetic Study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30822797/),%,48,22826,DB00145,Glycine
,1774814,t1/2,There was also a slow terminal third phase with a long half-life after both intravenous (t1/2 = 23 h) and oral (t1/2 = 22 h) administration.,Pharmacokinetics and bioavailability of 2-mercaptopropionylglycine administered intravenously and orally in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1774814/),h,23,22874,DB00145,Glycine
,1774814,t1/2,There was also a slow terminal third phase with a long half-life after both intravenous (t1/2 = 23 h) and oral (t1/2 = 22 h) administration.,Pharmacokinetics and bioavailability of 2-mercaptopropionylglycine administered intravenously and orally in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1774814/),h,22,22875,DB00145,Glycine
,1774814,Vss,A deep pool of reversibly tissue-bound 2-MPG was indicated by a Vss of 3.3 +/- 0.9 l/kg body weight and the long terminal elimination phase.,Pharmacokinetics and bioavailability of 2-mercaptopropionylglycine administered intravenously and orally in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1774814/),[l] / [body·kg·weight],3.3,22876,DB00145,Glycine
,1774814,Total clearance,Total clearance was estimated as 4.1 +/- 0.9 ml/min/kg body weight.,Pharmacokinetics and bioavailability of 2-mercaptopropionylglycine administered intravenously and orally in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1774814/),[ml] / [kg·min],4.1,22877,DB00145,Glycine
,1774814,absolute bioavailability (FAUC),The absolute bioavailability (FAUC) was 88 +/- 20% in normal dogs.,Pharmacokinetics and bioavailability of 2-mercaptopropionylglycine administered intravenously and orally in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1774814/),%,88,22878,DB00145,Glycine
,11228340,Oral bioavailability,"Oral bioavailability, measured as melagatran in plasma, is about 20% after oral administration of H 376/95, which is 2.7-5.5 times higher than after oral administration of melagatran.","The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11228340/),%,20,24799,DB00145,Glycine
,11228340,inhibition constant (K(i)) ratio,"Pharmacodynamic properties: H 376/95 is inactive towards human alpha-thrombin compared with melagatran [inhibition constant (K(i)) ratio, 185 times], a potential advantage for patients with silent gastrointestinal bleeding.","The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11228340/),times,185,24800,DB00145,Glycine
,10727128,LOQs,"The LOQs estimated for TP, 2-mpa and SA13 were 0.5, 0.5 and 2 ng/ml, respectively.",Simultaneous determination of tiopronin and its metabolites in rat blood by LC-ESI-MS-MS using methyl acrylate for stabilization of thiol group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10727128/),[ng] / [ml],0.5,24898,DB00145,Glycine
,10727128,LOQs,"The LOQs estimated for TP, 2-mpa and SA13 were 0.5, 0.5 and 2 ng/ml, respectively.",Simultaneous determination of tiopronin and its metabolites in rat blood by LC-ESI-MS-MS using methyl acrylate for stabilization of thiol group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10727128/),[ng] / [ml],2,24899,DB00145,Glycine
,1505618,tmax,The absorption of tiopronin was slow (tmax between 4 and 6 h) and the plasma concentrations subsequently fell biexponentially.,The pharmacokinetics of tiopronin and its principal metabolite (2-mercaptopropionic acid) after oral administration to healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505618/),h,4 and 6,26134,DB00145,Glycine
,1505618,tmax,The principal metabolite 2-MPA appeared later in the plasma (tmax between 10 and 12 h after a lag-time of 3 h) then disappeared monoexponentially.,The pharmacokinetics of tiopronin and its principal metabolite (2-mercaptopropionic acid) after oral administration to healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505618/),h,10 and 12,26135,DB00145,Glycine
,1505618,lag-time,The principal metabolite 2-MPA appeared later in the plasma (tmax between 10 and 12 h after a lag-time of 3 h) then disappeared monoexponentially.,The pharmacokinetics of tiopronin and its principal metabolite (2-mercaptopropionic acid) after oral administration to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505618/),h,3,26136,DB00145,Glycine
,2760849,biological half-life,"When cystathionine (100 mg/kg) was administered i.p. in rats, it was eliminated from rat serum with a biological half-life of 1.19 +/- 0.23 hr.",Hepatoprotective effects of cystathionine against acetaminophen-induced necrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760849/),h,1.19,26756,DB00145,Glycine
,2760849,half-life,"Subsequent to the decrease of serum cystathionine, the concentration of cyst(e)ine increased up to 14.5 +/- 1.2 mg/l, and then decreased with a half-life of 4.12 +/- 0.82 hr.",Hepatoprotective effects of cystathionine against acetaminophen-induced necrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760849/),h,4.12,26757,DB00145,Glycine
,2760849,half-life,"The concomitant administration of taurine (100 mg/kg) did not change the half-life of cystathionine (1.42 +/- 0.33 hr), but significantly increased the half-life of cyst(e)ine (19.1 +/- 0.56 hr).",Hepatoprotective effects of cystathionine against acetaminophen-induced necrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760849/),h,1.42,26758,DB00145,Glycine
,2760849,half-life,"The concomitant administration of taurine (100 mg/kg) did not change the half-life of cystathionine (1.42 +/- 0.33 hr), but significantly increased the half-life of cyst(e)ine (19.1 +/- 0.56 hr).",Hepatoprotective effects of cystathionine against acetaminophen-induced necrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760849/),h,19.1,26759,DB00145,Glycine
,3699064,plasma half-life,125I-CGT-Na was found to have a short plasma half-life of 1.6 +/- 0.4 min in rats and 3.1 +/- 0.7 min in dogs.,Iodinated cholylglycyltyrosine: a new agent for hepatobiliary imaging. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3699064/),min,1.6,27277,DB00145,Glycine
,3699064,plasma half-life,125I-CGT-Na was found to have a short plasma half-life of 1.6 +/- 0.4 min in rats and 3.1 +/- 0.7 min in dogs.,Iodinated cholylglycyltyrosine: a new agent for hepatobiliary imaging. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3699064/),min,3.1,27278,DB00145,Glycine
,3699064,biliary transit time (50% retention time),"Biliary clearance studies showed the cumulative biliary output of the tracer over 20 min in rats to be 95.7% of the total dose administered, with a mean biliary transit time (50% retention time) of 4.0 +/- 0.1 min, i.e. similar to the biliary kinetics of taurocholate.",Iodinated cholylglycyltyrosine: a new agent for hepatobiliary imaging. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3699064/),min,4.0,27279,DB00145,Glycine
,16762550,oral bioavailability,"These molecules also exhibit superior pharmacological and pharmacokinetic parameters, relative to all GlyT1 inhibitors of the spiropiperidine family, culminating in the identification of 16b with an oral bioavailability of approximately 60%.","4-Substituted-8-(1-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one as a novel class of highly selective GlyT1 inhibitors with superior pharmacological and pharmacokinetic parameters. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16762550/),%,60,29264,DB00145,Glycine
,28178632,bioaccessibility,"The bioaccessibility indexes of phenolic compounds in EETg were 48.65 and 69.28% in the presence and absence of enzymes, respectively.",Impact of bioaccessibility and bioavailability of phenolic compounds in biological systems upon the antioxidant activity of the ethanolic extract of Triplaris gardneriana seeds. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28178632/),%,48.65,30061,DB00145,Glycine
,28178632,bioaccessibility,"The bioaccessibility indexes of phenolic compounds in EETg were 48.65 and 69.28% in the presence and absence of enzymes, respectively.",Impact of bioaccessibility and bioavailability of phenolic compounds in biological systems upon the antioxidant activity of the ethanolic extract of Triplaris gardneriana seeds. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28178632/),%,69.28,30062,DB00145,Glycine
,28178632,bioaccessible,"Among the identified phenolics classes, flavonoids, represented by galloylated procyanidins type B, proved to be more bioaccessible, 81.48 and 96.29% in the post-intestinal phase with and without enzymes, respectively.",Impact of bioaccessibility and bioavailability of phenolic compounds in biological systems upon the antioxidant activity of the ethanolic extract of Triplaris gardneriana seeds. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28178632/),%,81.48,30063,DB00145,Glycine
,28178632,bioaccessible,"Among the identified phenolics classes, flavonoids, represented by galloylated procyanidins type B, proved to be more bioaccessible, 81.48 and 96.29% in the post-intestinal phase with and without enzymes, respectively.",Impact of bioaccessibility and bioavailability of phenolic compounds in biological systems upon the antioxidant activity of the ethanolic extract of Triplaris gardneriana seeds. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28178632/),%,96.29,30064,DB00145,Glycine
,8656642,plasma clearance,TP-9201 had a plasma clearance of 9.9 +/- 2 ml/min/kg and a volume of distribution that was larger than plasma volume.,"Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8656642/),[ml] / [kg·min],9.9,31019,DB00145,Glycine
,8656642,half life (t1/2),"After discontinuation of TP-9201, recovery of platelet aggregation had a half life (t1/2) of 2-3 h and was complete < or = 24 h.","Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8656642/),h,2-3,31020,DB00145,Glycine
,12534635,t(1/2),"We found rapid absorption (t(1/2),abs 00.28 h, s.d. 0.17) and distribution (t(1/2), lambda1 00.59 h, s.d. 0.22) of betaine.",Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534635/),h,00.28,31708,DB00145,Glycine
,12534635,t(1/2),"We found rapid absorption (t(1/2),abs 00.28 h, s.d. 0.17) and distribution (t(1/2), lambda1 00.59 h, s.d. 0.22) of betaine.",Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534635/),h,00.59,31709,DB00145,Glycine
,12534635,Cmax,A Cmax of 0.94 mmol l-1 (s.d. 0.19) was reached after tmax 00.90 h (s.d. 0.33).,Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534635/),[mM] / [l],0.94,31710,DB00145,Glycine
,12534635,tmax,A Cmax of 0.94 mmol l-1 (s.d. 0.19) was reached after tmax 00.90 h (s.d. 0.33).,Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534635/),h,00.90,31711,DB00145,Glycine
,12534635,"elimination half life t(1/2), z","The elimination half life t(1/2), z was 14.38 h (s.d. 7.17).",Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534635/),h,14.38,31712,DB00145,Glycine
,12534635,"t(1/2), lambda1","After repeated dosage, t(1/2), lambda1 (01.77 h, s.d. 0.75) and t(1/2), z (41.17 h, s.d. 13.50) increased significantly (95% CI 0.73, 01.64 h and 19.90, 33.70 h, respectively), whereas absorption remained unchanged.",Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534635/),h,01.77,31713,DB00145,Glycine
,12534635,"t(1/2), z","After repeated dosage, t(1/2), lambda1 (01.77 h, s.d. 0.75) and t(1/2), z (41.17 h, s.d. 13.50) increased significantly (95% CI 0.73, 01.64 h and 19.90, 33.70 h, respectively), whereas absorption remained unchanged.",Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534635/),h,41.17,31714,DB00145,Glycine
,26337806,T max,Ixazomib was rapidly absorbed with a median T max of 1.5 h on day 1 and 2.0 h on day 15 of cycle 1 and had a geometric mean terminal half-life of 6.1 days.,Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26337806/),h,1.5,33350,DB00145,Glycine
,26337806,T max,Ixazomib was rapidly absorbed with a median T max of 1.5 h on day 1 and 2.0 h on day 15 of cycle 1 and had a geometric mean terminal half-life of 6.1 days.,Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26337806/),h,2.0,33351,DB00145,Glycine
,26337806,terminal half-life,Ixazomib was rapidly absorbed with a median T max of 1.5 h on day 1 and 2.0 h on day 15 of cycle 1 and had a geometric mean terminal half-life of 6.1 days.,Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26337806/),d,6.1,33352,DB00145,Glycine
,14643509,absolute recovery,"The absolute recovery for UDCA, GDCA, TDCA and the internal standard was 87.3, 83.7, 79.5 and 95.8%, respectively.",High-performance liquid chromatographic mass spectrometric method for the determination of ursodeoxycholic acid and its glycine and taurine conjugates in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14643509/),%,87.3,35169,DB00145,Glycine
,14643509,absolute recovery,"The absolute recovery for UDCA, GDCA, TDCA and the internal standard was 87.3, 83.7, 79.5 and 95.8%, respectively.",High-performance liquid chromatographic mass spectrometric method for the determination of ursodeoxycholic acid and its glycine and taurine conjugates in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14643509/),%,83.7,35170,DB00145,Glycine
,14643509,absolute recovery,"The absolute recovery for UDCA, GDCA, TDCA and the internal standard was 87.3, 83.7, 79.5 and 95.8%, respectively.",High-performance liquid chromatographic mass spectrometric method for the determination of ursodeoxycholic acid and its glycine and taurine conjugates in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14643509/),%,79.5,35171,DB00145,Glycine
,14643509,absolute recovery,"The absolute recovery for UDCA, GDCA, TDCA and the internal standard was 87.3, 83.7, 79.5 and 95.8%, respectively.",High-performance liquid chromatographic mass spectrometric method for the determination of ursodeoxycholic acid and its glycine and taurine conjugates in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14643509/),%,95.8,35172,DB00145,Glycine
,8682153,basal plasma concentrations,The basal plasma concentrations of free GSH (3.3 +/- 1.3 vs.,Decreased release of glutathione into the systemic circulation of patients with HIV infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8682153/),,3.3,35805,DB00145,Glycine
,8682153,input,The input of GSH into the circulation (12.9 +/- 5.7 vs. 30.1 +/- 11.7 mumol min-1; P < 0.01) and the clearance of GSH (25 +/- 7 vs. 35 +/- 7 mL min-1 kg-1) were significantly lower in patients with HIV-infection.,Decreased release of glutathione into the systemic circulation of patients with HIV infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8682153/),[μM] / [min],12.9,35806,DB00145,Glycine
,8682153,input,The input of GSH into the circulation (12.9 +/- 5.7 vs. 30.1 +/- 11.7 mumol min-1; P < 0.01) and the clearance of GSH (25 +/- 7 vs. 35 +/- 7 mL min-1 kg-1) were significantly lower in patients with HIV-infection.,Decreased release of glutathione into the systemic circulation of patients with HIV infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8682153/),[μM] / [min],30.1,35807,DB00145,Glycine
,8682153,clearance,The input of GSH into the circulation (12.9 +/- 5.7 vs. 30.1 +/- 11.7 mumol min-1; P < 0.01) and the clearance of GSH (25 +/- 7 vs. 35 +/- 7 mL min-1 kg-1) were significantly lower in patients with HIV-infection.,Decreased release of glutathione into the systemic circulation of patients with HIV infection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8682153/),[ml] / [kg·min],25,35808,DB00145,Glycine
,8682153,clearance,The input of GSH into the circulation (12.9 +/- 5.7 vs. 30.1 +/- 11.7 mumol min-1; P < 0.01) and the clearance of GSH (25 +/- 7 vs. 35 +/- 7 mL min-1 kg-1) were significantly lower in patients with HIV-infection.,Decreased release of glutathione into the systemic circulation of patients with HIV infection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8682153/),[ml] / [kg·min],35,35809,DB00145,Glycine
,8916010,elimination half-life (T1/2),"It was shown that the elimination half-life (T1/2) of norfloxacin at 20 degrees C (10 ppm: 13.95 +/- 1.18 hr, 100 ppm: 11.71 +/- 1.32 hr) was significantly shorter than that at 12 degrees C (10 ppm: 16.61 +/- 1.47 hr, 100 ppm: 16.32 +/- 1.19 hr) in flounders.","Comparative pharmacokinetics and tissue distribution of norfloxacin-glycine acetate in flounder, (Paralichthys olivaceus) at two different temperatures. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916010/),h,13.95,36377,DB00145,Glycine
,8916010,elimination half-life (T1/2),"It was shown that the elimination half-life (T1/2) of norfloxacin at 20 degrees C (10 ppm: 13.95 +/- 1.18 hr, 100 ppm: 11.71 +/- 1.32 hr) was significantly shorter than that at 12 degrees C (10 ppm: 16.61 +/- 1.47 hr, 100 ppm: 16.32 +/- 1.19 hr) in flounders.","Comparative pharmacokinetics and tissue distribution of norfloxacin-glycine acetate in flounder, (Paralichthys olivaceus) at two different temperatures. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916010/),h,11.71,36378,DB00145,Glycine
,8916010,elimination half-life (T1/2),"It was shown that the elimination half-life (T1/2) of norfloxacin at 20 degrees C (10 ppm: 13.95 +/- 1.18 hr, 100 ppm: 11.71 +/- 1.32 hr) was significantly shorter than that at 12 degrees C (10 ppm: 16.61 +/- 1.47 hr, 100 ppm: 16.32 +/- 1.19 hr) in flounders.","Comparative pharmacokinetics and tissue distribution of norfloxacin-glycine acetate in flounder, (Paralichthys olivaceus) at two different temperatures. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916010/),h,16.61,36379,DB00145,Glycine
,8916010,elimination half-life (T1/2),"It was shown that the elimination half-life (T1/2) of norfloxacin at 20 degrees C (10 ppm: 13.95 +/- 1.18 hr, 100 ppm: 11.71 +/- 1.32 hr) was significantly shorter than that at 12 degrees C (10 ppm: 16.61 +/- 1.47 hr, 100 ppm: 16.32 +/- 1.19 hr) in flounders.","Comparative pharmacokinetics and tissue distribution of norfloxacin-glycine acetate in flounder, (Paralichthys olivaceus) at two different temperatures. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916010/),h,16.32,36380,DB00145,Glycine
,8916010,Mean residence time (MRT),"Mean residence time (MRT) was calculated at 12 degrees C (10 ppm: 194.87 +/- 29.88 hr, 100 ppm: 1,222.37 +/- 161.45 hr) and 20 degrees C (10 ppm: 168.42 +/- 25.85, 100 ppm: 606.14 +/- 122.75 hr).","Comparative pharmacokinetics and tissue distribution of norfloxacin-glycine acetate in flounder, (Paralichthys olivaceus) at two different temperatures. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916010/),h,194.87,36381,DB00145,Glycine
,8916010,Mean residence time (MRT),"Mean residence time (MRT) was calculated at 12 degrees C (10 ppm: 194.87 +/- 29.88 hr, 100 ppm: 1,222.37 +/- 161.45 hr) and 20 degrees C (10 ppm: 168.42 +/- 25.85, 100 ppm: 606.14 +/- 122.75 hr).","Comparative pharmacokinetics and tissue distribution of norfloxacin-glycine acetate in flounder, (Paralichthys olivaceus) at two different temperatures. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916010/),h,"1,222.37",36382,DB00145,Glycine
,8916010,Mean residence time (MRT),"Mean residence time (MRT) was calculated at 12 degrees C (10 ppm: 194.87 +/- 29.88 hr, 100 ppm: 1,222.37 +/- 161.45 hr) and 20 degrees C (10 ppm: 168.42 +/- 25.85, 100 ppm: 606.14 +/- 122.75 hr).","Comparative pharmacokinetics and tissue distribution of norfloxacin-glycine acetate in flounder, (Paralichthys olivaceus) at two different temperatures. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916010/),h,168.42,36383,DB00145,Glycine
,8916010,Mean residence time (MRT),"Mean residence time (MRT) was calculated at 12 degrees C (10 ppm: 194.87 +/- 29.88 hr, 100 ppm: 1,222.37 +/- 161.45 hr) and 20 degrees C (10 ppm: 168.42 +/- 25.85, 100 ppm: 606.14 +/- 122.75 hr).","Comparative pharmacokinetics and tissue distribution of norfloxacin-glycine acetate in flounder, (Paralichthys olivaceus) at two different temperatures. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916010/),h,606.14,36384,DB00145,Glycine
,31629309,flow rate,"IFN, DZN, and EQL separation was achieved by using acetonitrile and acetic acid (0.1%) in the ratio of 90:10 (% v/v) as mobile phase under isocratic conditions at a flow rate of 0.6 mL/min on Atlantis C18 (4.6 × 250 mm, 5.0 μm) column.","LC-ESI-MS/MS method for the simultaneous determination of isoformononetin, daidzein, and equol in rat plasma: Application to a preclinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31629309/),[ml] / [min],0.6,39847,DB00145,Glycine
,31629309,oral bioavailability,The oral bioavailability of IFN was found to be poor (21.6%).,"LC-ESI-MS/MS method for the simultaneous determination of isoformononetin, daidzein, and equol in rat plasma: Application to a preclinical pharmacokinetic study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31629309/),%,21.6,39848,DB00145,Glycine
,31629309,clearance,IFN was found to have a moderate clearance (2.9 L/h/kg) and a large apparent volume of distribution (12.1 L/kg).,"LC-ESI-MS/MS method for the simultaneous determination of isoformononetin, daidzein, and equol in rat plasma: Application to a preclinical pharmacokinetic study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31629309/),[l] / [h·kg],2.9,39849,DB00145,Glycine
,31629309,apparent volume of distribution,IFN was found to have a moderate clearance (2.9 L/h/kg) and a large apparent volume of distribution (12.1 L/kg).,"LC-ESI-MS/MS method for the simultaneous determination of isoformononetin, daidzein, and equol in rat plasma: Application to a preclinical pharmacokinetic study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31629309/),[l] / [kg],12.1,39850,DB00145,Glycine
,31629309,plasma half-life (t1/2),The plasma half-life (t1/2) and maximum attainable concentration (Cmax) of IFN at systemic circulation was found to be 1.9 ± 0.6 h and 269.3 ± 0.4 after oral administration.,"LC-ESI-MS/MS method for the simultaneous determination of isoformononetin, daidzein, and equol in rat plasma: Application to a preclinical pharmacokinetic study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31629309/),h,1.9,39851,DB00145,Glycine
,31629309,maximum attainable concentration (Cmax),The plasma half-life (t1/2) and maximum attainable concentration (Cmax) of IFN at systemic circulation was found to be 1.9 ± 0.6 h and 269.3 ± 0.4 after oral administration.,"LC-ESI-MS/MS method for the simultaneous determination of isoformononetin, daidzein, and equol in rat plasma: Application to a preclinical pharmacokinetic study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31629309/),,269.3,39852,DB00145,Glycine
,9510985,mean residence time,"At doses of 0.1-5 mumol kg-1, the mean residence time was about 10 min in the rat, 35 min in the dog, and 20 min in the cynomolgus monkey.","Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9510985/),min,10,41957,DB00145,Glycine
,9510985,mean residence time,"At doses of 0.1-5 mumol kg-1, the mean residence time was about 10 min in the rat, 35 min in the dog, and 20 min in the cynomolgus monkey.","Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9510985/),min,35,41958,DB00145,Glycine
,9510985,mean residence time,"At doses of 0.1-5 mumol kg-1, the mean residence time was about 10 min in the rat, 35 min in the dog, and 20 min in the cynomolgus monkey.","Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9510985/),min,20,41959,DB00145,Glycine
,9510985,bioavailability,"The bioavailability was 4.8% at 20 mumol kg-1 and 32-51% at 500 mumol kg-1 in rats, 14% at 10 mumol kg-1 and 34-44% at 150 mumol kg-1 in dogs, and 2.1% at 1 mumol kg-1 in cynomolgus monkeys.","Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9510985/),%,4.8,41960,DB00145,Glycine
,9510985,bioavailability,"The bioavailability was 4.8% at 20 mumol kg-1 and 32-51% at 500 mumol kg-1 in rats, 14% at 10 mumol kg-1 and 34-44% at 150 mumol kg-1 in dogs, and 2.1% at 1 mumol kg-1 in cynomolgus monkeys.","Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9510985/),%,32-51,41961,DB00145,Glycine
,9510985,bioavailability,"The bioavailability was 4.8% at 20 mumol kg-1 and 32-51% at 500 mumol kg-1 in rats, 14% at 10 mumol kg-1 and 34-44% at 150 mumol kg-1 in dogs, and 2.1% at 1 mumol kg-1 in cynomolgus monkeys.","Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9510985/),%,14,41962,DB00145,Glycine
,9510985,bioavailability,"The bioavailability was 4.8% at 20 mumol kg-1 and 32-51% at 500 mumol kg-1 in rats, 14% at 10 mumol kg-1 and 34-44% at 150 mumol kg-1 in dogs, and 2.1% at 1 mumol kg-1 in cynomolgus monkeys.","Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9510985/),%,34-44,41963,DB00145,Glycine
,9510985,bioavailability,"The bioavailability was 4.8% at 20 mumol kg-1 and 32-51% at 500 mumol kg-1 in rats, 14% at 10 mumol kg-1 and 34-44% at 150 mumol kg-1 in dogs, and 2.1% at 1 mumol kg-1 in cynomolgus monkeys.","Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9510985/),%,2.1,41964,DB00145,Glycine
,9510985,plasma protein binding,"The plasma protein binding of inogatran in rat, dog, and human plasma, was 20-28%.","Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9510985/),%,20-28,41965,DB00145,Glycine
,9510985,blood-plasma concentration ratio,"The blood-plasma concentration ratio was 0.39-0.56, indicating limited distribution into red blood cells.","Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9510985/),,0.39-0.56,41966,DB00145,Glycine
,20815935,cross-membrane permeability (Pm*),The cross-membrane permeability (Pm*) determined in rat jejunal perfusion of D-phenylglycine-L-dopa was higher than that of L-dopa (2.58 ± 0.14 vs. 0.94 ± 0.10).,Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20815935/),,2.58,44913,DB00145,Glycine
,20815935,cross-membrane permeability (Pm*),The cross-membrane permeability (Pm*) determined in rat jejunal perfusion of D-phenylglycine-L-dopa was higher than that of L-dopa (2.58 ± 0.14 vs. 0.94 ± 0.10).,Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20815935/),,0.94,44914,DB00145,Glycine
,6105060,half-life,"In one dog, PAB levels reached a peak, which was low relative to that of other metabolites, at 1 hr after a single 5-mg/kg oral dose and decreased with a half-life of 1.2 hr.",Metabolism and disposition of peptido-aminobenzophenone (2-o-chlorobenzoyl-4-chloro-N-methyl-N-glycylglycinanilide) and its major benzodiazepine metabolites in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6105060/),h,1.2,46643,DB00145,Glycine
,14520682,absorption lag time,"After oral administration to healthy humans in the fasting state, the plasma concentration of azosemide reached its peak at 3-4 h with an absorption lag time of approximately 1 h and a terminal half-life of 2-3 h.",Pharmacokinetics and pharmacodynamics of azosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520682/),h,1,47148,DB00145,Glycine
,14520682,terminal half-life,"After oral administration to healthy humans in the fasting state, the plasma concentration of azosemide reached its peak at 3-4 h with an absorption lag time of approximately 1 h and a terminal half-life of 2-3 h.",Pharmacokinetics and pharmacodynamics of azosemide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520682/),h,2-3,47149,DB00145,Glycine
,14520682,absolute oral bioavailability,The estimated extent of absolute oral bioavailability in humans was approximately 20.4%.,Pharmacokinetics and pharmacodynamics of azosemide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520682/),%,20.4,47150,DB00145,Glycine
greater,14520682,protein binding,The protein binding to 4% human serum albumin was greater than 95% at azosemide concentrations ranging from 10 to 100 microg/ml using an equilibrium dialysis technique.,Pharmacokinetics and pharmacodynamics of azosemide. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520682/),%,95,47151,DB00145,Glycine
,14520682,apparent post-pseudodistribution volume of distribution (Vdbeta),"The poor affinity of human tissues to azosemide was supported by the relatively small value of the apparent post-pseudodistribution volume of distribution (Vdbeta), 0.262 l/kg.",Pharmacokinetics and pharmacodynamics of azosemide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520682/),[l] / [kg],0.262,47152,DB00145,Glycine
,14520682,total body clearance,"In humans, total body clearance, renal clearance and terminal half-life of azosemide were 112 ml/min, 41.6 ml/min and 2.03 h, respectively.",Pharmacokinetics and pharmacodynamics of azosemide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520682/),[ml] / [min],112,47153,DB00145,Glycine
,14520682,renal clearance,"In humans, total body clearance, renal clearance and terminal half-life of azosemide were 112 ml/min, 41.6 ml/min and 2.03 h, respectively.",Pharmacokinetics and pharmacodynamics of azosemide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520682/),[ml] / [min],41.6,47154,DB00145,Glycine
,14520682,terminal half-life,"In humans, total body clearance, renal clearance and terminal half-life of azosemide were 112 ml/min, 41.6 ml/min and 2.03 h, respectively.",Pharmacokinetics and pharmacodynamics of azosemide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520682/),h,2.03,47155,DB00145,Glycine
,33429252,V,"The samples were separated via gradient elution with a C18 column (Phenomenex Kinetex, C18, 2.6 μm, 100 Å, 50 × 2.1 mm) using 0.1 % formic acid aqueous solution (A) and acetonitrile-methanol (1:1, V:V) (B) as a mobile phase at a 0.6 mL/min flow rate.",Detection of sivelestat and its metabolite in small volumes of plasma from Chinese ALI/ARDS patients with SIRS via high-throughput UPLC-MS/MS: A pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33429252/),[ml] / [min],0.6,47412,DB00145,Glycine
,33429252,flow rate,"The samples were separated via gradient elution with a C18 column (Phenomenex Kinetex, C18, 2.6 μm, 100 Å, 50 × 2.1 mm) using 0.1 % formic acid aqueous solution (A) and acetonitrile-methanol (1:1, V:V) (B) as a mobile phase at a 0.6 mL/min flow rate.",Detection of sivelestat and its metabolite in small volumes of plasma from Chinese ALI/ARDS patients with SIRS via high-throughput UPLC-MS/MS: A pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33429252/),[ml] / [min],0.6,47413,DB00145,Glycine
,33429252,m,"UPLC-MS/MS spectra were generated in positive ion mode, and multiple reaction monitoring (MRM) was used to detect the following transitions: m/z 435.1 → 360.0 for sivelestat, m/z 469.0 → 394.0 for sivelestat-IS, m/z 351.0 → 276.0 for XW-IMP-A, and m/z 384.9 → 310.0 for XW-IMP-A-IS.",Detection of sivelestat and its metabolite in small volumes of plasma from Chinese ALI/ARDS patients with SIRS via high-throughput UPLC-MS/MS: A pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33429252/),,435.1,47414,DB00145,Glycine
,33429252,m/,"UPLC-MS/MS spectra were generated in positive ion mode, and multiple reaction monitoring (MRM) was used to detect the following transitions: m/z 435.1 → 360.0 for sivelestat, m/z 469.0 → 394.0 for sivelestat-IS, m/z 351.0 → 276.0 for XW-IMP-A, and m/z 384.9 → 310.0 for XW-IMP-A-IS.",Detection of sivelestat and its metabolite in small volumes of plasma from Chinese ALI/ARDS patients with SIRS via high-throughput UPLC-MS/MS: A pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33429252/),,469.0,47415,DB00145,Glycine
,33429252,m/z,"UPLC-MS/MS spectra were generated in positive ion mode, and multiple reaction monitoring (MRM) was used to detect the following transitions: m/z 435.1 → 360.0 for sivelestat, m/z 469.0 → 394.0 for sivelestat-IS, m/z 351.0 → 276.0 for XW-IMP-A, and m/z 384.9 → 310.0 for XW-IMP-A-IS.",Detection of sivelestat and its metabolite in small volumes of plasma from Chinese ALI/ARDS patients with SIRS via high-throughput UPLC-MS/MS: A pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33429252/),,351.0,47416,DB00145,Glycine
,33429252,m/z,"UPLC-MS/MS spectra were generated in positive ion mode, and multiple reaction monitoring (MRM) was used to detect the following transitions: m/z 435.1 → 360.0 for sivelestat, m/z 469.0 → 394.0 for sivelestat-IS, m/z 351.0 → 276.0 for XW-IMP-A, and m/z 384.9 → 310.0 for XW-IMP-A-IS.",Detection of sivelestat and its metabolite in small volumes of plasma from Chinese ALI/ARDS patients with SIRS via high-throughput UPLC-MS/MS: A pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33429252/),,276.0,47417,DB00145,Glycine
,33429252,m/z,"UPLC-MS/MS spectra were generated in positive ion mode, and multiple reaction monitoring (MRM) was used to detect the following transitions: m/z 435.1 → 360.0 for sivelestat, m/z 469.0 → 394.0 for sivelestat-IS, m/z 351.0 → 276.0 for XW-IMP-A, and m/z 384.9 → 310.0 for XW-IMP-A-IS.",Detection of sivelestat and its metabolite in small volumes of plasma from Chinese ALI/ARDS patients with SIRS via high-throughput UPLC-MS/MS: A pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33429252/),,384.9,47418,DB00145,Glycine
,33429252,m/z,"UPLC-MS/MS spectra were generated in positive ion mode, and multiple reaction monitoring (MRM) was used to detect the following transitions: m/z 435.1 → 360.0 for sivelestat, m/z 469.0 → 394.0 for sivelestat-IS, m/z 351.0 → 276.0 for XW-IMP-A, and m/z 384.9 → 310.0 for XW-IMP-A-IS.",Detection of sivelestat and its metabolite in small volumes of plasma from Chinese ALI/ARDS patients with SIRS via high-throughput UPLC-MS/MS: A pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33429252/),,310.0,47419,DB00145,Glycine
,1459365,half-life,The decay was exponential with a half-life consistent with that of rat or mouse albumin (approx 24 hr).,"Adduction of hemoglobin and albumin in vivo by metabolites of trichloroethylene, trichloroacetate, and dichloroacetate in rats and mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1459365/),h,24,48710,DB00145,Glycine
,30292894,encapsulation efficiency (EE),"The mean encapsulation efficiency (EE), particle size, and polydispersity index (PDI) of the optimized liposomal formulation (NGR1@Liposomes) were 49.49%, 308.3 nm, and 0.229, respectively.",Improved oral bioavailability of notoginsenoside R1 with sodium glycocholate-mediated liposomes: Preparation by supercritical fluid technology and evaluation in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30292894/),%,49.49,49131,DB00145,Glycine
,30292894,particle size,"The mean encapsulation efficiency (EE), particle size, and polydispersity index (PDI) of the optimized liposomal formulation (NGR1@Liposomes) were 49.49%, 308.3 nm, and 0.229, respectively.",Improved oral bioavailability of notoginsenoside R1 with sodium glycocholate-mediated liposomes: Preparation by supercritical fluid technology and evaluation in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30292894/),nm,308.3,49132,DB00145,Glycine
,30292894,polydispersity index (PDI),"The mean encapsulation efficiency (EE), particle size, and polydispersity index (PDI) of the optimized liposomal formulation (NGR1@Liposomes) were 49.49%, 308.3 nm, and 0.229, respectively.",Improved oral bioavailability of notoginsenoside R1 with sodium glycocholate-mediated liposomes: Preparation by supercritical fluid technology and evaluation in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30292894/),,0.229,49133,DB00145,Glycine
,30292894,particle size,"SGC-mediated liposomes (NGR1@SGC-Liposomes) were formulated based on the optimal preparation conditions and the mean EE, particle size, and PDI were 41.51%, 200.1 nm, and 0.130, respectively.",Improved oral bioavailability of notoginsenoside R1 with sodium glycocholate-mediated liposomes: Preparation by supercritical fluid technology and evaluation in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30292894/),nm,200.1,49134,DB00145,Glycine
,9625488,association constant (K),"Scatchard plot analysis of ONO-5046 binding to bovine serum albumin (BSA) in-vitro indicated that the association constant (K) and number of binding sites (n) were 6.91 x 10(4) (M(-1)) and 4.33, respectively.","Hepatic clearance of ONO-5046, a novel neutrophil elastase inhibitor, in rats and in the rat perfused liver. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625488/),1/[M],6.91 x 10(4),49455,DB00145,Glycine
,9625488,number of binding sites (n),"Scatchard plot analysis of ONO-5046 binding to bovine serum albumin (BSA) in-vitro indicated that the association constant (K) and number of binding sites (n) were 6.91 x 10(4) (M(-1)) and 4.33, respectively.","Hepatic clearance of ONO-5046, a novel neutrophil elastase inhibitor, in rats and in the rat perfused liver. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625488/),,4.33,49456,DB00145,Glycine
,9625488,total plasma clearance,The total plasma clearance of ONO-5046 in rats was constant (approximately 9 mL min(-1) kg(-1)) under different steady-state plasma concentrations (5-50 microM) a value equivalent to the hepatic clearance.,"Hepatic clearance of ONO-5046, a novel neutrophil elastase inhibitor, in rats and in the rat perfused liver. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625488/),[ml] / [kg·min],9,49457,DB00145,Glycine
,7655429,plasma maximum concentration,The plasma maximum concentration of ABPC was 78.71 micrograms/ml 10 min after its rectal administration at 100 mg/kg with 1.5% GA MHPh.,Promotion of rectal absorption of sodium ampicillin by disodium glycyrrhetinic acid 3 beta-O-monohemiphthalate in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7655429/),[μg] / [ml],78.71,49820,DB00145,Glycine
,7655429,bioavailability,"The bioavailability of ABPC with and without 1.5% GA MHPh was 82.12% and 3.92%, respectively.",Promotion of rectal absorption of sodium ampicillin by disodium glycyrrhetinic acid 3 beta-O-monohemiphthalate in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7655429/),%,82.12,49821,DB00145,Glycine
,7655429,bioavailability,"The bioavailability of ABPC with and without 1.5% GA MHPh was 82.12% and 3.92%, respectively.",Promotion of rectal absorption of sodium ampicillin by disodium glycyrrhetinic acid 3 beta-O-monohemiphthalate in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7655429/),%,3.92,49822,DB00145,Glycine
,7667199,fe,"Valproyl glycine and valproyl GABA were partially excreted unchanged in the urine (fe = 50% and 34%, respectively), while the urinary metabolites of the amide derivatives were valproyl glycine and valproyl GABA.",Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7667199/),%,50,50114,DB00145,Glycine
,7667199,fe,"Valproyl glycine and valproyl GABA were partially excreted unchanged in the urine (fe = 50% and 34%, respectively), while the urinary metabolites of the amide derivatives were valproyl glycine and valproyl GABA.",Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7667199/),%,34,50115,DB00145,Glycine
,21338263,S/N ratios,Chromatograms exhibit clean 2.0-min running time peaks and S/N ratios for the LLOQ were approximately 15:1.,Pharmacokinetics of diphenylboroxazolidones of L-α-amino acids with activity on the CNS: quantification in rat DBS by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21338263/),,15:1,50372,DB00145,Glycine
,32296873,half-life,Ivosidenib was rapidly absorbed and slowly eliminated (half-life 72-138 h) after single and multiple dosing.,Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32296873/),h,72-138,50711,DB00145,Glycine
,32787144,IC50,"Remarkably, oral administration of 17, with an IC50 of 64.2 nM toward PHD2, was found to stabilize HIF-α, elevate erythropoietin (EPO), and alleviate anemia in a cisplatin-induced anemia mouse model with an oral dose of 25 mg/kg.","Discovery of Clinical Candidate (5-(3-(4-Chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an Orally Bioavailable Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32787144/),nM,64.2,52614,DB00145,Glycine
,32787144,oral bioavailabilities,"Rat and dog studies showed that 17 has good pharmacokinetic properties, with oral bioavailabilities of 55.7 and 54.0%, respectively, and shows excellent safety profiles even at a high dose of 200 mg/kg in these animals.","Discovery of Clinical Candidate (5-(3-(4-Chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an Orally Bioavailable Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32787144/),%,55.7,52615,DB00145,Glycine
,32787144,oral bioavailabilities,"Rat and dog studies showed that 17 has good pharmacokinetic properties, with oral bioavailabilities of 55.7 and 54.0%, respectively, and shows excellent safety profiles even at a high dose of 200 mg/kg in these animals.","Discovery of Clinical Candidate (5-(3-(4-Chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an Orally Bioavailable Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32787144/),%,54.0,52616,DB00145,Glycine
,31674861,t½,Results: Cmax for all subjects was reached after 10-15 min and decreased with a t½ of ∼30 min.,"Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31674861/),min,∼30,53921,DB00145,Glycine
,29138048,Zeta potential,"By optimizing preparation conditions, nanoparticles with expected size (157.3-197.7 nm), Zeta potential (24.35-34.37 mV), polydispersity index (0.365-0.512), entrapment efficiency (70.60-86.52%) and loading capacity (30.92-56.81%), proper morphology and desirable release pattern were obtained.",In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138048/),mv,24.35-34.37,53939,DB00145,Glycine
,29138048,polydispersity,"By optimizing preparation conditions, nanoparticles with expected size (157.3-197.7 nm), Zeta potential (24.35-34.37 mV), polydispersity index (0.365-0.512), entrapment efficiency (70.60-86.52%) and loading capacity (30.92-56.81%), proper morphology and desirable release pattern were obtained.",In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138048/),,0.365-0.512,53940,DB00145,Glycine
,29138048,entra,"By optimizing preparation conditions, nanoparticles with expected size (157.3-197.7 nm), Zeta potential (24.35-34.37 mV), polydispersity index (0.365-0.512), entrapment efficiency (70.60-86.52%) and loading capacity (30.92-56.81%), proper morphology and desirable release pattern were obtained.",In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138048/),%,70.60-86.52,53941,DB00145,Glycine
,29138048,loading capacity,"By optimizing preparation conditions, nanoparticles with expected size (157.3-197.7 nm), Zeta potential (24.35-34.37 mV), polydispersity index (0.365-0.512), entrapment efficiency (70.60-86.52%) and loading capacity (30.92-56.81%), proper morphology and desirable release pattern were obtained.",In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138048/),%,30.92-56.81,53942,DB00145,Glycine
,29138048,relative bioavailability,"In animal model, oral administration of glycyl-glycine and alanyl-alanine conjugate nanoparticles of trimethyl chitosan demonstrated reasonable increase in Serum insulin level with relative bioavailability of 17.19% and 15.46% for glycyl-glycine and alanyl-alanine conjugate nanoparticles, respectively, and reduction in Serum glucose level compared with trimethyl chitosan nanoparticles (p < 0.05).",In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138048/),%,17.19,53943,DB00145,Glycine
,29138048,relative bioavailability,"In animal model, oral administration of glycyl-glycine and alanyl-alanine conjugate nanoparticles of trimethyl chitosan demonstrated reasonable increase in Serum insulin level with relative bioavailability of 17.19% and 15.46% for glycyl-glycine and alanyl-alanine conjugate nanoparticles, respectively, and reduction in Serum glucose level compared with trimethyl chitosan nanoparticles (p < 0.05).",In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138048/),%,15.46,53944,DB00145,Glycine
,10198343,urinary clearances,"During intravenous infusion of carboxyamidated gastrin-17, progastrin fragment-(1-35), and glycine-extended gastrin-17, the respective urinary clearances amounted to 0.08 +/- 0.02, 0.46 +/- 0.08, and 0. 02 +/- 0.01%, respectively, of the glomerular filtration rate.",Excretion of progastrin products in human urine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10198343/),%,0.08,55405,DB00145,Glycine
,10198343,urinary clearances,"During intravenous infusion of carboxyamidated gastrin-17, progastrin fragment-(1-35), and glycine-extended gastrin-17, the respective urinary clearances amounted to 0.08 +/- 0.02, 0.46 +/- 0.08, and 0. 02 +/- 0.01%, respectively, of the glomerular filtration rate.",Excretion of progastrin products in human urine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10198343/),%,0.46,55406,DB00145,Glycine
,10198343,urinary clearances,"During intravenous infusion of carboxyamidated gastrin-17, progastrin fragment-(1-35), and glycine-extended gastrin-17, the respective urinary clearances amounted to 0.08 +/- 0.02, 0.46 +/- 0.08, and 0. 02 +/- 0.01%, respectively, of the glomerular filtration rate.",Excretion of progastrin products in human urine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10198343/),%,0. 02,55407,DB00145,Glycine
,10198343,metabolic clearance rate,"The metabolic clearance rate of the three peptides was 24.4 +/- 1.3, 6.0 +/- 0.4, and 8.6 +/- 0.7 ml.",Excretion of progastrin products in human urine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10198343/),ml,24.4,55408,DB00145,Glycine
,10198343,metabolic clearance rate,"The metabolic clearance rate of the three peptides was 24.4 +/- 1.3, 6.0 +/- 0.4, and 8.6 +/- 0.7 ml.",Excretion of progastrin products in human urine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10198343/),ml,6.0,55409,DB00145,Glycine
,10198343,metabolic clearance rate,"The metabolic clearance rate of the three peptides was 24.4 +/- 1.3, 6.0 +/- 0.4, and 8.6 +/- 0.7 ml.",Excretion of progastrin products in human urine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10198343/),ml,8.6,55410,DB00145,Glycine
,14603503,time to reach maximum concentration (t(max)),"Moreover, the time to reach maximum concentration (t(max)) decreased from 2.2 with the untreated drug to 0.5 h with the coground product, and the mean permanence time of DHEA within physiological levels was four times longer for the coground product compared with the untreated drug.",Enhancement of dehydroepiandrosterone solubility and bioavailability by ternary complexation with alpha-cyclodextrin and glycine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603503/),h,2.2,57241,DB00145,Glycine
,14603503,time to reach maximum concentration (t(max)),"Moreover, the time to reach maximum concentration (t(max)) decreased from 2.2 with the untreated drug to 0.5 h with the coground product, and the mean permanence time of DHEA within physiological levels was four times longer for the coground product compared with the untreated drug.",Enhancement of dehydroepiandrosterone solubility and bioavailability by ternary complexation with alpha-cyclodextrin and glycine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603503/),h,0.5,57242,DB00145,Glycine
,7736921,constant flow rate,The fate of varying input concentrations (0.002-372 microM) of benzoic acid was examined in the single-pass isolated perfused rat kidney preparation under constant flow rate (8 ml min-1.organ-1).,Benzoic acid glycine conjugation in the isolated perfused rat kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736921/),[ml] / [min·organ],8,58482,DB00145,Glycine
,7736921,steady-state renal extraction ratio,"With an increasing concentration of benzoate, the steady-state renal extraction ratio decreased from 0.24 to 0.1.",Benzoic acid glycine conjugation in the isolated perfused rat kidney. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736921/),,0.24,58483,DB00145,Glycine
,7736921,steady-state renal extraction ratio,"With an increasing concentration of benzoate, the steady-state renal extraction ratio decreased from 0.24 to 0.1.",Benzoic acid glycine conjugation in the isolated perfused rat kidney. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736921/),,0.1,58484,DB00145,Glycine
,7736921,fractional excretion,"Little unchanged drug was found in the urine; the urinary clearance of benzoate was low (0.018 ml-1 min-1.g-1) and concentration-independent, yielding a rather constant fractional excretion of approximately 0.2.",Benzoic acid glycine conjugation in the isolated perfused rat kidney. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736921/),,0.2,58485,DB00145,Glycine
,7736921,Vmax,"the plasma unbound logarithmic average concentrations of benzoate, overall kinetic constants (KM = 5.3 microM and Vmax = 195 nmol min-1.g-1) that likely reflect glycine conjugation were obtained.",Benzoic acid glycine conjugation in the isolated perfused rat kidney. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736921/),[nM] / [g·min],195,58486,DB00145,Glycine
,7736921,apparent renal extraction ratio (excretion rate/formation rate,The formed hippurate either returned to the venous circulation or was excreted into urine without further biotransformation; the apparent renal extraction ratio (excretion rate/formation rate of hippurate) was quite high (approximately 0.48).,Benzoic acid glycine conjugation in the isolated perfused rat kidney. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736921/),,0.48,58487,DB00145,Glycine
,1501070,terminal half-lives,"After single, intravenous doses of 1 at 5 mg/kg, the mean terminal half-lives of 1 in plasma were 2.6 h in the dog and 3.8 h in the monkey.","Disposition of 8-methyl-8-azabicyclo[3,2,1]octan-3-yl 3,5-dichlorobenzoate, a potent 5-hydroxytryptamine antagonist, and two metabolites in dogs and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501070/),h,2.6,58515,DB00145,Glycine
,1501070,terminal half-lives,"After single, intravenous doses of 1 at 5 mg/kg, the mean terminal half-lives of 1 in plasma were 2.6 h in the dog and 3.8 h in the monkey.","Disposition of 8-methyl-8-azabicyclo[3,2,1]octan-3-yl 3,5-dichlorobenzoate, a potent 5-hydroxytryptamine antagonist, and two metabolites in dogs and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501070/),h,3.8,58516,DB00145,Glycine
,1501070,half-life,The mean half-life of the N-demethylated metabolite in dogs (approximately 20 h) was very similar to that in monkeys.,"Disposition of 8-methyl-8-azabicyclo[3,2,1]octan-3-yl 3,5-dichlorobenzoate, a potent 5-hydroxytryptamine antagonist, and two metabolites in dogs and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501070/),h,20,58517,DB00145,Glycine
,1501070,half-life,"However, the mean half-life of the N-oxide metabolite in dogs (10.8 h) was different from that in monkeys (3.9 h).","Disposition of 8-methyl-8-azabicyclo[3,2,1]octan-3-yl 3,5-dichlorobenzoate, a potent 5-hydroxytryptamine antagonist, and two metabolites in dogs and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501070/),h,10.8,58518,DB00145,Glycine
,1501070,half-life,"However, the mean half-life of the N-oxide metabolite in dogs (10.8 h) was different from that in monkeys (3.9 h).","Disposition of 8-methyl-8-azabicyclo[3,2,1]octan-3-yl 3,5-dichlorobenzoate, a potent 5-hydroxytryptamine antagonist, and two metabolites in dogs and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501070/),h,3.9,58519,DB00145,Glycine
,1501070,steady-state volume of distribution,The steady-state volume of distribution of 1 was 16 L/kg in dogs and 8.9 L/kg in monkeys.,"Disposition of 8-methyl-8-azabicyclo[3,2,1]octan-3-yl 3,5-dichlorobenzoate, a potent 5-hydroxytryptamine antagonist, and two metabolites in dogs and monkeys. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501070/),[l] / [kg],16,58520,DB00145,Glycine
,1501070,steady-state volume of distribution,The steady-state volume of distribution of 1 was 16 L/kg in dogs and 8.9 L/kg in monkeys.,"Disposition of 8-methyl-8-azabicyclo[3,2,1]octan-3-yl 3,5-dichlorobenzoate, a potent 5-hydroxytryptamine antagonist, and two metabolites in dogs and monkeys. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501070/),[l] / [kg],8.9,58521,DB00145,Glycine
,15948037,survival time,"The mean survival time of the mice treated with RGD-SSL-DOX, RGDm-SSL-DOX, and SSL-DOX was 55, 49, and 44 days, respectively.",Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948037/),d,55,58538,DB00145,Glycine
,15948037,survival time,"The mean survival time of the mice treated with RGD-SSL-DOX, RGDm-SSL-DOX, and SSL-DOX was 55, 49, and 44 days, respectively.",Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948037/),d,49,58539,DB00145,Glycine
,15948037,survival time,"The mean survival time of the mice treated with RGD-SSL-DOX, RGDm-SSL-DOX, and SSL-DOX was 55, 49, and 44 days, respectively.",Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948037/),d,44,58540,DB00145,Glycine
,3417643,rate of disappearance,"(a) N terminus: the rate of disappearance of Ala-Leu was greater (p less than 0.01) than those of Gly-Leu, Phe-Leu, and Arg-Leu (208 +/- 13, 135 +/- 13, 116 +/- 12, and 127 +/- 12, respectively).",Specificity and mechanism of influence of amino acid residues on hepatic clearance of oligopeptides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3417643/),,208,58597,DB00145,Glycine
,3417643,rate of disappearance,"(a) N terminus: the rate of disappearance of Ala-Leu was greater (p less than 0.01) than those of Gly-Leu, Phe-Leu, and Arg-Leu (208 +/- 13, 135 +/- 13, 116 +/- 12, and 127 +/- 12, respectively).",Specificity and mechanism of influence of amino acid residues on hepatic clearance of oligopeptides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3417643/),,135,58598,DB00145,Glycine
,3417643,rate of disappearance,"(a) N terminus: the rate of disappearance of Ala-Leu was greater (p less than 0.01) than those of Gly-Leu, Phe-Leu, and Arg-Leu (208 +/- 13, 135 +/- 13, 116 +/- 12, and 127 +/- 12, respectively).",Specificity and mechanism of influence of amino acid residues on hepatic clearance of oligopeptides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3417643/),,116,58599,DB00145,Glycine
,3417643,rate of disappearance,"(a) N terminus: the rate of disappearance of Ala-Leu was greater (p less than 0.01) than those of Gly-Leu, Phe-Leu, and Arg-Leu (208 +/- 13, 135 +/- 13, 116 +/- 12, and 127 +/- 12, respectively).",Specificity and mechanism of influence of amino acid residues on hepatic clearance of oligopeptides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3417643/),,127,58600,DB00145,Glycine
,3417643,rate of disappearance,(b) C terminus: the rate of disappearance of Leu-Ala (244 +/- 18) was significantly greater (p less than 0.01) than that of Leu-Gly (145 +/- 16).,Specificity and mechanism of influence of amino acid residues on hepatic clearance of oligopeptides. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3417643/),,244,58601,DB00145,Glycine
,3417643,rate of disappearance,(b) C terminus: the rate of disappearance of Leu-Ala (244 +/- 18) was significantly greater (p less than 0.01) than that of Leu-Gly (145 +/- 16).,Specificity and mechanism of influence of amino acid residues on hepatic clearance of oligopeptides. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3417643/),,145,58602,DB00145,Glycine
,9574457,extraction ratio,"The fraction of PAH excreted by the kidney CLR/CLS calculated from HPLC data (n = 143) is, as expected, always < 1 (mean = 0.73 +/- 0.11), whereas the colorimetric method gives a mean extraction ratio of 0.87 +/- 0.13 implying unphysio-logical values (> 1) in some cases.",Specific determination of PAH and its N-acetyl metabolite by HPLC increases the accuracy and precision of PAH clearance measurements. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9574457/),,0.87,59868,DB00145,Glycine
,31682027,Cmax,A large interindividual variability was observed for the PAS Cmax (40.42-68.55 mg/L) following 4 g twice daily; (62.69-102.41 mg/L) for 8 g once daily and a similar wide Cmax range found for the metabolites acetyl-PAS and glycine-PAS.,Pharmacokinetics of Para-Aminosalicylic Acid and Its 2 Major Metabolites: A Potential Relationship to the Development of Gastrointestinal Intolerance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31682027/),[mg] / [l],40.42-68.55,59958,DB00145,Glycine
,31682027,Cmax,A large interindividual variability was observed for the PAS Cmax (40.42-68.55 mg/L) following 4 g twice daily; (62.69-102.41 mg/L) for 8 g once daily and a similar wide Cmax range found for the metabolites acetyl-PAS and glycine-PAS.,Pharmacokinetics of Para-Aminosalicylic Acid and Its 2 Major Metabolites: A Potential Relationship to the Development of Gastrointestinal Intolerance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31682027/),[mg] / [l],62.69-102.41,59959,DB00145,Glycine
,11534935,glucose-to-lipids ratio,Eight healthy volunteers received peripheral PN for 10 h providing 10.5 mg N x kg(-1) x h(-1) and 2.0 kcal x kg(-1) x h(-1) (glucose-to-lipids ratio: 70/30%).,Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),%,70,60120,DB00145,Glycine
,11534935,glucose-to-lipids ratio,Eight healthy volunteers received peripheral PN for 10 h providing 10.5 mg N x kg(-1) x h(-1) and 2.0 kcal x kg(-1) x h(-1) (glucose-to-lipids ratio: 70/30%).,Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),%,30,60121,DB00145,Glycine
,11534935,DeltaN,DeltaN was: 0.8+/-0.5 gN/10 h.,Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[gn] / [10·h],0.8,60122,DB00145,Glycine
<,11534935,Cl,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[l] / [min],0.5,60123,DB00145,Glycine
<,11534935,Clr,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[ml] / [min],1.5,60124,DB00145,Glycine
>,11534935,Reab,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),%,99,60125,DB00145,Glycine
>,11534935,Reten,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),,99,60126,DB00145,Glycine
<,11534935,Cl,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[l] / [min],0.6,60127,DB00145,Glycine
,11534935,Cl,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[l] / [min],2.8,60128,DB00145,Glycine
<,11534935,Clr,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[ml] / [min],3,60129,DB00145,Glycine
,11534935,Clr,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[ml] / [min],6.8,60130,DB00145,Glycine
,11534935,Clr,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[ml] / [min],8.2,60131,DB00145,Glycine
,11534935,Clr,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[ml] / [min],8.8,60132,DB00145,Glycine
>,11534935,Reab,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),%,98,60133,DB00145,Glycine
,11534935,Reab,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),,95,60134,DB00145,Glycine
,11534935,Reab,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),,94,60135,DB00145,Glycine
,11534935,Reab,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),,94,60136,DB00145,Glycine
>,11534935,Reten,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),%,97,60137,DB00145,Glycine
,11534935,Reten,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),,94,60138,DB00145,Glycine
,11534935,Reten,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),,95,60139,DB00145,Glycine
,238816,half-life (t1/2),The half-life (t1/2) of radioactivity in monkey or dog plasma was 1 and 5 hr.,"Metabolism of p-(cyclopropylcarbonyl)phenylacetic acid (SQ 20,650). Species Differences. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/238816/),h,1,63375,DB00145,Glycine
,238816,half-life (t1/2),The half-life (t1/2) of radioactivity in monkey or dog plasma was 1 and 5 hr.,"Metabolism of p-(cyclopropylcarbonyl)phenylacetic acid (SQ 20,650). Species Differences. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/238816/),h,5,63376,DB00145,Glycine
,238816,half-lives,"At 50 mg/kg, these half-lives increased to 3.5 and 7.7 hr. respectively.","Metabolism of p-(cyclopropylcarbonyl)phenylacetic acid (SQ 20,650). Species Differences. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/238816/),h,3.5,63377,DB00145,Glycine
,238816,half-lives,"At 50 mg/kg, these half-lives increased to 3.5 and 7.7 hr. respectively.","Metabolism of p-(cyclopropylcarbonyl)phenylacetic acid (SQ 20,650). Species Differences. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/238816/),h,7.7,63378,DB00145,Glycine
,8212419,apparent half-life,The apparent half-life of glycine varied 10-fold (range 26-245 min) and increased in direct proportion to the amount of glycine given.,Dose-dependent half-life of glycine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8212419/),min,26-245,64006,DB00145,Glycine
,2913287,plasma protein binding,"The methoxybenzoylglycines showed nonlinear plasma protein binding varying between 10 and 70%, rapid clearance from plasma, largely by renal excretion (72-84% of the administered dose).","Renal clearance of substituted hippurates in the dog. II. 4-Amino-, hydroxy- and methoxy-substituted benzoylglycines. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2913287/),%,10 and 70,69483,DB00145,Glycine
,2913287,tubular transport maximum (TM),"The kinetic parameters of tubular secretion were estimated with a physiologically based kidney model: 2-hydroxy, tubular transport maximum (TM) = 4.4 +/- 0.9 mg/min, Michael-Menten constant of the tubular secretion mechanism (KT) = 23 +/- 8 micrograms/ml; 2-methoxy-TM = 11.7 +/- 4.9 mg/min, KT = 42 +/- 9 micrograms/ml; 3-methoxy-TM = 8.8 +/- 1.0 mg/mn, KT = 27 +/- 20 micrograms/ml.","Renal clearance of substituted hippurates in the dog. II. 4-Amino-, hydroxy- and methoxy-substituted benzoylglycines. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2913287/),[mg] / [min],4.4,69484,DB00145,Glycine
,2913287,Michael-Menten constant of the tubular secretion mechanism (KT),"The kinetic parameters of tubular secretion were estimated with a physiologically based kidney model: 2-hydroxy, tubular transport maximum (TM) = 4.4 +/- 0.9 mg/min, Michael-Menten constant of the tubular secretion mechanism (KT) = 23 +/- 8 micrograms/ml; 2-methoxy-TM = 11.7 +/- 4.9 mg/min, KT = 42 +/- 9 micrograms/ml; 3-methoxy-TM = 8.8 +/- 1.0 mg/mn, KT = 27 +/- 20 micrograms/ml.","Renal clearance of substituted hippurates in the dog. II. 4-Amino-, hydroxy- and methoxy-substituted benzoylglycines. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2913287/),[μg] / [ml],23,69485,DB00145,Glycine
,2913287,KT,"The kinetic parameters of tubular secretion were estimated with a physiologically based kidney model: 2-hydroxy, tubular transport maximum (TM) = 4.4 +/- 0.9 mg/min, Michael-Menten constant of the tubular secretion mechanism (KT) = 23 +/- 8 micrograms/ml; 2-methoxy-TM = 11.7 +/- 4.9 mg/min, KT = 42 +/- 9 micrograms/ml; 3-methoxy-TM = 8.8 +/- 1.0 mg/mn, KT = 27 +/- 20 micrograms/ml.","Renal clearance of substituted hippurates in the dog. II. 4-Amino-, hydroxy- and methoxy-substituted benzoylglycines. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2913287/),[μg] / [ml],42,69486,DB00145,Glycine
,2913287,KT,"The kinetic parameters of tubular secretion were estimated with a physiologically based kidney model: 2-hydroxy, tubular transport maximum (TM) = 4.4 +/- 0.9 mg/min, Michael-Menten constant of the tubular secretion mechanism (KT) = 23 +/- 8 micrograms/ml; 2-methoxy-TM = 11.7 +/- 4.9 mg/min, KT = 42 +/- 9 micrograms/ml; 3-methoxy-TM = 8.8 +/- 1.0 mg/mn, KT = 27 +/- 20 micrograms/ml.","Renal clearance of substituted hippurates in the dog. II. 4-Amino-, hydroxy- and methoxy-substituted benzoylglycines. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2913287/),[μg] / [ml],27,69487,DB00145,Glycine
,2913287,CLint,"Inasmuch as secretion of the other compounds was not saturated, only the intrinsic secretion clearance (CLint) = TM/KT could be estimated; 4-amino-CLint = 145 +/- 50 ml/min, 3-hydroxy-CLint = 194 +/- 21 ml/min, 4-hydroxy-CLint = 153 +/- 23 ml/min and 4-methoxy-CLint = 201 +/- 47 ml/min.","Renal clearance of substituted hippurates in the dog. II. 4-Amino-, hydroxy- and methoxy-substituted benzoylglycines. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2913287/),[ml] / [min],145,69488,DB00145,Glycine
,2913287,CLint,"Inasmuch as secretion of the other compounds was not saturated, only the intrinsic secretion clearance (CLint) = TM/KT could be estimated; 4-amino-CLint = 145 +/- 50 ml/min, 3-hydroxy-CLint = 194 +/- 21 ml/min, 4-hydroxy-CLint = 153 +/- 23 ml/min and 4-methoxy-CLint = 201 +/- 47 ml/min.","Renal clearance of substituted hippurates in the dog. II. 4-Amino-, hydroxy- and methoxy-substituted benzoylglycines. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2913287/),[ml] / [min],194,69489,DB00145,Glycine
,2913287,CLint,"Inasmuch as secretion of the other compounds was not saturated, only the intrinsic secretion clearance (CLint) = TM/KT could be estimated; 4-amino-CLint = 145 +/- 50 ml/min, 3-hydroxy-CLint = 194 +/- 21 ml/min, 4-hydroxy-CLint = 153 +/- 23 ml/min and 4-methoxy-CLint = 201 +/- 47 ml/min.","Renal clearance of substituted hippurates in the dog. II. 4-Amino-, hydroxy- and methoxy-substituted benzoylglycines. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2913287/),[ml] / [min],153,69490,DB00145,Glycine
,2913287,CLint,"Inasmuch as secretion of the other compounds was not saturated, only the intrinsic secretion clearance (CLint) = TM/KT could be estimated; 4-amino-CLint = 145 +/- 50 ml/min, 3-hydroxy-CLint = 194 +/- 21 ml/min, 4-hydroxy-CLint = 153 +/- 23 ml/min and 4-methoxy-CLint = 201 +/- 47 ml/min.","Renal clearance of substituted hippurates in the dog. II. 4-Amino-, hydroxy- and methoxy-substituted benzoylglycines. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2913287/),[ml] / [min],201,69491,DB00145,Glycine
,20978103,elimination half-life (t(1/2)),The maximum plasma concentration (C(max)) of drug was reached at approximately 1 h and the elimination half-life (t(1/2)) was approximately 3.5 h.,Metabolism and disposition of 14C-labeled peliglitazar in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20978103/),h,3.5,70060,DB00145,Glycine
,27352308,terminal half-life (t ½),"Mean terminal half-life (t ½) appeared to be longer (17.7 vs. 12.8 h) in subjects with moderate hepatic impairment, however intersubject variability on apparent total systemic clearance after single oral dosing (CL/F), apparent volume of distribution at equilibrium after oral administration (V z/F) and t ½ was approximately twofold higher.","Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27352308/),h,17.7,70123,DB00145,Glycine
,27352308,terminal half-life (t ½),"Mean terminal half-life (t ½) appeared to be longer (17.7 vs. 12.8 h) in subjects with moderate hepatic impairment, however intersubject variability on apparent total systemic clearance after single oral dosing (CL/F), apparent volume of distribution at equilibrium after oral administration (V z/F) and t ½ was approximately twofold higher.","Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27352308/),h,12.8,70124,DB00145,Glycine
,30758648,Tmax,Median Tmax of both unchanged ivosidenib and radioactivity in plasma was 4 h.,"Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758648/),h,4,70762,DB00145,Glycine
,30758648,Plasma t½,"Plasma t½ values for total radioactivity and ivosidenib were 71.7 and 53.4 h, respectively.","Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758648/),h,71.7,70763,DB00145,Glycine
,30758648,Plasma t½,"Plasma t½ values for total radioactivity and ivosidenib were 71.7 and 53.4 h, respectively.","Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758648/),h,53.4,70764,DB00145,Glycine
,30758648,AUC0-72,"The mean AUC0-72 blood-to-plasma total radioactivity concentration ratio was 0.565, indicating minimal partitioning to red blood cells.","Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758648/),,0.565,70765,DB00145,Glycine
,30758648,blood-to-plasma total radioactivity concentration ratio,"The mean AUC0-72 blood-to-plasma total radioactivity concentration ratio was 0.565, indicating minimal partitioning to red blood cells.","Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758648/),,0.565,70766,DB00145,Glycine
,30758648,recovery of radioactivity,"The mean recovery of radioactivity in excreta was 94.3% over 360 h post-dose; the majority was excreted in feces (77.4 ± 9.62%) with a low percentage recovered in urine (16.9 ± 5.62%), suggesting fecal excretion is the primary route of elimination.","Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758648/),%,94.3,70767,DB00145,Glycine
,30758648,recovery of radioactivity,"The mean recovery of radioactivity in excreta was 94.3% over 360 h post-dose; the majority was excreted in feces (77.4 ± 9.62%) with a low percentage recovered in urine (16.9 ± 5.62%), suggesting fecal excretion is the primary route of elimination.","Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758648/),%,77.4,70768,DB00145,Glycine
,1286128,Time-to-peak,"Time-to-peak for all three analytes showed a trend to increase with increasing doses of TTPG, being: 0.42, 0.40 and 0.67 h (P < 0.01) with TTPG; 0.53, 0.47 and 0.73 h (P < 0.05) with TCA; and 1.33, 2.13 and 2.58 h (P < 0.01) with tiopronin.",Pharmacokinetics of 2-(alpha-thenoylthio)-propionylglycine (TTPG) in healthy volunteers--an oral dose-proportionality investigation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1286128/),h,0.42,72912,DB00145,Glycine
,1286128,Time-to-peak,"Time-to-peak for all three analytes showed a trend to increase with increasing doses of TTPG, being: 0.42, 0.40 and 0.67 h (P < 0.01) with TTPG; 0.53, 0.47 and 0.73 h (P < 0.05) with TCA; and 1.33, 2.13 and 2.58 h (P < 0.01) with tiopronin.",Pharmacokinetics of 2-(alpha-thenoylthio)-propionylglycine (TTPG) in healthy volunteers--an oral dose-proportionality investigation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1286128/),h,0.40,72913,DB00145,Glycine
,1286128,Time-to-peak,"Time-to-peak for all three analytes showed a trend to increase with increasing doses of TTPG, being: 0.42, 0.40 and 0.67 h (P < 0.01) with TTPG; 0.53, 0.47 and 0.73 h (P < 0.05) with TCA; and 1.33, 2.13 and 2.58 h (P < 0.01) with tiopronin.",Pharmacokinetics of 2-(alpha-thenoylthio)-propionylglycine (TTPG) in healthy volunteers--an oral dose-proportionality investigation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1286128/),h,0.67,72914,DB00145,Glycine
,1286128,Time-to-peak,"Time-to-peak for all three analytes showed a trend to increase with increasing doses of TTPG, being: 0.42, 0.40 and 0.67 h (P < 0.01) with TTPG; 0.53, 0.47 and 0.73 h (P < 0.05) with TCA; and 1.33, 2.13 and 2.58 h (P < 0.01) with tiopronin.",Pharmacokinetics of 2-(alpha-thenoylthio)-propionylglycine (TTPG) in healthy volunteers--an oral dose-proportionality investigation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1286128/),h,0.53,72915,DB00145,Glycine
,1286128,Time-to-peak,"Time-to-peak for all three analytes showed a trend to increase with increasing doses of TTPG, being: 0.42, 0.40 and 0.67 h (P < 0.01) with TTPG; 0.53, 0.47 and 0.73 h (P < 0.05) with TCA; and 1.33, 2.13 and 2.58 h (P < 0.01) with tiopronin.",Pharmacokinetics of 2-(alpha-thenoylthio)-propionylglycine (TTPG) in healthy volunteers--an oral dose-proportionality investigation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1286128/),h,0.47,72916,DB00145,Glycine
,1286128,Time-to-peak,"Time-to-peak for all three analytes showed a trend to increase with increasing doses of TTPG, being: 0.42, 0.40 and 0.67 h (P < 0.01) with TTPG; 0.53, 0.47 and 0.73 h (P < 0.05) with TCA; and 1.33, 2.13 and 2.58 h (P < 0.01) with tiopronin.",Pharmacokinetics of 2-(alpha-thenoylthio)-propionylglycine (TTPG) in healthy volunteers--an oral dose-proportionality investigation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1286128/),h,0.73,72917,DB00145,Glycine
,1286128,Time-to-peak,"Time-to-peak for all three analytes showed a trend to increase with increasing doses of TTPG, being: 0.42, 0.40 and 0.67 h (P < 0.01) with TTPG; 0.53, 0.47 and 0.73 h (P < 0.05) with TCA; and 1.33, 2.13 and 2.58 h (P < 0.01) with tiopronin.",Pharmacokinetics of 2-(alpha-thenoylthio)-propionylglycine (TTPG) in healthy volunteers--an oral dose-proportionality investigation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1286128/),h,1.33,72918,DB00145,Glycine
,1286128,Time-to-peak,"Time-to-peak for all three analytes showed a trend to increase with increasing doses of TTPG, being: 0.42, 0.40 and 0.67 h (P < 0.01) with TTPG; 0.53, 0.47 and 0.73 h (P < 0.05) with TCA; and 1.33, 2.13 and 2.58 h (P < 0.01) with tiopronin.",Pharmacokinetics of 2-(alpha-thenoylthio)-propionylglycine (TTPG) in healthy volunteers--an oral dose-proportionality investigation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1286128/),h,2.13,72919,DB00145,Glycine
,1286128,Time-to-peak,"Time-to-peak for all three analytes showed a trend to increase with increasing doses of TTPG, being: 0.42, 0.40 and 0.67 h (P < 0.01) with TTPG; 0.53, 0.47 and 0.73 h (P < 0.05) with TCA; and 1.33, 2.13 and 2.58 h (P < 0.01) with tiopronin.",Pharmacokinetics of 2-(alpha-thenoylthio)-propionylglycine (TTPG) in healthy volunteers--an oral dose-proportionality investigation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1286128/),h,2.58,72920,DB00145,Glycine
,1286128,Cmax,"Cmax showed the opposite behaviour with values (ng ml-1) normalized to the dose of 540 mg: 1235, 905 and 513 (P < 0.001) with TTPG; 888, 547 and 383 (P < 0.001) with TCA; and 7290, 6950 and 5170 (P < 0.01) with tiopronin.",Pharmacokinetics of 2-(alpha-thenoylthio)-propionylglycine (TTPG) in healthy volunteers--an oral dose-proportionality investigation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1286128/),[ng] / [ml],1235,72921,DB00145,Glycine
,1286128,Cmax,"Cmax showed the opposite behaviour with values (ng ml-1) normalized to the dose of 540 mg: 1235, 905 and 513 (P < 0.001) with TTPG; 888, 547 and 383 (P < 0.001) with TCA; and 7290, 6950 and 5170 (P < 0.01) with tiopronin.",Pharmacokinetics of 2-(alpha-thenoylthio)-propionylglycine (TTPG) in healthy volunteers--an oral dose-proportionality investigation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1286128/),[ng] / [ml],905,72922,DB00145,Glycine
,1286128,Cmax,"Cmax showed the opposite behaviour with values (ng ml-1) normalized to the dose of 540 mg: 1235, 905 and 513 (P < 0.001) with TTPG; 888, 547 and 383 (P < 0.001) with TCA; and 7290, 6950 and 5170 (P < 0.01) with tiopronin.",Pharmacokinetics of 2-(alpha-thenoylthio)-propionylglycine (TTPG) in healthy volunteers--an oral dose-proportionality investigation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1286128/),[ng] / [ml],513,72923,DB00145,Glycine
,1286128,Cmax,"Cmax showed the opposite behaviour with values (ng ml-1) normalized to the dose of 540 mg: 1235, 905 and 513 (P < 0.001) with TTPG; 888, 547 and 383 (P < 0.001) with TCA; and 7290, 6950 and 5170 (P < 0.01) with tiopronin.",Pharmacokinetics of 2-(alpha-thenoylthio)-propionylglycine (TTPG) in healthy volunteers--an oral dose-proportionality investigation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1286128/),[ng] / [ml],888,72924,DB00145,Glycine
,1286128,Cmax,"Cmax showed the opposite behaviour with values (ng ml-1) normalized to the dose of 540 mg: 1235, 905 and 513 (P < 0.001) with TTPG; 888, 547 and 383 (P < 0.001) with TCA; and 7290, 6950 and 5170 (P < 0.01) with tiopronin.",Pharmacokinetics of 2-(alpha-thenoylthio)-propionylglycine (TTPG) in healthy volunteers--an oral dose-proportionality investigation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1286128/),[ng] / [ml],547,72925,DB00145,Glycine
,1286128,Cmax,"Cmax showed the opposite behaviour with values (ng ml-1) normalized to the dose of 540 mg: 1235, 905 and 513 (P < 0.001) with TTPG; 888, 547 and 383 (P < 0.001) with TCA; and 7290, 6950 and 5170 (P < 0.01) with tiopronin.",Pharmacokinetics of 2-(alpha-thenoylthio)-propionylglycine (TTPG) in healthy volunteers--an oral dose-proportionality investigation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1286128/),[ng] / [ml],383,72926,DB00145,Glycine
,1286128,Cmax,"Cmax showed the opposite behaviour with values (ng ml-1) normalized to the dose of 540 mg: 1235, 905 and 513 (P < 0.001) with TTPG; 888, 547 and 383 (P < 0.001) with TCA; and 7290, 6950 and 5170 (P < 0.01) with tiopronin.",Pharmacokinetics of 2-(alpha-thenoylthio)-propionylglycine (TTPG) in healthy volunteers--an oral dose-proportionality investigation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1286128/),[ng] / [ml],7290,72927,DB00145,Glycine
,1286128,Cmax,"Cmax showed the opposite behaviour with values (ng ml-1) normalized to the dose of 540 mg: 1235, 905 and 513 (P < 0.001) with TTPG; 888, 547 and 383 (P < 0.001) with TCA; and 7290, 6950 and 5170 (P < 0.01) with tiopronin.",Pharmacokinetics of 2-(alpha-thenoylthio)-propionylglycine (TTPG) in healthy volunteers--an oral dose-proportionality investigation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1286128/),[ng] / [ml],6950,72928,DB00145,Glycine
,1286128,Cmax,"Cmax showed the opposite behaviour with values (ng ml-1) normalized to the dose of 540 mg: 1235, 905 and 513 (P < 0.001) with TTPG; 888, 547 and 383 (P < 0.001) with TCA; and 7290, 6950 and 5170 (P < 0.01) with tiopronin.",Pharmacokinetics of 2-(alpha-thenoylthio)-propionylglycine (TTPG) in healthy volunteers--an oral dose-proportionality investigation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1286128/),[ng] / [ml],5170,72929,DB00145,Glycine
,25377318,Ka,"Ixazomib was absorbed rapidly (Ka 0.5 h(-1)), with dose- and time-independent pharmacokinetics.",Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25377318/),1/[h],0.5,73569,DB00145,Glycine
,25377318,absolute bioavailability,"Estimated absolute bioavailability and clearance were 60% and 2l h(-1), respectively.",Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25377318/),%,60,73570,DB00145,Glycine
,25377318,clearance,"Estimated absolute bioavailability and clearance were 60% and 2l h(-1), respectively.",Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25377318/),[l] / [h],2,73571,DB00145,Glycine
,33486718,apparent clearance,"A two-compartment model with first-order absorption adequately described roxadustat pharmacokinetics, with parameter estimates (relative standard error) for apparent clearance of 1.1 (0.0223) L/h in NDD subjects, and apparent central and peripheral volumes of distribution of 14.9 (0.0278) L and 9.5 (0.0872) L, respectively.",Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33486718/),[l] / [h],1.1,74526,DB00145,Glycine
,33486718,apparent central,"A two-compartment model with first-order absorption adequately described roxadustat pharmacokinetics, with parameter estimates (relative standard error) for apparent clearance of 1.1 (0.0223) L/h in NDD subjects, and apparent central and peripheral volumes of distribution of 14.9 (0.0278) L and 9.5 (0.0872) L, respectively.",Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33486718/),l,14.9,74527,DB00145,Glycine
,33486718,peripheral volumes of distribution,"A two-compartment model with first-order absorption adequately described roxadustat pharmacokinetics, with parameter estimates (relative standard error) for apparent clearance of 1.1 (0.0223) L/h in NDD subjects, and apparent central and peripheral volumes of distribution of 14.9 (0.0278) L and 9.5 (0.0872) L, respectively.",Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33486718/),l,9.5,74528,DB00145,Glycine
,18644951,elimination half-lives,"Unchanged doripenem and doripenem-M-1 accounted for means of 80.7% and 12.7% of the area under the plasma total-radioactivity-versus-time curve (area under the concentration-time curve extrapolated to infinity) and exhibited elimination half-lives of 1.1 and 2.5 h, respectively.","Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18644951/),h,1.1,75942,DB00145,Glycine
,18644951,elimination half-lives,"Unchanged doripenem and doripenem-M-1 accounted for means of 80.7% and 12.7% of the area under the plasma total-radioactivity-versus-time curve (area under the concentration-time curve extrapolated to infinity) and exhibited elimination half-lives of 1.1 and 2.5 h, respectively.","Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18644951/),h,2.5,75943,DB00145,Glycine
,18644951,Total clearance,"Total clearance of doripenem was 16 liters/h, and renal clearance was 12.5 liters/h.","Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18644951/),[l] / [h],16,75944,DB00145,Glycine
,18644951,renal clearance,"Total clearance of doripenem was 16 liters/h, and renal clearance was 12.5 liters/h.","Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18644951/),[l] / [h],12.5,75945,DB00145,Glycine
,9145216,bioavailability,"When ONO-5046 solution was administered into the whole intestine via the bile duct at a dose of 5 mumol/rat, the extent of bioavailability was only 1.5%.","First-pass metabolism of ONO-5046 (N-[2-[4-(2,2-dimethylpropionyloxy) phenylsulfonylamino]benzoyl]aminoacetic acid), a novel elastase inhibitor, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145216/),%,1.5,76172,DB00145,Glycine
,9145216,recovery percentage,"The recovery percentage of ONO-5046 in the mesenteric plasma was small (2.58 +/- 0.04% at a dose of 1 mumol/rat), and the remaining ONO-5046 recovered in the mesenteric plasma and in the intestinal loop was a metabolite of ONO-5046 (El-601, N-[2-[(4-hydroxyphenyl)sulfonylamino]benzoyl]amino-acetic acid).","First-pass metabolism of ONO-5046 (N-[2-[4-(2,2-dimethylpropionyloxy) phenylsulfonylamino]benzoyl]aminoacetic acid), a novel elastase inhibitor, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145216/),%,2.58,76173,DB00145,Glycine
,15813033,Mw,In vitro drug release experiments were carried out with a dialysis bag (Mw cut-off 12000 - 14000).,[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),,12000 - 14000,76690,DB00145,Glycine
,15813033,particle size,"The particle size of liposomes with glycinate buffer, citrate buffer and ammonium sulfate as the inner water phase were (103 +/- 8), (102 +/- 12) and (97 +/- 8) nm.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),,103,76691,DB00145,Glycine
,15813033,particle size,"The particle size of liposomes with glycinate buffer, citrate buffer and ammonium sulfate as the inner water phase were (103 +/- 8), (102 +/- 12) and (97 +/- 8) nm.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),,102,76692,DB00145,Glycine
,15813033,particle size,"The particle size of liposomes with glycinate buffer, citrate buffer and ammonium sulfate as the inner water phase were (103 +/- 8), (102 +/- 12) and (97 +/- 8) nm.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),,97,76693,DB00145,Glycine
,15813033,zeta potential,"The zeta potential and the encapsulation ratio were (-21.3 +/- 0.5), (-21.7 +/- 0.4), (-20.9 +/- 0.7) mV and 47.8%, 96.7%, 98.6%, respectively.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),m,21.3,76694,DB00145,Glycine
,15813033,encapsulation ratio,"The zeta potential and the encapsulation ratio were (-21.3 +/- 0.5), (-21.7 +/- 0.4), (-20.9 +/- 0.7) mV and 47.8%, 96.7%, 98.6%, respectively.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),m,21.7,76695,DB00145,Glycine
,15813033,encapsulation ratio,"The zeta potential and the encapsulation ratio were (-21.3 +/- 0.5), (-21.7 +/- 0.4), (-20.9 +/- 0.7) mV and 47.8%, 96.7%, 98.6%, respectively.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),m,20.9,76696,DB00145,Glycine
,15813033,encapsulation ratio,"The zeta potential and the encapsulation ratio were (-21.3 +/- 0.5), (-21.7 +/- 0.4), (-20.9 +/- 0.7) mV and 47.8%, 96.7%, 98.6%, respectively.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),%,47.8,76697,DB00145,Glycine
,15813033,encapsulation ratio,"The zeta potential and the encapsulation ratio were (-21.3 +/- 0.5), (-21.7 +/- 0.4), (-20.9 +/- 0.7) mV and 47.8%, 96.7%, 98.6%, respectively.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),,96,76698,DB00145,Glycine
,15813033,MRT (mean retention time),"Pharmacokinetic study showed that the MRT (mean retention time) of liposomes with glycinate buffer, citrate buffer and ammonium sulfate as the inner water phase were 12.13, 23.31 and 29.79 h, respectively.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),h,12.13,76699,DB00145,Glycine
,15813033,MRT (mean retention time),"Pharmacokinetic study showed that the MRT (mean retention time) of liposomes with glycinate buffer, citrate buffer and ammonium sulfate as the inner water phase were 12.13, 23.31 and 29.79 h, respectively.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),h,23.31,76700,DB00145,Glycine
,15813033,MRT (mean retention time),"Pharmacokinetic study showed that the MRT (mean retention time) of liposomes with glycinate buffer, citrate buffer and ammonium sulfate as the inner water phase were 12.13, 23.31 and 29.79 h, respectively.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),h,29.79,76701,DB00145,Glycine
,30080045,ED50,"In an in vivo efficacy model (7 S,8 R)-27a, dose-dependently reversed L-687,414 induced hyperlocomotion in mice with an ED50 of 0.8 mg/kg.",Discovery of Novel Aminotetralines and Aminochromanes as Selective and Competitive Glycine Transporter 1 (GlyT1) Inhibitors. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30080045/),[mg] / [kg],0.8,79044,DB00145,Glycine
,15545085,elimination half-life,"While the conventional liposomes had a short elimination half-life (28 min), the liposomes modified with library-PE had a much longer half-life (170 min), while library-SA provided no improvement of the liposome pharmacokinetics.",Novel long-circulating liposomes containing peptide library-lipid conjugates: synthesis and in vivo behavior. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15545085/),min,28,79458,DB00145,Glycine
,15545085,half-life,"While the conventional liposomes had a short elimination half-life (28 min), the liposomes modified with library-PE had a much longer half-life (170 min), while library-SA provided no improvement of the liposome pharmacokinetics.",Novel long-circulating liposomes containing peptide library-lipid conjugates: synthesis and in vivo behavior. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15545085/),min,170,79459,DB00145,Glycine
,15545085,half-life,PEG-PE greatly improved the half-life of the liposomes (400 min) while PEG-SA only provided a marginal improvement.,Novel long-circulating liposomes containing peptide library-lipid conjugates: synthesis and in vivo behavior. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15545085/),min,400,79460,DB00145,Glycine
,8626044,half-lives,"The elimination in plasma after bolus injection was biexponential, the half-lives being 4.1 +/- 0.2 and 21.8 +/- 0.9 min, and clearance and apparent volume of distribution being 7.9 +/- 0.6 ml/kg/min and 69.5 +/- 2.7 ml/kg, respectively.",Metabolism and influence of glycine-extended gastrin on gastric acid secretion in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626044/),min,4.1,80607,DB00145,Glycine
,8626044,half-lives,"The elimination in plasma after bolus injection was biexponential, the half-lives being 4.1 +/- 0.2 and 21.8 +/- 0.9 min, and clearance and apparent volume of distribution being 7.9 +/- 0.6 ml/kg/min and 69.5 +/- 2.7 ml/kg, respectively.",Metabolism and influence of glycine-extended gastrin on gastric acid secretion in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626044/),min,21.8,80608,DB00145,Glycine
,8626044,clearance,"The elimination in plasma after bolus injection was biexponential, the half-lives being 4.1 +/- 0.2 and 21.8 +/- 0.9 min, and clearance and apparent volume of distribution being 7.9 +/- 0.6 ml/kg/min and 69.5 +/- 2.7 ml/kg, respectively.",Metabolism and influence of glycine-extended gastrin on gastric acid secretion in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626044/),[ml] / [kg·min],7.9,80609,DB00145,Glycine
,8626044,apparent volume of distribution,"The elimination in plasma after bolus injection was biexponential, the half-lives being 4.1 +/- 0.2 and 21.8 +/- 0.9 min, and clearance and apparent volume of distribution being 7.9 +/- 0.6 ml/kg/min and 69.5 +/- 2.7 ml/kg, respectively.",Metabolism and influence of glycine-extended gastrin on gastric acid secretion in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626044/),[ml] / [kg],69.5,80610,DB00145,Glycine
,8865318,absolute bioavailability,The absolute bioavailability of the peptide after buccal delivery for 4 hours could be increased from 1.0 +/- 0.3 to 5.3 +/- 1.1% (mean +/- SD.) by co-administration of 10 mM GDC (0.45% w/v)).,In vivo buccal delivery of the peptide drug buserelin with glycodeoxycholate as an absorption enhancer in pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865318/),%,1.0,81837,DB00145,Glycine
,8865318,absolute bioavailability,The absolute bioavailability of the peptide after buccal delivery for 4 hours could be increased from 1.0 +/- 0.3 to 5.3 +/- 1.1% (mean +/- SD.) by co-administration of 10 mM GDC (0.45% w/v)).,In vivo buccal delivery of the peptide drug buserelin with glycodeoxycholate as an absorption enhancer in pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865318/),%,5.3,81838,DB00145,Glycine
,33493392,ΔQTcF),The plasma ivosidenib concentration-QT analysis showed a mean change in QTc using Fridericia's method (ΔQTcF) of 17.2 msec at the approved 500 mg q.d. dose.,Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33493392/),ms,17.2,83048,DB00145,Glycine
,18083074,flow rate,"The mobile phase was a mixture of 0.05 M phosphate buffer with the pH adjusted to 2.6 and acetonitrile (74:26, v/v) at a flow rate of 1.0 mL/min.","A rapid and validated HPLC method to quantify racecadotril metabolite, thiorphan, in human plasma using solid-phase extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18083074/),[ml] / [min],1.0,83295,DB00145,Glycine
,18083074,extraction recovery,"The extraction recovery for plasma samples of thiorphan at 0.1, 0.4 and 2.0 microg/mL was 93.5%, 98.2% and 97.8%, respectively.","A rapid and validated HPLC method to quantify racecadotril metabolite, thiorphan, in human plasma using solid-phase extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18083074/),%,93.5,83296,DB00145,Glycine
,18083074,extraction recovery,"The extraction recovery for plasma samples of thiorphan at 0.1, 0.4 and 2.0 microg/mL was 93.5%, 98.2% and 97.8%, respectively.","A rapid and validated HPLC method to quantify racecadotril metabolite, thiorphan, in human plasma using solid-phase extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18083074/),%,98.2,83297,DB00145,Glycine
,18083074,extraction recovery,"The extraction recovery for plasma samples of thiorphan at 0.1, 0.4 and 2.0 microg/mL was 93.5%, 98.2% and 97.8%, respectively.","A rapid and validated HPLC method to quantify racecadotril metabolite, thiorphan, in human plasma using solid-phase extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18083074/),%,97.8,83298,DB00145,Glycine
,3680588,peak concentration,"The mean peak concentration of aspirin was 6.5 micrograms/mL in plasma (range, 4.9-8.9 micrograms/mL), reached in 26 minutes (range, 13-33 minutes).",Disposition of aspirin and its metabolites in the semen of man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680588/),[μg] / [ml],6.5,85256,DB00145,Glycine
,3680588,half-life,The half-life of aspirin was 31 minutes.,Disposition of aspirin and its metabolites in the semen of man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680588/),min,31,85257,DB00145,Glycine
,3680588,peak concentration,"The mean peak concentration of salicylate in plasma was 49 micrograms/mL (range, 42-62 micrograms/mL), reached in 2.5 hours (range, 2.0-2.8 hours).",Disposition of aspirin and its metabolites in the semen of man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680588/),[μg] / [ml],49,85258,DB00145,Glycine
,3680588,concentration ratio,Salicylate distributed rapidly into semen and maintained a concentration ratio (semen/plasma) of 0.15.,Disposition of aspirin and its metabolites in the semen of man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680588/),,0.15,85259,DB00145,Glycine
,26341813,AUC0-inf ratios,"The predicted AUC0-inf ratios for the interaction with ketoconazole and erythromycin were 7.7 and 1.9, respectively.",Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26341813/),,7.7,87366,DB00145,Glycine
,26341813,AUC0-inf ratios,"The predicted AUC0-inf ratios for the interaction with ketoconazole and erythromycin were 7.7 and 1.9, respectively.",Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26341813/),,1.9,87367,DB00145,Glycine
,17238815,Elimination half-life,Elimination half-life of regenerated GCV from YVGCV administration was observed to be 157 min.,Corneal absorption and anterior chamber pharmacokinetics of dipeptide monoester prodrugs of ganciclovir (GCV): in vivo comparative evaluation of these prodrugs with Val-GCV and GCV in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17238815/),min,157,87634,DB00145,Glycine
,17162469,absolute oral bioavailability,"In the mouse, rat, and monkey the absolute oral bioavailability of muraglitazar ranged from 64 to 88%, and in the dog oral bioavailability was approximately 18%.","Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17162469/),%,64 to 88,87747,DB00145,Glycine
,17162469,oral bioavailability,"In the mouse, rat, and monkey the absolute oral bioavailability of muraglitazar ranged from 64 to 88%, and in the dog oral bioavailability was approximately 18%.","Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17162469/),%,18,87748,DB00145,Glycine
,17162469,systemic clearance,"The systemic clearance values of muraglitazar in the mouse, rat, dog, and cynomolgus monkey were 1.2, 3.0, 12.3 and 1.2 ml min-1 kg-1, respectively.","Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17162469/),[ml] / [kg·min],1.2,87749,DB00145,Glycine
,17162469,systemic clearance,"The systemic clearance values of muraglitazar in the mouse, rat, dog, and cynomolgus monkey were 1.2, 3.0, 12.3 and 1.2 ml min-1 kg-1, respectively.","Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17162469/),[ml] / [kg·min],3.0,87750,DB00145,Glycine
,17162469,systemic clearance,"The systemic clearance values of muraglitazar in the mouse, rat, dog, and cynomolgus monkey were 1.2, 3.0, 12.3 and 1.2 ml min-1 kg-1, respectively.","Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17162469/),[ml] / [kg·min],12.3,87751,DB00145,Glycine
,17162469,terminal elimination half-life,The terminal elimination half-life was 2.4 h in dogs and 7.3 h in rats.,"Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17162469/),h,2.4,87752,DB00145,Glycine
,17162469,terminal elimination half-life,The terminal elimination half-life was 2.4 h in dogs and 7.3 h in rats.,"Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17162469/),h,7.3,87753,DB00145,Glycine
,17162469,systemic plasma clearance,The systemic plasma clearance of muraglitazar in humans was predicted to be approximately 12-14 ml min-1 kg-1 based on allometry or by scaling of in vitro clearance parameters.,"Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17162469/),[ml] / [kg·min],12-14,87754,DB00145,Glycine
,9367208,recovery,Mean recovery of these compounds from plasma averages 75%.,"Isolation of N,N-dialkylated derivatives of valproylglycinamide from dog plasma by active charcoal adsorption and their quantification by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9367208/),%,75,88544,DB00145,Glycine
,20845455,t(1/2),"The in vivo elimination of N-Gly-CBZ following IV administration in rats was biphasic in nature with a t(1/2) of about 1.1 min, which was very similar to the t(1/2) for appearance of CBZ.",In vitro and in vivo evaluation of a novel water-soluble N-glycyl prodrug (N-GLY-CBZ) of carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845455/),min,1.1,88889,DB00145,Glycine
,20845455,relative AUC ratio,The mean value for the relative AUC ratio for CBZ from N-Gly-CBZ and CBZ from a cyclodextrin solution showed that N-Gly-CBZ delivered a (± SD) 98 ± 16% (± SD) equivalent dose of CBZ in six rats.,In vitro and in vivo evaluation of a novel water-soluble N-glycyl prodrug (N-GLY-CBZ) of carbamazepine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845455/),,98,88890,DB00145,Glycine
,20845455,overall absolute oral bioavailability,The overall absolute oral bioavailability of CBZ from N-Gly-CBZ was determined to be 41 ± 14% in three rats.,In vitro and in vivo evaluation of a novel water-soluble N-glycyl prodrug (N-GLY-CBZ) of carbamazepine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845455/),%,41,88891,DB00145,Glycine
,20845455,relative oral bioavailability,The relative oral bioavailability of CBZ from N-Gly-CBZ compared to an oral CBZ control was 1.72 ± 0.54.,In vitro and in vivo evaluation of a novel water-soluble N-glycyl prodrug (N-GLY-CBZ) of carbamazepine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845455/),,1.72,88892,DB00145,Glycine
,32959915,recovery,"The mean recovery was 82.16%, with 2.38 and 79.78% of the radioactive dose excreted in urine and faeces, respectively.","Metabolic disposition of [14 C]-abivertinib, an epidermal growth factor receptor tyrosine kinase inhibitor: Role of glutathione conjugation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959915/),%,82.16,89201,DB00145,Glycine
,32959915,recovery,"The mean recovery was 82.16%, with 2.38 and 79.78% of the radioactive dose excreted in urine and faeces, respectively.","Metabolic disposition of [14 C]-abivertinib, an epidermal growth factor receptor tyrosine kinase inhibitor: Role of glutathione conjugation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959915/),%,2.38,89202,DB00145,Glycine
,32959915,recovery,"The mean recovery was 82.16%, with 2.38 and 79.78% of the radioactive dose excreted in urine and faeces, respectively.","Metabolic disposition of [14 C]-abivertinib, an epidermal growth factor receptor tyrosine kinase inhibitor: Role of glutathione conjugation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959915/),%,79.78,89203,DB00145,Glycine
,16616769,t(1/2),"Both the uncompetitive NMDA antagonist ketamine and the glycine(B) antagonist MRZ 2/576 inhibited neuronal responses to iontophoretic NMDA in anaesthetised rats with the time course consistent with their known pharmacokinetics (t(1/2) approximately 10-12min, similar in control and nerve-injured rats).",The antiallodynic effect of NMDA antagonists in neuropathic pain outlasts the duration of the in vivo NMDA antagonism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16616769/),min,10-12,90636,DB00145,Glycine
,2970910,time to reach peak concentration,"Nafarelin, a potent gonadotropin-releasing hormone (GnRH) agonist, was absorbed rapidly into systemic circulation (time to reach peak concentration, 20 to 40 minutes) after intranasal but not after sublingual or vaginal administration.","Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2970910/),min,20 to 40,90804,DB00145,Glycine
,2970910,Serum elimination half-life,Serum elimination half-life was about 2 hours.,"Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2970910/),h,2,90805,DB00145,Glycine
,2970910,Bioavailability,Bioavailability of this nasal formulation relative to a single subcutaneous dose averaged 21%.,"Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2970910/),%,21,90806,DB00145,Glycine
,19568235,shedding,There was no apparent PK interaction and the shedding of soluble TNF-receptors did not increase to 0.8 microg m(-2).,"Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19568235/),[μg] / [(m)^2],0.8,91527,DB00145,Glycine
,3145331,elimination t1/2,Both peptides were rapidly cleared from plasma (estimated elimination t1/2: 4 min for the glycyl peptide and less than 2 min for the alanyl peptide).,In vivo utilization of cystine-containing synthetic short-chain peptides after intravenous bolus injection in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145331/),min,4,91528,DB00145,Glycine
less,3145331,elimination t1/2,Both peptides were rapidly cleared from plasma (estimated elimination t1/2: 4 min for the glycyl peptide and less than 2 min for the alanyl peptide).,In vivo utilization of cystine-containing synthetic short-chain peptides after intravenous bolus injection in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145331/),min,2,91529,DB00145,Glycine
,7467395,apparent half-life,"(182 +/- 65, range 85-221 micrograms equiv./ml) at 1-1.5 h after an oral dose, and declined rapidly with an apparent half-life of about 0.5 h.",The metabolic fate of tizoprolique acid in baboons. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7467395/),h,0.5,91869,DB00145,Glycine
,14640546,IC(50),"The structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones revealed an optimal R9 substitution with ethoxymethyl 19 (VEGF-R2 IC(50) = 4 nM) and isopropoxymethyl 21 (VEGF-R2 IC(50) = 8 nM) being the most potent inhibitors in the series.","A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14640546/),nM,4,91951,DB00145,Glycine
,14640546,IC(50),"The structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones revealed an optimal R9 substitution with ethoxymethyl 19 (VEGF-R2 IC(50) = 4 nM) and isopropoxymethyl 21 (VEGF-R2 IC(50) = 8 nM) being the most potent inhibitors in the series.","A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14640546/),nM,8,91952,DB00145,Glycine
,14640546,IC(50),"Compound 21 (R9 isopropoxymethyl, CEP-5214) was identified as a potent, low-nanomolar pan inhibitor of human VEGF-R tyrosine kinases, displaying IC(50) values of 16, 8, and 4 nM for VEGF-R1/FLT-1, VEGF-R2/KDR, and VEGF-R3/FLT-4, respectively, with cellular activity equivalent to the isolated enzyme activity.","A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14640546/),nM,16,91953,DB00145,Glycine
,14640546,IC(50),"Compound 21 (R9 isopropoxymethyl, CEP-5214) was identified as a potent, low-nanomolar pan inhibitor of human VEGF-R tyrosine kinases, displaying IC(50) values of 16, 8, and 4 nM for VEGF-R1/FLT-1, VEGF-R2/KDR, and VEGF-R3/FLT-4, respectively, with cellular activity equivalent to the isolated enzyme activity.","A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14640546/),nM,8,91954,DB00145,Glycine
,14640546,IC(50),"Compound 21 (R9 isopropoxymethyl, CEP-5214) was identified as a potent, low-nanomolar pan inhibitor of human VEGF-R tyrosine kinases, displaying IC(50) values of 16, 8, and 4 nM for VEGF-R1/FLT-1, VEGF-R2/KDR, and VEGF-R3/FLT-4, respectively, with cellular activity equivalent to the isolated enzyme activity.","A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14640546/),nM,4,91955,DB00145,Glycine
,29869307,responses,"The optimized formulation's responses were 0.30%, 3.4 kg, and 6.12 s for Y1, Y2, and Y3, respectively.",Preparation and Optimization of Fast-Disintegrating Tablet Containing Naratriptan Hydrochloride Using D-Optimal Mixture Design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29869307/),%,0.30,94296,DB00145,Glycine
,29869307,responses,"The optimized formulation's responses were 0.30%, 3.4 kg, and 6.12 s for Y1, Y2, and Y3, respectively.",Preparation and Optimization of Fast-Disintegrating Tablet Containing Naratriptan Hydrochloride Using D-Optimal Mixture Design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29869307/),kg,3.4,94297,DB00145,Glycine
,29869307,responses,"The optimized formulation's responses were 0.30%, 3.4 kg, and 6.12 s for Y1, Y2, and Y3, respectively.",Preparation and Optimization of Fast-Disintegrating Tablet Containing Naratriptan Hydrochloride Using D-Optimal Mixture Design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29869307/),s,6.12,94298,DB00145,Glycine
,9459334,inhibition constant (Ki),"The potent inhibition of thrombin by melagatran was demonstrated by a low inhibition constant (Ki) for thrombin (0.002 micromol/l) and prolongation of clotting time to twice the control value in coagulation assays at low concentrations (0.010, 0.59 and 2.2 micromol/l for thrombin time, activated partial thromboplastin time and prothrombin time, respectively).","Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459334/),[μM] / [l],0.002,97012,DB00145,Glycine
,9459334,IC50,"Furthermore, thrombin-induced platelet aggregation was inhibited at the same concentration (IC50-value 0.002 micromol/l) as the Ki-value for thrombin.","Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459334/),[μM] / [l],0.002,97013,DB00145,Glycine
<,15527823,half-life,The short half-life (<2 min) in blood was subsequently associated with modest and inconsistent neuroprotection.,"Neuroprotective effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate (GPE) following intravenous infusion in hypoxic-ischemic adult rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15527823/),min,2,97069,DB00145,Glycine
,18955447,distribution half-life,"Na pharmacokinetics were characterized by a rapid distribution phase (distribution half-life, 1 hour) and a relatively slow elimination phase (elimination half-life, 27 hours).","Phase I study of ON 01910. Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18955447/),h,1,98965,DB00145,Glycine
,18955447,elimination half-life,"Na pharmacokinetics were characterized by a rapid distribution phase (distribution half-life, 1 hour) and a relatively slow elimination phase (elimination half-life, 27 hours).","Phase I study of ON 01910. Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18955447/),h,27,98966,DB00145,Glycine
,12851531,IC(50),"The ETP IC(50) values for melagatran and the low-molecular-weight heparin dalteparin were 0.44 micromol/l and 0.06 IU/ml, respectively.","Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851531/),[μM] / [l],0.44,99817,DB00145,Glycine
,12851531,IC(50),"The ETP IC(50) values for melagatran and the low-molecular-weight heparin dalteparin were 0.44 micromol/l and 0.06 IU/ml, respectively.","Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851531/),[iu] / [ml],0.06,99818,DB00145,Glycine
,24877651,Tmax,"Single dose intraperitoneal application of ornithine in wild-type mice lead to fast ornithine uptake (Tmax ≤ 10 min) and elimination (T1/2=24 min), and a decline of guanidinoacetate.","Stable isotope dilution microquantification of creatine metabolites in plasma, whole blood and dried blood spots for pharmacological studies in mouse models of creatine deficiency. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24877651/),min,10,100129,DB00145,Glycine
,24877651,T1/2,"Single dose intraperitoneal application of ornithine in wild-type mice lead to fast ornithine uptake (Tmax ≤ 10 min) and elimination (T1/2=24 min), and a decline of guanidinoacetate.","Stable isotope dilution microquantification of creatine metabolites in plasma, whole blood and dried blood spots for pharmacological studies in mouse models of creatine deficiency. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24877651/),min,24,100130,DB00145,Glycine
larger,6117443,Tissue/blood ratios of radioactivity concentration,"Tissue/blood ratios of radioactivity concentration in most of the rat tissues were much larger than 1.0, indicating that TP has a high affinity for the tissues.","Disposition and metabolism of timiperone in the rat, dog, and monkey. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6117443/),,1.0,100500,DB00145,Glycine
,19726314,t(max),"ml(-1)) 3.612-/+1.2393 (R), 3.644-/+1.540 (T); t(max) 4.333-/+1.0853 (R), 3.611-/+1.420 (T); t((1/2))(h) 18.245-/+11.270 (R), 23.403-/+10.500 (T); AUC0-t (microg.h.ml(-1)) 18.732-/+6.92318 (R), 18.713-/+6.585 (T); AUC0-infinity (microg.h.ml(-1)) 21.900-/+7.31220 (R), 20.780-/+7.965 (T).",[Bioequivalence of tiopronin enteric capsules in healthy volunteers]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726314/),,4.333,101176,DB00145,Glycine
,19726314,t(max),"ml(-1)) 3.612-/+1.2393 (R), 3.644-/+1.540 (T); t(max) 4.333-/+1.0853 (R), 3.611-/+1.420 (T); t((1/2))(h) 18.245-/+11.270 (R), 23.403-/+10.500 (T); AUC0-t (microg.h.ml(-1)) 18.732-/+6.92318 (R), 18.713-/+6.585 (T); AUC0-infinity (microg.h.ml(-1)) 21.900-/+7.31220 (R), 20.780-/+7.965 (T).",[Bioequivalence of tiopronin enteric capsules in healthy volunteers]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726314/),,3.611,101177,DB00145,Glycine
,19726314,t((1/2)),"ml(-1)) 3.612-/+1.2393 (R), 3.644-/+1.540 (T); t(max) 4.333-/+1.0853 (R), 3.611-/+1.420 (T); t((1/2))(h) 18.245-/+11.270 (R), 23.403-/+10.500 (T); AUC0-t (microg.h.ml(-1)) 18.732-/+6.92318 (R), 18.713-/+6.585 (T); AUC0-infinity (microg.h.ml(-1)) 21.900-/+7.31220 (R), 20.780-/+7.965 (T).",[Bioequivalence of tiopronin enteric capsules in healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726314/),h,18.245,101178,DB00145,Glycine
,19726314,t((1/2)),"ml(-1)) 3.612-/+1.2393 (R), 3.644-/+1.540 (T); t(max) 4.333-/+1.0853 (R), 3.611-/+1.420 (T); t((1/2))(h) 18.245-/+11.270 (R), 23.403-/+10.500 (T); AUC0-t (microg.h.ml(-1)) 18.732-/+6.92318 (R), 18.713-/+6.585 (T); AUC0-infinity (microg.h.ml(-1)) 21.900-/+7.31220 (R), 20.780-/+7.965 (T).",[Bioequivalence of tiopronin enteric capsules in healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726314/),h,23.403,101179,DB00145,Glycine
,19726314,AUC0-t,"ml(-1)) 3.612-/+1.2393 (R), 3.644-/+1.540 (T); t(max) 4.333-/+1.0853 (R), 3.611-/+1.420 (T); t((1/2))(h) 18.245-/+11.270 (R), 23.403-/+10.500 (T); AUC0-t (microg.h.ml(-1)) 18.732-/+6.92318 (R), 18.713-/+6.585 (T); AUC0-infinity (microg.h.ml(-1)) 21.900-/+7.31220 (R), 20.780-/+7.965 (T).",[Bioequivalence of tiopronin enteric capsules in healthy volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726314/),[h·μg] / [ml],18.732,101180,DB00145,Glycine
,19726314,AUC0-t,"ml(-1)) 3.612-/+1.2393 (R), 3.644-/+1.540 (T); t(max) 4.333-/+1.0853 (R), 3.611-/+1.420 (T); t((1/2))(h) 18.245-/+11.270 (R), 23.403-/+10.500 (T); AUC0-t (microg.h.ml(-1)) 18.732-/+6.92318 (R), 18.713-/+6.585 (T); AUC0-infinity (microg.h.ml(-1)) 21.900-/+7.31220 (R), 20.780-/+7.965 (T).",[Bioequivalence of tiopronin enteric capsules in healthy volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726314/),[h·μg] / [ml],18.713,101181,DB00145,Glycine
,19726314,AUC0-infinity,"ml(-1)) 3.612-/+1.2393 (R), 3.644-/+1.540 (T); t(max) 4.333-/+1.0853 (R), 3.611-/+1.420 (T); t((1/2))(h) 18.245-/+11.270 (R), 23.403-/+10.500 (T); AUC0-t (microg.h.ml(-1)) 18.732-/+6.92318 (R), 18.713-/+6.585 (T); AUC0-infinity (microg.h.ml(-1)) 21.900-/+7.31220 (R), 20.780-/+7.965 (T).",[Bioequivalence of tiopronin enteric capsules in healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726314/),[h·μg] / [ml],21.900,101182,DB00145,Glycine
,19726314,AUC0-infinity,"ml(-1)) 3.612-/+1.2393 (R), 3.644-/+1.540 (T); t(max) 4.333-/+1.0853 (R), 3.611-/+1.420 (T); t((1/2))(h) 18.245-/+11.270 (R), 23.403-/+10.500 (T); AUC0-t (microg.h.ml(-1)) 18.732-/+6.92318 (R), 18.713-/+6.585 (T); AUC0-infinity (microg.h.ml(-1)) 21.900-/+7.31220 (R), 20.780-/+7.965 (T).",[Bioequivalence of tiopronin enteric capsules in healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726314/),[h·μg] / [ml],20.780,101183,DB00145,Glycine
,19726314,relative bioavailability,"The relative bioavailability of tiopronin enteric capsule was 103.712-/+23.956%, with 90% confidential intervals of ln(AUC0-->72), ln(AUC0-infinity) and ln(C(max)) of 91.1%-111.8%, 96.8%-118.3%, and 85.1%-113.0%, respectively.",[Bioequivalence of tiopronin enteric capsules in healthy volunteers]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726314/),%,103.712,101184,DB00145,Glycine
,19726314,relative bioavailability,"The relative bioavailability of tiopronin enteric capsule was 103.712-/+23.956%, with 90% confidential intervals of ln(AUC0-->72), ln(AUC0-infinity) and ln(C(max)) of 91.1%-111.8%, 96.8%-118.3%, and 85.1%-113.0%, respectively.",[Bioequivalence of tiopronin enteric capsules in healthy volunteers]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726314/),%,91.1,101185,DB00145,Glycine
,19726314,relative bioavailability,"The relative bioavailability of tiopronin enteric capsule was 103.712-/+23.956%, with 90% confidential intervals of ln(AUC0-->72), ln(AUC0-infinity) and ln(C(max)) of 91.1%-111.8%, 96.8%-118.3%, and 85.1%-113.0%, respectively.",[Bioequivalence of tiopronin enteric capsules in healthy volunteers]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726314/),%,111,101186,DB00145,Glycine
,19726314,relative bioavailability,"The relative bioavailability of tiopronin enteric capsule was 103.712-/+23.956%, with 90% confidential intervals of ln(AUC0-->72), ln(AUC0-infinity) and ln(C(max)) of 91.1%-111.8%, 96.8%-118.3%, and 85.1%-113.0%, respectively.",[Bioequivalence of tiopronin enteric capsules in healthy volunteers]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726314/),%,96.8,101187,DB00145,Glycine
,19726314,relative bioavailability,"The relative bioavailability of tiopronin enteric capsule was 103.712-/+23.956%, with 90% confidential intervals of ln(AUC0-->72), ln(AUC0-infinity) and ln(C(max)) of 91.1%-111.8%, 96.8%-118.3%, and 85.1%-113.0%, respectively.",[Bioequivalence of tiopronin enteric capsules in healthy volunteers]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726314/),%,118,101188,DB00145,Glycine
,19726314,relative bioavailability,"The relative bioavailability of tiopronin enteric capsule was 103.712-/+23.956%, with 90% confidential intervals of ln(AUC0-->72), ln(AUC0-infinity) and ln(C(max)) of 91.1%-111.8%, 96.8%-118.3%, and 85.1%-113.0%, respectively.",[Bioequivalence of tiopronin enteric capsules in healthy volunteers]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726314/),%,85.1,101189,DB00145,Glycine
,19726314,relative bioavailability,"The relative bioavailability of tiopronin enteric capsule was 103.712-/+23.956%, with 90% confidential intervals of ln(AUC0-->72), ln(AUC0-infinity) and ln(C(max)) of 91.1%-111.8%, 96.8%-118.3%, and 85.1%-113.0%, respectively.",[Bioequivalence of tiopronin enteric capsules in healthy volunteers]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726314/),%,113.0,101190,DB00145,Glycine
,3825179,Maximal plasma concentrations of total radioactivity,Maximal plasma concentrations of total radioactivity of 32.4 +/- 6.4 ng equiv./ml (mean +/- S.D.) were detected compared with maximum plasma concentrations of 14.1 +/- 5.9 ng/ml (mean +/- S.D.) of molsidomine.,The metabolism of [14C]N-ethoxycarbonyl-3-morpholinosydnonimine (molsidomine) in man. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3825179/),[equiv·ng] / [ml],32.4,101500,DB00145,Glycine
,3825179,maximum plasma concentrations,Maximal plasma concentrations of total radioactivity of 32.4 +/- 6.4 ng equiv./ml (mean +/- S.D.) were detected compared with maximum plasma concentrations of 14.1 +/- 5.9 ng/ml (mean +/- S.D.) of molsidomine.,The metabolism of [14C]N-ethoxycarbonyl-3-morpholinosydnonimine (molsidomine) in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3825179/),[ng] / [ml],14.1,101501,DB00145,Glycine
,3825179,half-life,"From the peak, concentrations of parent drug fell rapidly with a half-life of 1.25 +/- 0.38 h (mean +/- S.D.).",The metabolism of [14C]N-ethoxycarbonyl-3-morpholinosydnonimine (molsidomine) in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3825179/),h,1.25,101502,DB00145,Glycine
,3825179,terminal half-life,"In contrast, total radioactivity declined more slowly with a terminal half-life of 138 +/- 42.7 h (mean +/- S.D.).",The metabolism of [14C]N-ethoxycarbonyl-3-morpholinosydnonimine (molsidomine) in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3825179/),h,138,101503,DB00145,Glycine
,30117017,time to reach maximum plasma concentration,"Ixazomib absorption is rapid, with a median time to reach maximum plasma concentration of approximately 1 h post-dose.",Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30117017/),h,1,102068,DB00145,Glycine
,30117017,terminal half-life,Ixazomib pharmacokinetics (PK) are adequately described by a three-compartment model (terminal half-life of 9.5 days) with first-order linear absorption (oral bioavailability of 58%).,Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30117017/),d,9.5,102069,DB00145,Glycine
,30117017,oral bioavailability,Ixazomib pharmacokinetics (PK) are adequately described by a three-compartment model (terminal half-life of 9.5 days) with first-order linear absorption (oral bioavailability of 58%).,Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30117017/),%,58,102070,DB00145,Glycine
,1168111,half-life,Saralasin pharmacologic half-life of 3.9 min after intravenous administration to rats was similar to the biochemical half-life of 4.2 min.,Radioimmunoassay and pharmacokinetics of saralasin in the rat and hypertensive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1168111/),min,3.9,103500,DB00145,Glycine
,1168111,biochemical half-life,Saralasin pharmacologic half-life of 3.9 min after intravenous administration to rats was similar to the biochemical half-life of 4.2 min.,Radioimmunoassay and pharmacokinetics of saralasin in the rat and hypertensive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1168111/),min,4.2,103501,DB00145,Glycine
,1168111,half-life,The pharmacologic half-life in high-renin hypertensive patients averaged 8.2 with a biochemical half-life of 3.2 min.,Radioimmunoassay and pharmacokinetics of saralasin in the rat and hypertensive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1168111/),,8.2,103502,DB00145,Glycine
,1168111,biochemical half-life,The pharmacologic half-life in high-renin hypertensive patients averaged 8.2 with a biochemical half-life of 3.2 min.,Radioimmunoassay and pharmacokinetics of saralasin in the rat and hypertensive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1168111/),min,3.2,103503,DB00145,Glycine
,1168111,biochemical half-life,The biochemical half-life of 3.2 min is consistent with infusion time of less than 20 min required to achieve a stable plasma concentration and pharmacologic activity of saralasin during constant saralasin infusion into hypertensive man.,Radioimmunoassay and pharmacokinetics of saralasin in the rat and hypertensive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1168111/),min,3.2,103504,DB00145,Glycine
,744496,plasma clearance,"In controls plasma clearance was 415 +/- 24 ml min-1 m-2 (mean +/- SEM), equivalent to a 'first-pass' extraction by the liver of 85%.",Kinetics of 14C-glycocholic acid clearance in normal man and in patients with liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/744496/),[ml] / [(m)^2·min],415,104221,DB00145,Glycine
,6694094,t 1/2,"After absorption, sodium benzoate is conjugated with glycine to give hippuric acid which is rapidly eliminated (t 1/2 = 0.5 h).",Lumen perfusion of the human rectum in situ: a method to study mechanisms for rectal drug transport in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6694094/),h,0.5,105287,DB00145,Glycine
,16934046,biliary clearance,The fraction of the piperacillin dose excreted unchanged into bile was 1.1 +/- 0.3% (biliary clearance corrected for EF was 0.032 +/- 0.008 ml min(-1) kg(-1)).,Determination of the biliary excretion of piperacillin in humans using a novel method. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16934046/),[ml] / [kg·min],0.032,105722,DB00145,Glycine
,2386326,Recovery,"Recovery of sodium salicylate and SUA in goats amounted to 67.9 and 34.6% of the dose, respectively, after IV administration.",Elimination of salicylic acid in goats and cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2386326/),%,67.9,107937,DB00145,Glycine
,2386326,Recovery,"Recovery of sodium salicylate and SUA in goats amounted to 67.9 and 34.6% of the dose, respectively, after IV administration.",Elimination of salicylic acid in goats and cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2386326/),%,34.6,107938,DB00145,Glycine
,2386326,total recoveries,"After oral dosing, total recoveries were 30.2% (sodium salicylate) and 71.7% (SUA) of dose.",Elimination of salicylic acid in goats and cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2386326/),%,30.2,107939,DB00145,Glycine
,2386326,total recoveries,"After oral dosing, total recoveries were 30.2% (sodium salicylate) and 71.7% (SUA) of dose.",Elimination of salicylic acid in goats and cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2386326/),%,71.7,107940,DB00145,Glycine
,2916450,FSR,The plasma fibronectin FSR in the preterm neonates was 15.5 +/- 9.9%/d(means +/- SD) and the half-life was 5.55 +/- 2.25 d.,Fibronectin turnover in the premature neonate measured with [15N]glycine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2916450/),[%] / [d],15.5,107971,DB00145,Glycine
,2916450,half-life,The plasma fibronectin FSR in the preterm neonates was 15.5 +/- 9.9%/d(means +/- SD) and the half-life was 5.55 +/- 2.25 d.,Fibronectin turnover in the premature neonate measured with [15N]glycine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2916450/),d,5.55,107972,DB00145,Glycine
,2916450,FSR,In the adults the plasma fibronectin FSR ranged from 20 to 87%/d and half-life ranged between 0.79 and 3.47 d.,Fibronectin turnover in the premature neonate measured with [15N]glycine. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2916450/),[%] / [d],20 to 87,107973,DB00145,Glycine
,2916450,half-life,In the adults the plasma fibronectin FSR ranged from 20 to 87%/d and half-life ranged between 0.79 and 3.47 d.,Fibronectin turnover in the premature neonate measured with [15N]glycine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2916450/),d,0.79 and 3.47,107974,DB00145,Glycine
,7515977,IC50,"Thiorphan and CGS 24128 inhibited NEP in vitro with IC50 values of 5.0 +/- 0.2 and 4.3 +/- 0.2 nM, respectively.","Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7515977/),nM,5.0,108101,DB00145,Glycine
,7515977,IC50,"Thiorphan and CGS 24128 inhibited NEP in vitro with IC50 values of 5.0 +/- 0.2 and 4.3 +/- 0.2 nM, respectively.","Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7515977/),nM,4.3,108102,DB00145,Glycine
,7515977,urinary sodium excretion (UNaV),"The change in urinary sodium excretion (UNaV) produced by ANP was 28.8 +/- 4.0 and 15.8 +/- 1.8 muEq/kg/min in CGS 24128- and vehicle-treated rats, respectively.","Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7515977/),[mueq] / [kg·min],28.8,108103,DB00145,Glycine
,7515977,urinary sodium excretion (UNaV),"The change in urinary sodium excretion (UNaV) produced by ANP was 28.8 +/- 4.0 and 15.8 +/- 1.8 muEq/kg/min in CGS 24128- and vehicle-treated rats, respectively.","Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7515977/),[mueq] / [kg·min],15.8,108104,DB00145,Glycine
,7515977,delta UNaV,"ANP-induced natriuresis was also greater during continuous infusion of thiorphan (5 mg/kg bolus + 0.1 mg/kg/min i.v.; delta UNaV = 29.2 +/- 5.8 and 13.8 +/- 3.2 muEq/kg/min in drug- and vehicle-treated rats, respectively) but not when thiorphan was administered as a bolus (10 mg/kg i.v.) 60 min before the ANP challenge.","Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7515977/),[mueq] / [kg·min],29.2,108105,DB00145,Glycine
,7515977,delta UNaV,"ANP-induced natriuresis was also greater during continuous infusion of thiorphan (5 mg/kg bolus + 0.1 mg/kg/min i.v.; delta UNaV = 29.2 +/- 5.8 and 13.8 +/- 3.2 muEq/kg/min in drug- and vehicle-treated rats, respectively) but not when thiorphan was administered as a bolus (10 mg/kg i.v.) 60 min before the ANP challenge.","Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7515977/),[mueq] / [kg·min],13.8,108106,DB00145,Glycine
,19401458,rate of appearance,"In rats infused with [(13)C(2),(15)N-glycine]glutathione, the rate of appearance of plasma GSH was 2.1 micromol.min(-1).kg(-1), and the half-life of plasma GSH/GSSR was 6-8 min.",Dynamics of glutathione and ophthalmate traced with 2H-enriched body water in rats and humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19401458/),[μM] / [kg·min],2.1,109860,DB00145,Glycine
,19401458,half-life,"In rats infused with [(13)C(2),(15)N-glycine]glutathione, the rate of appearance of plasma GSH was 2.1 micromol.min(-1).kg(-1), and the half-life of plasma GSH/GSSR was 6-8 min.",Dynamics of glutathione and ophthalmate traced with 2H-enriched body water in rats and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19401458/),min,6-8,109861,DB00145,Glycine
,12739985,bioavailability,"The interindividual variability of melagatran AUC was low (coefficient of variation 19-26%), and the mean bioavailability of melagatran, estimated using a mean value for melagatran clearance obtained from Caucasian subjects in a previous study, was approximately 20% in all groups (range of mean values 19-23%).","No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739985/),%,20,113678,DB00145,Glycine
,14517494,half-life,The half-life of melagatran was about 2 h.,Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14517494/),h,2,115052,DB00145,Glycine
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,0.90,115460,DB00145,Glycine
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,0.52,115461,DB00145,Glycine
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,0.84,115462,DB00145,Glycine
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,1.01,115463,DB00145,Glycine
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,1.02,115464,DB00145,Glycine
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,1.27,115465,DB00145,Glycine
,11116752,i-,"Of the 11 compounds examined, only propofol had an i-value of 6.6; for all other compounds i-values were lower than 2.1.","Identification of UDP-glucuronosyltransferases involved in the human hepatic metabolism of GV150526, a novel glycine antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11116752/),,6.6,115760,DB00145,Glycine
lower,11116752,i-,"Of the 11 compounds examined, only propofol had an i-value of 6.6; for all other compounds i-values were lower than 2.1.","Identification of UDP-glucuronosyltransferases involved in the human hepatic metabolism of GV150526, a novel glycine antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11116752/),,2.1,115761,DB00145,Glycine
,15025860,fraction bioavailability,"The fraction bioavailability following oral and intraperitoneal administration was 0.06 and 0.7-1, respectively.","Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025860/),,0.06,116295,DB00145,Glycine
,15025860,fraction bioavailability,"The fraction bioavailability following oral and intraperitoneal administration was 0.06 and 0.7-1, respectively.","Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025860/),,0.7,116296,DB00145,Glycine
,15025860,plasma elimination half-lives,BAPSG exhibited short plasma elimination half-lives in the range 0.5-1.5 h.,"Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025860/),h,0.5-1.5,116297,DB00145,Glycine
,15025860,percent protein binding,BAPSG was bound to rat plasma proteins and the percent protein binding ranged from 83 to 99.8%.,"Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025860/),%,83 to 99.8,116298,DB00145,Glycine
,32166420,tumor inhibition rate,"More importantly, the tumor inhibition rate of TPGS-Gly-TXA9 (43.81%) on A549 xenograft nude mice was significantly increased compared with that of TXA9 (25.26%).","Design and Synthesis of Polymer Prodrugs for Improving Water-Solubility, Pharmacokinetic Behavior and Antitumor Efficacy of TXA9. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166420/),%,43.81,116565,DB00145,Glycine
,32166420,tumor inhibition rate,"More importantly, the tumor inhibition rate of TPGS-Gly-TXA9 (43.81%) on A549 xenograft nude mice was significantly increased compared with that of TXA9 (25.26%).","Design and Synthesis of Polymer Prodrugs for Improving Water-Solubility, Pharmacokinetic Behavior and Antitumor Efficacy of TXA9. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166420/),%,25,116566,DB00145,Glycine
,7564333,plasma clearance,"The mean plasma clearance of TP-9201 after intravenous infusions of 30, 150, and 600 mg/kg/day in rats was 20.2, 18.7, and 18.5 ml/min/kg, respectively.","Pharmacokinetics and pharmacodynamics of TP-9201, a GPIIbIIIa antagonist, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7564333/),[ml] / [kg·min],20.2,116598,DB00145,Glycine
,7564333,plasma clearance,"The mean plasma clearance of TP-9201 after intravenous infusions of 30, 150, and 600 mg/kg/day in rats was 20.2, 18.7, and 18.5 ml/min/kg, respectively.","Pharmacokinetics and pharmacodynamics of TP-9201, a GPIIbIIIa antagonist, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7564333/),[ml] / [kg·min],18.7,116599,DB00145,Glycine
,7564333,plasma clearance,"The mean plasma clearance of TP-9201 after intravenous infusions of 30, 150, and 600 mg/kg/day in rats was 20.2, 18.7, and 18.5 ml/min/kg, respectively.","Pharmacokinetics and pharmacodynamics of TP-9201, a GPIIbIIIa antagonist, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7564333/),[ml] / [kg·min],18.5,116600,DB00145,Glycine
,7564333,clearance,"In beagles, TP-9201 clearance was 9.0, 7.5, and 7.3 ml/min/kg, corresponding to infusions of 10, 75, and 600 mg/kg/day, respectively.","Pharmacokinetics and pharmacodynamics of TP-9201, a GPIIbIIIa antagonist, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7564333/),[ml] / [kg·min],9.0,116601,DB00145,Glycine
,7564333,clearance,"In beagles, TP-9201 clearance was 9.0, 7.5, and 7.3 ml/min/kg, corresponding to infusions of 10, 75, and 600 mg/kg/day, respectively.","Pharmacokinetics and pharmacodynamics of TP-9201, a GPIIbIIIa antagonist, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7564333/),[ml] / [kg·min],7.5,116602,DB00145,Glycine
,7564333,clearance,"In beagles, TP-9201 clearance was 9.0, 7.5, and 7.3 ml/min/kg, corresponding to infusions of 10, 75, and 600 mg/kg/day, respectively.","Pharmacokinetics and pharmacodynamics of TP-9201, a GPIIbIIIa antagonist, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7564333/),[ml] / [kg·min],7.3,116603,DB00145,Glycine
,7564333,terminal half-life (t1/2),"The volume of distribution was larger than plasma volume, and the terminal half-life (t1/2) was short in both species studied ranging from 0.5 to 0.7 h in rats and from 2.5 to 2.6 h in dogs.","Pharmacokinetics and pharmacodynamics of TP-9201, a GPIIbIIIa antagonist, in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7564333/),h,0.5 to 0.7,116604,DB00145,Glycine
,7564333,terminal half-life (t1/2),"The volume of distribution was larger than plasma volume, and the terminal half-life (t1/2) was short in both species studied ranging from 0.5 to 0.7 h in rats and from 2.5 to 2.6 h in dogs.","Pharmacokinetics and pharmacodynamics of TP-9201, a GPIIbIIIa antagonist, in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7564333/),h,2.5 to 2.6,116605,DB00145,Glycine
,7564333,IC50,"The estimated in vivo IC50 value and sigmoidicity were 124 and 3.5 ng/ml, respectively, suggesting that TP-9201 is a potent GPIIbIIIa antagonist with a steep concentration-effect relationship.","Pharmacokinetics and pharmacodynamics of TP-9201, a GPIIbIIIa antagonist, in rats and dogs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7564333/),[ng] / [ml],124,116606,DB00145,Glycine
,7564333,IC50,"The estimated in vivo IC50 value and sigmoidicity were 124 and 3.5 ng/ml, respectively, suggesting that TP-9201 is a potent GPIIbIIIa antagonist with a steep concentration-effect relationship.","Pharmacokinetics and pharmacodynamics of TP-9201, a GPIIbIIIa antagonist, in rats and dogs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7564333/),[ng] / [ml],3.5,116607,DB00145,Glycine
,2167278,urea synthesis rate,The urea synthesis rate during amino acid infusion was 27 mumols/kg per minute (normal range 20-24 mumols/kg per minute).,Increased amino acid clearance and urea synthesis in a patient with glucagonoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2167278/),[mumols] / [kg·min],27,118359,DB00145,Glycine
,15928099,clearance,Median iohexol clearance was similar with dalteparin (99-103 ml/min) and melagatran in the dialysis fluid (98-100 ml/min).,Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15928099/),[ml] / [min],99-103,118657,DB00145,Glycine
,15928099,clearance,Median iohexol clearance was similar with dalteparin (99-103 ml/min) and melagatran in the dialysis fluid (98-100 ml/min).,Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15928099/),[ml] / [min],98-100,118658,DB00145,Glycine
,15928099,clearance,"While the clearance of melagatran was low in patients with renal failure (mean+/-SD, 0.93+/-0.36 l/h), haemodialysis provided efficient clearance of melagatran (7.20+/-0.76 l/h).",Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15928099/),[l] / [h],0.93,118659,DB00145,Glycine
,15928099,clearance,"While the clearance of melagatran was low in patients with renal failure (mean+/-SD, 0.93+/-0.36 l/h), haemodialysis provided efficient clearance of melagatran (7.20+/-0.76 l/h).",Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15928099/),[l] / [h],7.20,118660,DB00145,Glycine
,15928099,clearance,Melagatran clearance by dialysis (104+/-10 ml/min) was comparable to iohexol clearance.,Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15928099/),[ml] / [min],104,118661,DB00145,Glycine
,27121262,time to reach peak concentration,"Ixazomib was rapidly absorbed (median time to reach peak concentration was 0.95-1.5 h) and highly bound to plasma proteins, with a similar mean fraction bound (~99%) across the three groups.","Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121262/),h,0.95-1.5,120686,DB00145,Glycine
,27121262,fraction bound,"Ixazomib was rapidly absorbed (median time to reach peak concentration was 0.95-1.5 h) and highly bound to plasma proteins, with a similar mean fraction bound (~99%) across the three groups.","Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121262/),%,99,120687,DB00145,Glycine
,12648028,Renal clearance,"Renal clearance of melagatran, was 7.7 L/h and 4.9 L/h in the younger and older subjects, respectively.","Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648028/),[l] / [h],7.7,123312,DB00145,Glycine
,12648028,Renal clearance,"Renal clearance of melagatran, was 7.7 L/h and 4.9 L/h in the younger and older subjects, respectively.","Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648028/),[l] / [h],4.9,123313,DB00145,Glycine
,12648028,bioavailability,"The mean bioavailability of melagatran in young and older subjects was approximately 18 and 12% , respectively, following oral administration of ximalagratan, and 38 and 45%, respectively, following subcutaneous administration of ximelagatran.","Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648028/),%,18,123314,DB00145,Glycine
,12648028,bioavailability,"The mean bioavailability of melagatran in young and older subjects was approximately 18 and 12% , respectively, following oral administration of ximalagratan, and 38 and 45%, respectively, following subcutaneous administration of ximelagatran.","Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648028/),%,12,123315,DB00145,Glycine
,12648028,bioavailability,"The mean bioavailability of melagatran in young and older subjects was approximately 18 and 12% , respectively, following oral administration of ximalagratan, and 38 and 45%, respectively, following subcutaneous administration of ximelagatran.","Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648028/),%,38,123316,DB00145,Glycine
,12648028,bioavailability,"The mean bioavailability of melagatran in young and older subjects was approximately 18 and 12% , respectively, following oral administration of ximalagratan, and 38 and 45%, respectively, following subcutaneous administration of ximelagatran.","Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648028/),%,45,123317,DB00145,Glycine
,8165188,bioavailability,Nasal bioavailability was low (4.4%) compared to i.m. (24%).,Effect of formulation additives upon the intranasal bioavailability of a peptide drug: tetracosactide (ACTH1-24). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165188/),%,4.4,123390,DB00145,Glycine
,8165188,bioavailability,Nasal bioavailability was low (4.4%) compared to i.m. (24%).,Effect of formulation additives upon the intranasal bioavailability of a peptide drug: tetracosactide (ACTH1-24). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165188/),%,24,123391,DB00145,Glycine
,8165188,bioavailability,Poloxamer 407 addition did not improve drug kinetics profiles and showed a non-significant decrease in bioavailability (4%).,Effect of formulation additives upon the intranasal bioavailability of a peptide drug: tetracosactide (ACTH1-24). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165188/),%,4,123392,DB00145,Glycine
,8165188,Tmax,"The sodium glycocholate effect was very fast (Tmax = 5 min), but did not last long.",Effect of formulation additives upon the intranasal bioavailability of a peptide drug: tetracosactide (ACTH1-24). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165188/),min,5,123393,DB00145,Glycine
,8165188,bioavailability,"On the other hand, maximum tetracosactide levels in plasma were reached after 15 min for the formulation containing bacitracin as enhancer, and tetracosactide bioavailability was strongly increased, to 24%, i.e., as much as after an i.m. injection.",Effect of formulation additives upon the intranasal bioavailability of a peptide drug: tetracosactide (ACTH1-24). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165188/),%,24,123394,DB00145,Glycine
,25622538,lag time,"The lag time appeared to be similar after the bolus ingestion of GAA (0.14 ± 0.17 hours for low-dose GAA, 0.31 ± 0.18 hours for medium-dose GAA, and 0.38 ± 0.32 hours for high-dose GAA; P = .05).",Single-dose oral guanidinoacetic acid exhibits dose-dependent pharmacokinetics in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25622538/),h,0.14,124256,DB00145,Glycine
,25622538,lag time,"The lag time appeared to be similar after the bolus ingestion of GAA (0.14 ± 0.17 hours for low-dose GAA, 0.31 ± 0.18 hours for medium-dose GAA, and 0.38 ± 0.32 hours for high-dose GAA; P = .05).",Single-dose oral guanidinoacetic acid exhibits dose-dependent pharmacokinetics in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25622538/),h,0.31,124257,DB00145,Glycine
,25622538,lag time,"The lag time appeared to be similar after the bolus ingestion of GAA (0.14 ± 0.17 hours for low-dose GAA, 0.31 ± 0.18 hours for medium-dose GAA, and 0.38 ± 0.32 hours for high-dose GAA; P = .05).",Single-dose oral guanidinoacetic acid exhibits dose-dependent pharmacokinetics in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25622538/),h,0.38,124258,DB00145,Glycine
<,25622538,elimination half-time,"No differences were found for elimination half-time between the low-dose and medium-dose groups (<1.75 hours), whereas the elimination half-time was significantly longer (>2.1 hours) for the high-dose GAA regimen (P = .001).",Single-dose oral guanidinoacetic acid exhibits dose-dependent pharmacokinetics in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25622538/),h,1.75,124259,DB00145,Glycine
>,25622538,elimination half-time,"No differences were found for elimination half-time between the low-dose and medium-dose groups (<1.75 hours), whereas the elimination half-time was significantly longer (>2.1 hours) for the high-dose GAA regimen (P = .001).",Single-dose oral guanidinoacetic acid exhibits dose-dependent pharmacokinetics in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25622538/),h,2.1,124260,DB00145,Glycine
,25622538,volume of distribution,"The volume of distribution was affected by the dosage of GAA applied (102.6 ± 17.3 L for low-dose GAA, 97.5 ± 15.7 L for medium-dose GAA, and 61.1 ± 12.7 L for high-dose GAA; P < .0001).",Single-dose oral guanidinoacetic acid exhibits dose-dependent pharmacokinetics in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25622538/),l,102.6,124261,DB00145,Glycine
,25622538,volume of distribution,"The volume of distribution was affected by the dosage of GAA applied (102.6 ± 17.3 L for low-dose GAA, 97.5 ± 15.7 L for medium-dose GAA, and 61.1 ± 12.7 L for high-dose GAA; P < .0001).",Single-dose oral guanidinoacetic acid exhibits dose-dependent pharmacokinetics in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25622538/),l,97.5,124262,DB00145,Glycine
,25622538,volume of distribution,"The volume of distribution was affected by the dosage of GAA applied (102.6 ± 17.3 L for low-dose GAA, 97.5 ± 15.7 L for medium-dose GAA, and 61.1 ± 12.7 L for high-dose GAA; P < .0001).",Single-dose oral guanidinoacetic acid exhibits dose-dependent pharmacokinetics in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25622538/),l,61.1,124263,DB00145,Glycine
,25325301,MTD,MTD was determined to be 2.34 mg/m(2).,"Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25325301/),[mg] / [m(2],2.34,125605,DB00145,Glycine
,25325301,terminal half-life,Plasma exposure increased dose proportionally from 0.5-3.11 mg/m(2); terminal half-life was 4-12 days after multiple dosing.,"Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25325301/),d,4-12,125606,DB00145,Glycine
,34321251,terminal half-life,"Ivosidenib was well absorbed, showed low clearance, and moderate to long terminal half-life (5.3-18.5 hours) in rats, dogs, and monkeys.","Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34321251/),h,5.3-18.5,126133,DB00145,Glycine
,34321251,Brain to plasma exposure ratio,"Brain to plasma exposure ratio was low (2.3%), plasma protein binding was high, and oxidative metabolism was the major elimination pathway.","Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34321251/),%,2.3,126134,DB00145,Glycine
,29229209,half-life,"Mean half-life values of AV-101 were consistent across doses, ranging with an average of 1.73h, with the highest Cmax (64.4μg/mL) and AUC0-t (196μgh/mL) values for AV-101 occurring in the 1440-mg dose group.","Randomized, double-blind, placebo-controlled, dose-escalation study: Investigation of the safety, pharmacokinetics, and antihyperalgesic activity of l-4-chlorokynurenine in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29229209/),h,1.73,126249,DB00145,Glycine
,29229209,Cmax,"Mean half-life values of AV-101 were consistent across doses, ranging with an average of 1.73h, with the highest Cmax (64.4μg/mL) and AUC0-t (196μgh/mL) values for AV-101 occurring in the 1440-mg dose group.","Randomized, double-blind, placebo-controlled, dose-escalation study: Investigation of the safety, pharmacokinetics, and antihyperalgesic activity of l-4-chlorokynurenine in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29229209/),[μg] / [ml],64.4,126250,DB00145,Glycine
,29229209,AUC0-t,"Mean half-life values of AV-101 were consistent across doses, ranging with an average of 1.73h, with the highest Cmax (64.4μg/mL) and AUC0-t (196μgh/mL) values for AV-101 occurring in the 1440-mg dose group.","Randomized, double-blind, placebo-controlled, dose-escalation study: Investigation of the safety, pharmacokinetics, and antihyperalgesic activity of l-4-chlorokynurenine in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29229209/),[μgh] / [ml],196,126251,DB00145,Glycine
,33641211,MTD,The MTD of ixazomib was 4 mg in combination with fulvestrant.,Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33641211/),mg,4,126943,DB00145,Glycine
,33641211,maximal concentration (Cmax ),"Plasma concentrations of the active form of ixazomib (MLN2238) in the 4-mg dose cohort had a median (range) maximal concentration (Cmax ) of 155 (122-171) ng/mL, time of maximal concentration (Tmax ) of 1 (1-1.5) hour, terminal elimination half-life of 66.6 (57.3-102.6) hour after initial dose, and area under the curve (AUC) of 5,025 (4,160-5,345) ng*h/mL.",Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33641211/),[ng] / [ml],155,126944,DB00145,Glycine
,33641211,time of maximal concentration (Tmax ),"Plasma concentrations of the active form of ixazomib (MLN2238) in the 4-mg dose cohort had a median (range) maximal concentration (Cmax ) of 155 (122-171) ng/mL, time of maximal concentration (Tmax ) of 1 (1-1.5) hour, terminal elimination half-life of 66.6 (57.3-102.6) hour after initial dose, and area under the curve (AUC) of 5,025 (4,160-5,345) ng*h/mL.",Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33641211/),h,1,126945,DB00145,Glycine
,33641211,terminal elimination half-life,"Plasma concentrations of the active form of ixazomib (MLN2238) in the 4-mg dose cohort had a median (range) maximal concentration (Cmax ) of 155 (122-171) ng/mL, time of maximal concentration (Tmax ) of 1 (1-1.5) hour, terminal elimination half-life of 66.6 (57.3-102.6) hour after initial dose, and area under the curve (AUC) of 5,025 (4,160-5,345) ng*h/mL.",Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33641211/),h,66.6,126946,DB00145,Glycine
,33641211,area under the curve (AUC),"Plasma concentrations of the active form of ixazomib (MLN2238) in the 4-mg dose cohort had a median (range) maximal concentration (Cmax ) of 155 (122-171) ng/mL, time of maximal concentration (Tmax ) of 1 (1-1.5) hour, terminal elimination half-life of 66.6 (57.3-102.6) hour after initial dose, and area under the curve (AUC) of 5,025 (4,160-5,345) ng*h/mL.",Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33641211/),[h·ng] / [ml],"5,025",126947,DB00145,Glycine
,33641211,progression-free survival,"One partial response was observed, and median progression-free survival was 51 days (range, 47-137).",Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33641211/),d,51,126948,DB00145,Glycine
,25562534,Michaelis constant,"Using a Michaelis constant of 32.8mM, the model estimated a maximal oral absorption rate (Vmax) of 64.6mmol/min and dose-dependent bioavailability with a maximum of 60.9%.",Is oral absorption of vigabatrin carrier-mediated? ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25562534/),mM,32.8,128187,DB00145,Glycine
,25562534,maximal oral absorption rate (Vmax),"Using a Michaelis constant of 32.8mM, the model estimated a maximal oral absorption rate (Vmax) of 64.6mmol/min and dose-dependent bioavailability with a maximum of 60.9%.",Is oral absorption of vigabatrin carrier-mediated? ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25562534/),[mM] / [min],64.6,128188,DB00145,Glycine
,25562534,bioavailability,"Using a Michaelis constant of 32.8mM, the model estimated a maximal oral absorption rate (Vmax) of 64.6mmol/min and dose-dependent bioavailability with a maximum of 60.9%.",Is oral absorption of vigabatrin carrier-mediated? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25562534/),%,60.9,128189,DB00145,Glycine
,25562534,Bioavailability,"Bioavailability was 58.5-60.8% at 0.3-30mg/kg doses, but decreased to 46.8% at 300mg/kg.",Is oral absorption of vigabatrin carrier-mediated? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25562534/),%,58.5-60.8,128190,DB00145,Glycine
,25562534,Bioavailability,"Bioavailability was 58.5-60.8% at 0.3-30mg/kg doses, but decreased to 46.8% at 300mg/kg.",Is oral absorption of vigabatrin carrier-mediated? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25562534/),%,46.8,128191,DB00145,Glycine
,24904120,MTD,The MTD was determined to be 2.97 mg/m(2).,Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24904120/),[mg] / [m(2],2.97,128549,DB00145,Glycine
,24904120,terminal half-life,"Pharmacokinetic studies suggested a long terminal half-life of 3.6 to 11.3 days, supporting once-weekly dosing.",Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24904120/),d,3.6 to 11.3,128550,DB00145,Glycine
,9244143,clearance,"The following PK parameters were obtained for valproyl glycinamide and valproyl glycine, respectively: clearance, 7.1 and 16 ml/ min/kg; volume of distribution (Vss), 0.78 and 0.41 l/kg; half-life, 1.1 and 0.37 h; and mean residence time, 1.8 and 0.4 h.",The disposition of valproyl glycinamide and valproyl glycine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9244143/),[ml] / [kg·min],7.1,128899,DB00145,Glycine
,9244143,clearance,"The following PK parameters were obtained for valproyl glycinamide and valproyl glycine, respectively: clearance, 7.1 and 16 ml/ min/kg; volume of distribution (Vss), 0.78 and 0.41 l/kg; half-life, 1.1 and 0.37 h; and mean residence time, 1.8 and 0.4 h.",The disposition of valproyl glycinamide and valproyl glycine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9244143/),[ml] / [kg·min],16,128900,DB00145,Glycine
,9244143,volume of distribution (Vss),"The following PK parameters were obtained for valproyl glycinamide and valproyl glycine, respectively: clearance, 7.1 and 16 ml/ min/kg; volume of distribution (Vss), 0.78 and 0.41 l/kg; half-life, 1.1 and 0.37 h; and mean residence time, 1.8 and 0.4 h.",The disposition of valproyl glycinamide and valproyl glycine in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9244143/),[l] / [kg],0.78,128901,DB00145,Glycine
,9244143,volume of distribution (Vss),"The following PK parameters were obtained for valproyl glycinamide and valproyl glycine, respectively: clearance, 7.1 and 16 ml/ min/kg; volume of distribution (Vss), 0.78 and 0.41 l/kg; half-life, 1.1 and 0.37 h; and mean residence time, 1.8 and 0.4 h.",The disposition of valproyl glycinamide and valproyl glycine in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9244143/),[l] / [kg],0.41,128902,DB00145,Glycine
,9244143,half-life,"The following PK parameters were obtained for valproyl glycinamide and valproyl glycine, respectively: clearance, 7.1 and 16 ml/ min/kg; volume of distribution (Vss), 0.78 and 0.41 l/kg; half-life, 1.1 and 0.37 h; and mean residence time, 1.8 and 0.4 h.",The disposition of valproyl glycinamide and valproyl glycine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9244143/),h,1.1,128903,DB00145,Glycine
,9244143,half-life,"The following PK parameters were obtained for valproyl glycinamide and valproyl glycine, respectively: clearance, 7.1 and 16 ml/ min/kg; volume of distribution (Vss), 0.78 and 0.41 l/kg; half-life, 1.1 and 0.37 h; and mean residence time, 1.8 and 0.4 h.",The disposition of valproyl glycinamide and valproyl glycine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9244143/),h,0.37,128904,DB00145,Glycine
,9244143,mean residence time,"The following PK parameters were obtained for valproyl glycinamide and valproyl glycine, respectively: clearance, 7.1 and 16 ml/ min/kg; volume of distribution (Vss), 0.78 and 0.41 l/kg; half-life, 1.1 and 0.37 h; and mean residence time, 1.8 and 0.4 h.",The disposition of valproyl glycinamide and valproyl glycine in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9244143/),h,1.8,128905,DB00145,Glycine
,9244143,mean residence time,"The following PK parameters were obtained for valproyl glycinamide and valproyl glycine, respectively: clearance, 7.1 and 16 ml/ min/kg; volume of distribution (Vss), 0.78 and 0.41 l/kg; half-life, 1.1 and 0.37 h; and mean residence time, 1.8 and 0.4 h.",The disposition of valproyl glycinamide and valproyl glycine in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9244143/),h,0.4,128906,DB00145,Glycine
,32978634,steady-state AUC0-∞,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,3.23,129349,DB00145,Glycine
,32978634,steady-state AUC0-∞,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,1.90,129350,DB00145,Glycine
,32978634,Cmax ratios,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,2.26,129351,DB00145,Glycine
,32978634,Cmax ratios,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,1.90,129352,DB00145,Glycine
,32978634,Cmax ratios,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,1.52,129353,DB00145,Glycine
,3381541,half-lives of plasma levels,"2. The half-lives of plasma levels for the alpha and beta phase and systemic availability were 6 min, 42 min and 26-50% respectively in rats, and 8 min, 66 min and 5% respectively in dogs.","Disposition of 6-chloro-2-pyridylmethyl nitrate, a new anti-anginal compound, in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3381541/),min,6,129642,DB00145,Glycine
,3381541,half-lives of plasma levels,"2. The half-lives of plasma levels for the alpha and beta phase and systemic availability were 6 min, 42 min and 26-50% respectively in rats, and 8 min, 66 min and 5% respectively in dogs.","Disposition of 6-chloro-2-pyridylmethyl nitrate, a new anti-anginal compound, in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3381541/),min,42,129643,DB00145,Glycine
,3381541,half-lives of plasma levels,"2. The half-lives of plasma levels for the alpha and beta phase and systemic availability were 6 min, 42 min and 26-50% respectively in rats, and 8 min, 66 min and 5% respectively in dogs.","Disposition of 6-chloro-2-pyridylmethyl nitrate, a new anti-anginal compound, in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3381541/),%,26-50,129644,DB00145,Glycine
,3381541,half-lives of plasma levels,"2. The half-lives of plasma levels for the alpha and beta phase and systemic availability were 6 min, 42 min and 26-50% respectively in rats, and 8 min, 66 min and 5% respectively in dogs.","Disposition of 6-chloro-2-pyridylmethyl nitrate, a new anti-anginal compound, in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3381541/),min,8,129645,DB00145,Glycine
,3381541,half-lives of plasma levels,"2. The half-lives of plasma levels for the alpha and beta phase and systemic availability were 6 min, 42 min and 26-50% respectively in rats, and 8 min, 66 min and 5% respectively in dogs.","Disposition of 6-chloro-2-pyridylmethyl nitrate, a new anti-anginal compound, in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3381541/),min,66,129646,DB00145,Glycine
,3381541,half-lives of plasma levels,"2. The half-lives of plasma levels for the alpha and beta phase and systemic availability were 6 min, 42 min and 26-50% respectively in rats, and 8 min, 66 min and 5% respectively in dogs.","Disposition of 6-chloro-2-pyridylmethyl nitrate, a new anti-anginal compound, in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3381541/),%,5,129647,DB00145,Glycine
,15895233,half-life,"Urinary recovery of parent drug was low (2% of dose in 24 h), partly because of the long half-life of XK469 (approximately 3 days).",Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15895233/),d,3,131071,DB00145,Glycine
,22837388,t(½),"Although D-serine levels were rapidly diminished in wild-type mice (t(½) = 1.2 h), sustained drug levels over the course of 4 h (t(½) > 10 h) were observed in mice lacking DAAO.",Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22837388/),h,1.2,131861,DB00145,Glycine
>,22837388,t(½),"Although D-serine levels were rapidly diminished in wild-type mice (t(½) = 1.2 h), sustained drug levels over the course of 4 h (t(½) > 10 h) were observed in mice lacking DAAO.",Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22837388/),h,10,131862,DB00145,Glycine
,1437854,apparent distribution volume,"The apparent distribution volume for the excess glycine was 33 +/- 9 L, the half-life was 41 +/- 7 min, and the total body clearance was 0.56 +/- 0.08 L/min, while the renal clearance for glycine was 36 +/- 14 ml/min (mean +/- SD).",Amino acid concentrations in serum and urine after intravenous infusion of 1.5% glycine in prostatectomy patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437854/),l,33,132023,DB00145,Glycine
,1437854,half-life,"The apparent distribution volume for the excess glycine was 33 +/- 9 L, the half-life was 41 +/- 7 min, and the total body clearance was 0.56 +/- 0.08 L/min, while the renal clearance for glycine was 36 +/- 14 ml/min (mean +/- SD).",Amino acid concentrations in serum and urine after intravenous infusion of 1.5% glycine in prostatectomy patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437854/),min,41,132024,DB00145,Glycine
,1437854,total body clearance,"The apparent distribution volume for the excess glycine was 33 +/- 9 L, the half-life was 41 +/- 7 min, and the total body clearance was 0.56 +/- 0.08 L/min, while the renal clearance for glycine was 36 +/- 14 ml/min (mean +/- SD).",Amino acid concentrations in serum and urine after intravenous infusion of 1.5% glycine in prostatectomy patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437854/),[l] / [min],0.56,132025,DB00145,Glycine
,1437854,renal clearance,"The apparent distribution volume for the excess glycine was 33 +/- 9 L, the half-life was 41 +/- 7 min, and the total body clearance was 0.56 +/- 0.08 L/min, while the renal clearance for glycine was 36 +/- 14 ml/min (mean +/- SD).",Amino acid concentrations in serum and urine after intravenous infusion of 1.5% glycine in prostatectomy patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437854/),[ml] / [min],36,132026,DB00145,Glycine
,12846595,CL(R),"In the severe renal impairment and control groups, respectively, the mean CL(R) of melagatran was 12.5 and 81.3 mL/min after subcutaneous administration of melagatran and 14.3 and 107 mL/min after oral administration of ximelagatran.",Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12846595/),[ml] / [min],12.5,132359,DB00145,Glycine
,12846595,CL(R),"In the severe renal impairment and control groups, respectively, the mean CL(R) of melagatran was 12.5 and 81.3 mL/min after subcutaneous administration of melagatran and 14.3 and 107 mL/min after oral administration of ximelagatran.",Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12846595/),[ml] / [min],81.3,132360,DB00145,Glycine
,12846595,CL(R),"In the severe renal impairment and control groups, respectively, the mean CL(R) of melagatran was 12.5 and 81.3 mL/min after subcutaneous administration of melagatran and 14.3 and 107 mL/min after oral administration of ximelagatran.",Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12846595/),[ml] / [min],14.3,132361,DB00145,Glycine
,12846595,CL(R),"In the severe renal impairment and control groups, respectively, the mean CL(R) of melagatran was 12.5 and 81.3 mL/min after subcutaneous administration of melagatran and 14.3 and 107 mL/min after oral administration of ximelagatran.",Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12846595/),[ml] / [min],107,132362,DB00145,Glycine
,15801935,elimination half-life,The elimination half-life of CHF3381 was estimated to be 4-6 h.,"Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801935/),h,4-6,132937,DB00145,Glycine
,15801935,peak effects at steady-state,"CHF3381 dose-dependently inhibited MAO-A activity with peak effects at steady-state of 27 +/- 4%, 46 +/- 2% and 65 +/- 5% after 100 mg twice daily, 200 mg twice daily and 400 mg twice daily, respectively.","Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801935/),%,27,132938,DB00145,Glycine
,15801935,peak effects at steady-state,"CHF3381 dose-dependently inhibited MAO-A activity with peak effects at steady-state of 27 +/- 4%, 46 +/- 2% and 65 +/- 5% after 100 mg twice daily, 200 mg twice daily and 400 mg twice daily, respectively.","Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801935/),%,46,132939,DB00145,Glycine
,15801935,peak effects at steady-state,"CHF3381 dose-dependently inhibited MAO-A activity with peak effects at steady-state of 27 +/- 4%, 46 +/- 2% and 65 +/- 5% after 100 mg twice daily, 200 mg twice daily and 400 mg twice daily, respectively.","Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801935/),%,65,132940,DB00145,Glycine
,24493827,MTD,The MTD is 560 mg twice daily.,"Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24493827/),mg,560,133649,DB00145,Glycine
,3996442,plasma clearance,"Extrapolating to man (1.73 m3), plasma clearance with both ruthenocene derivatives was approximately 500-600 ml/min.",Ru-labeled ruthenocenoyl-glycine: comparison of clearance with hippuran. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3996442/),[ml] / [min],500-600,134988,DB00145,Glycine
,10978858,Bioavailability,"Bioavailability studies showed that absorption of BioZn-AAS was not statistically different than absorption from other sources in female rats (25.65% +/- 2.20% for BioZn-AAS, 28.24% +/- 4. 60% for ZnSO(4), 24.91% +/- 4.02% for Zn[OH](2), and 25.51% +/- 2. 70% for Zn-gluconate).","Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10978858/),%,25.65,137122,DB00145,Glycine
,10978858,Bioavailability,"Bioavailability studies showed that absorption of BioZn-AAS was not statistically different than absorption from other sources in female rats (25.65% +/- 2.20% for BioZn-AAS, 28.24% +/- 4. 60% for ZnSO(4), 24.91% +/- 4.02% for Zn[OH](2), and 25.51% +/- 2. 70% for Zn-gluconate).","Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10978858/),%,28.24,137123,DB00145,Glycine
,10978858,Bioavailability,"Bioavailability studies showed that absorption of BioZn-AAS was not statistically different than absorption from other sources in female rats (25.65% +/- 2.20% for BioZn-AAS, 28.24% +/- 4. 60% for ZnSO(4), 24.91% +/- 4.02% for Zn[OH](2), and 25.51% +/- 2. 70% for Zn-gluconate).","Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10978858/),%,24.91,137124,DB00145,Glycine
,10978858,Bioavailability,"Bioavailability studies showed that absorption of BioZn-AAS was not statistically different than absorption from other sources in female rats (25.65% +/- 2.20% for BioZn-AAS, 28.24% +/- 4. 60% for ZnSO(4), 24.91% +/- 4.02% for Zn[OH](2), and 25.51% +/- 2. 70% for Zn-gluconate).","Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10978858/),%,25.51,137125,DB00145,Glycine
,10978858,absorption,"Bioavailability studies showed that absorption of BioZn-AAS was not statistically different than absorption from other sources in female rats (25.65% +/- 2.20% for BioZn-AAS, 28.24% +/- 4. 60% for ZnSO(4), 24.91% +/- 4.02% for Zn[OH](2), and 25.51% +/- 2. 70% for Zn-gluconate).","Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10978858/),%,25.65,137126,DB00145,Glycine
,10978858,absorption,"Bioavailability studies showed that absorption of BioZn-AAS was not statistically different than absorption from other sources in female rats (25.65% +/- 2.20% for BioZn-AAS, 28.24% +/- 4. 60% for ZnSO(4), 24.91% +/- 4.02% for Zn[OH](2), and 25.51% +/- 2. 70% for Zn-gluconate).","Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10978858/),%,28.24,137127,DB00145,Glycine
,10978858,absorption,"Bioavailability studies showed that absorption of BioZn-AAS was not statistically different than absorption from other sources in female rats (25.65% +/- 2.20% for BioZn-AAS, 28.24% +/- 4. 60% for ZnSO(4), 24.91% +/- 4.02% for Zn[OH](2), and 25.51% +/- 2. 70% for Zn-gluconate).","Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10978858/),%,24.91,137128,DB00145,Glycine
,10978858,absorption,"Bioavailability studies showed that absorption of BioZn-AAS was not statistically different than absorption from other sources in female rats (25.65% +/- 2.20% for BioZn-AAS, 28.24% +/- 4. 60% for ZnSO(4), 24.91% +/- 4.02% for Zn[OH](2), and 25.51% +/- 2. 70% for Zn-gluconate).","Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10978858/),%,25.51,137129,DB00145,Glycine
,10978858,absorption,"In the case of the male rats, absorption of BioZn-AAS (27.97% +/- 4.20%) was higher (P<0.05) than that from the other compounds (23.15% +/- 2.90% for ZnSO(4), 22.62% +/- 3.90% for Zn[OH](2), and 22.30% +/- 3.90% for Zn-gluconate).","Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10978858/),%,27.97,137130,DB00145,Glycine
,10978858,absorption,"In the case of the male rats, absorption of BioZn-AAS (27.97% +/- 4.20%) was higher (P<0.05) than that from the other compounds (23.15% +/- 2.90% for ZnSO(4), 22.62% +/- 3.90% for Zn[OH](2), and 22.30% +/- 3.90% for Zn-gluconate).","Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10978858/),%,23.15,137131,DB00145,Glycine
,10978858,absorption,"In the case of the male rats, absorption of BioZn-AAS (27.97% +/- 4.20%) was higher (P<0.05) than that from the other compounds (23.15% +/- 2.90% for ZnSO(4), 22.62% +/- 3.90% for Zn[OH](2), and 22.30% +/- 3.90% for Zn-gluconate).","Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10978858/),%,22.62,137132,DB00145,Glycine
,10978858,absorption,"In the case of the male rats, absorption of BioZn-AAS (27.97% +/- 4.20%) was higher (P<0.05) than that from the other compounds (23.15% +/- 2.90% for ZnSO(4), 22.62% +/- 3.90% for Zn[OH](2), and 22.30% +/- 3.90% for Zn-gluconate).","Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10978858/),%,22.30,137133,DB00145,Glycine
,10978858,oral lethal dose 50 (LD(50)),The value of oral lethal dose 50 (LD(50)) was 2000 mg/kg for female rats and 1900 mg/kg for male rats.,"Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10978858/),[mg] / [kg],2000,137134,DB00145,Glycine
,10978858,oral lethal dose 50 (LD(50)),The value of oral lethal dose 50 (LD(50)) was 2000 mg/kg for female rats and 1900 mg/kg for male rats.,"Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10978858/),[mg] / [kg],1900,137135,DB00145,Glycine
,12238936,IC(50),"Among these compounds, the glycine derivative 3a and beta-alanine derivative 3f exhibited the most potent inhibition of squalene synthase prepared from HepG2 cells (IC(50) = 15 nM).","Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12238936/),nM,15,137142,DB00145,Glycine
,12238936,ED(50),"On the other hand, the piperidine-4-acetic acid derivative 4a, which was prepared by acetylation of 3j, was the most effective inhibitor of cholesterol synthesis in rat liver (ED(50) = 2.9 mg/kg, po).","Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12238936/),[mg] / [kg],2.9,137143,DB00145,Glycine
,17595342,terminal plasma half-life,"Although the 100 residue HAP fusion showed a behavior very similar to the unfused Fab fragment, with a terminal plasma half-life of ca. 2 h, the 200 residue HAPylated Fab fragment gave rise to a significantly prolonged half-life of ca. 6 h.",Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17595342/),h,2,137476,DB00145,Glycine
,17595342,half-life,"Although the 100 residue HAP fusion showed a behavior very similar to the unfused Fab fragment, with a terminal plasma half-life of ca. 2 h, the 200 residue HAPylated Fab fragment gave rise to a significantly prolonged half-life of ca. 6 h.",Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17595342/),h,6,137477,DB00145,Glycine
,16506266,ssow rate,"Separation was carried out on a BDS Hypersil C(18) analytical column (2 x 50 mm, 3 microm) and an effective chromatographic separation of muraglitazar (3.31 min) and trazadone (2.27 min) was achieved at a ssow rate of 0.3 mL/min.",Liquid chromatography/mass spectrometry for the quantitation of muraglitazar in monkey plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16506266/),[ml] / [min],0.3,137856,DB00145,Glycine
,16506266,extraction recoveries,"The average extraction recoveries of muraglitazar and IS were 83.3 and 91.9%, respectively.",Liquid chromatography/mass spectrometry for the quantitation of muraglitazar in monkey plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16506266/),%,83.3,137857,DB00145,Glycine
,16506266,extraction recoveries,"The average extraction recoveries of muraglitazar and IS were 83.3 and 91.9%, respectively.",Liquid chromatography/mass spectrometry for the quantitation of muraglitazar in monkey plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16506266/),%,91.9,137858,DB00145,Glycine
,1149363,steady-state plasma levels,"Average values for lidocaine steady-state plasma levels (2.3 mug/ml) clearance (12.3 ml/min/kg), terminal half-life (148 min), and total volume of distribution (1.9 L/kg) were found, and are similar to those values reported for normal subjects MFGX and after lidocaine infusion averaged 1/5-2/3 of the corresponding lidocaine level, as in nonuremic subjects, and plateaued by 6-8 hr.",Pharmacokinetics and metabolism of lidocaine in patients with renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1149363/),[μg] / [ml],2.3,138057,DB00145,Glycine
,1149363,clearance,"Average values for lidocaine steady-state plasma levels (2.3 mug/ml) clearance (12.3 ml/min/kg), terminal half-life (148 min), and total volume of distribution (1.9 L/kg) were found, and are similar to those values reported for normal subjects MFGX and after lidocaine infusion averaged 1/5-2/3 of the corresponding lidocaine level, as in nonuremic subjects, and plateaued by 6-8 hr.",Pharmacokinetics and metabolism of lidocaine in patients with renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1149363/),[ml] / [kg·min],12.3,138058,DB00145,Glycine
,1149363,terminal half-life,"Average values for lidocaine steady-state plasma levels (2.3 mug/ml) clearance (12.3 ml/min/kg), terminal half-life (148 min), and total volume of distribution (1.9 L/kg) were found, and are similar to those values reported for normal subjects MFGX and after lidocaine infusion averaged 1/5-2/3 of the corresponding lidocaine level, as in nonuremic subjects, and plateaued by 6-8 hr.",Pharmacokinetics and metabolism of lidocaine in patients with renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1149363/),min,148,138059,DB00145,Glycine
,1149363,total volume of distribution,"Average values for lidocaine steady-state plasma levels (2.3 mug/ml) clearance (12.3 ml/min/kg), terminal half-life (148 min), and total volume of distribution (1.9 L/kg) were found, and are similar to those values reported for normal subjects MFGX and after lidocaine infusion averaged 1/5-2/3 of the corresponding lidocaine level, as in nonuremic subjects, and plateaued by 6-8 hr.",Pharmacokinetics and metabolism of lidocaine in patients with renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1149363/),[l] / [kg],1.9,138060,DB00145,Glycine
,6527280,urine excretion,The specificity of I was higher as indicated by 94% in the bile at 90 min compared to 91% for II in normal rats and a urine excretion of 0.3% for I compared with 1.9% for II.,"Comparison of 99mTc-N-pyridoxyl-5-methyltryptophan and 99mTc-N-(3-bromo-2,4,6-trimethylacetanilide)-iminodiace tate as hepatobiliary radiopharmaceuticals in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6527280/),%,0.3,138284,DB00145,Glycine
,6527280,urine excretion,The specificity of I was higher as indicated by 94% in the bile at 90 min compared to 91% for II in normal rats and a urine excretion of 0.3% for I compared with 1.9% for II.,"Comparison of 99mTc-N-pyridoxyl-5-methyltryptophan and 99mTc-N-(3-bromo-2,4,6-trimethylacetanilide)-iminodiace tate as hepatobiliary radiopharmaceuticals in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6527280/),%,1.9,138285,DB00145,Glycine
,6527280,clearance,"The clearance of II was 70 mL/min/kg in normal and 47 mL/min/kg in treated rats; clearance of I was 51 and 30 mL/min/kg in normal and treated rats, respectively.","Comparison of 99mTc-N-pyridoxyl-5-methyltryptophan and 99mTc-N-(3-bromo-2,4,6-trimethylacetanilide)-iminodiace tate as hepatobiliary radiopharmaceuticals in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6527280/),[ml] / [kg·min],70,138286,DB00145,Glycine
,6527280,clearance,"The clearance of II was 70 mL/min/kg in normal and 47 mL/min/kg in treated rats; clearance of I was 51 and 30 mL/min/kg in normal and treated rats, respectively.","Comparison of 99mTc-N-pyridoxyl-5-methyltryptophan and 99mTc-N-(3-bromo-2,4,6-trimethylacetanilide)-iminodiace tate as hepatobiliary radiopharmaceuticals in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6527280/),[ml] / [kg·min],47,138287,DB00145,Glycine
,6527280,clearance,"The clearance of II was 70 mL/min/kg in normal and 47 mL/min/kg in treated rats; clearance of I was 51 and 30 mL/min/kg in normal and treated rats, respectively.","Comparison of 99mTc-N-pyridoxyl-5-methyltryptophan and 99mTc-N-(3-bromo-2,4,6-trimethylacetanilide)-iminodiace tate as hepatobiliary radiopharmaceuticals in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6527280/),[ml] / [kg·min],51,138288,DB00145,Glycine
,6527280,clearance,"The clearance of II was 70 mL/min/kg in normal and 47 mL/min/kg in treated rats; clearance of I was 51 and 30 mL/min/kg in normal and treated rats, respectively.","Comparison of 99mTc-N-pyridoxyl-5-methyltryptophan and 99mTc-N-(3-bromo-2,4,6-trimethylacetanilide)-iminodiace tate as hepatobiliary radiopharmaceuticals in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6527280/),[ml] / [kg·min],30,138289,DB00145,Glycine
,12953347,tmax,CHF 3381 was absorbed rapidly (tmax = 0.5-2 h) and cleared from plasma with a half-life of 3 to 4 hours.,"Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12953347/),h,0.5-2,139185,DB00145,Glycine
,12953347,half-life,CHF 3381 was absorbed rapidly (tmax = 0.5-2 h) and cleared from plasma with a half-life of 3 to 4 hours.,"Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12953347/),h,3 to 4,139186,DB00145,Glycine
,12953347,tmax,"Ingestion of food did not affect the extent of absorption of the drug, while the rate of absorption was considerably reduced (tmax = 4 h).","Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12953347/),h,4,139187,DB00145,Glycine
,12953347,half-life,The compound is rapidly absorbed and cleared from plasma with a half-life of 3 to 4 hours.,"Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12953347/),h,3 to 4,139188,DB00145,Glycine
,18655161,m/z,LC-MS was performed in the selected ion monitoring and positive ion mode using target ions at m/z: 575 for the diastereomic derivatives of tiopronin and m/z: 603 for the derivative of N-isobutyryl-D-cysteine (internal standard).,Stereoselective analysis of tiopronin enantiomers in rat plasma using high-performance liquid chromatography-electrospray ionization mass spectrometry after chiral derivatization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655161/),,575,139337,DB00145,Glycine
,18509604,systemic clearance,A two-compartment model described MEB (2.5 mCi) systemic disposition in humans (systemic clearance = 16.2 +/- 2.7 ml min(-1) kg(-1)); biliary excretion was the predominant route of hepatic elimination (efflux rate constants ratio canalicular/sinusoidal = 3.4 +/- 0.8).,"Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18509604/),[ml] / [kg·min],16.2,141859,DB00145,Glycine
,18509604,efflux rate constants ratio,A two-compartment model described MEB (2.5 mCi) systemic disposition in humans (systemic clearance = 16.2 +/- 2.7 ml min(-1) kg(-1)); biliary excretion was the predominant route of hepatic elimination (efflux rate constants ratio canalicular/sinusoidal = 3.4 +/- 0.8).,"Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18509604/),,3.4,141860,DB00145,Glycine
,9806957,plasma elimination half-lives,"DCA plasma elimination half-lives were 0.1 +/- 0.02 and 5.4 +/- 0.8 hr in young adult rats (180-265 g, 3-4 months of age) given one or two doses of DCA, respectively, and 9.7 +/- 1 hr in large, 16-month-old rats given two DCA doses.","Pharmacokinetics and metabolism of [14C]dichloroacetate in male Sprague-Dawley rats. Identification of glycine conjugates, including hippurate, as urinary metabolites of dichloroacetate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806957/),h,0.1,143359,DB00145,Glycine
,9806957,plasma elimination half-lives,"DCA plasma elimination half-lives were 0.1 +/- 0.02 and 5.4 +/- 0.8 hr in young adult rats (180-265 g, 3-4 months of age) given one or two doses of DCA, respectively, and 9.7 +/- 1 hr in large, 16-month-old rats given two DCA doses.","Pharmacokinetics and metabolism of [14C]dichloroacetate in male Sprague-Dawley rats. Identification of glycine conjugates, including hippurate, as urinary metabolites of dichloroacetate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806957/),h,5.4,143360,DB00145,Glycine
,9806957,plasma elimination half-lives,"DCA plasma elimination half-lives were 0.1 +/- 0.02 and 5.4 +/- 0.8 hr in young adult rats (180-265 g, 3-4 months of age) given one or two doses of DCA, respectively, and 9.7 +/- 1 hr in large, 16-month-old rats given two DCA doses.","Pharmacokinetics and metabolism of [14C]dichloroacetate in male Sprague-Dawley rats. Identification of glycine conjugates, including hippurate, as urinary metabolites of dichloroacetate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806957/),h,9.7,143361,DB00145,Glycine
,23789936,absolute oral bioavailability,Mean absolute oral bioavailability ranged from 13·9% (fed) to 34·8% (fasting) in 12 patients treated at the 560 mg b.i.d. dose level.,Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23789936/),%,13·9,143544,DB00145,Glycine
,23789936,absolute oral bioavailability,Mean absolute oral bioavailability ranged from 13·9% (fed) to 34·8% (fasting) in 12 patients treated at the 560 mg b.i.d. dose level.,Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23789936/),%,34·8,143545,DB00145,Glycine
,3420013,Extraction recovery,Extraction recovery was 73 +/- 14% (mean +/- S.D.; n = 11) and good linearity was achieved in the concentration range of 0.25-128 pg/tube.,Radioimmunoassay of desglycinamide-arginine vasopressin and its application in a pharmacokinetic study in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3420013/),%,73,144231,DB00145,Glycine
,3420013,detection limit,"Instantaneous tracer addition resulted in a detection limit of 250 fg/tube, whereas 24 hours preincubation and delayed tracer addition resulted in a detection limit of 100 fg/tube.",Radioimmunoassay of desglycinamide-arginine vasopressin and its application in a pharmacokinetic study in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3420013/),f,100,144232,DB00145,Glycine
,3420013,t1/2,DGAVP plasma concentration showed a rapid distribution phase (t1/2 = 1.0 +/- 0.2 min) and a somewhat slower elimination phase (t1/2 = 7.2 +/- 2.1 min).,Radioimmunoassay of desglycinamide-arginine vasopressin and its application in a pharmacokinetic study in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3420013/),min,1.0,144233,DB00145,Glycine
,3420013,t1/2,DGAVP plasma concentration showed a rapid distribution phase (t1/2 = 1.0 +/- 0.2 min) and a somewhat slower elimination phase (t1/2 = 7.2 +/- 2.1 min).,Radioimmunoassay of desglycinamide-arginine vasopressin and its application in a pharmacokinetic study in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3420013/),min,7.2,144234,DB00145,Glycine
,3420013,CLss,High clearance values (CLss = 97 +/- 30 ml.min-1) suggest rapid metabolism by amino- and carboxy-peptidases.,Radioimmunoassay of desglycinamide-arginine vasopressin and its application in a pharmacokinetic study in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3420013/),[ml] / [min],97,144235,DB00145,Glycine
,29228824,brain targeting efficiency,"A high brain targeting efficiency (199.3%, 230%) for gel and insert, respectively and a direct nose to brain transport (49.8%, 56.95%) for gel and insert, respectively confirmed that there is a direct nose to brain transport of GH following nasal administration of GH spanlastic loaded in nasal gel and insert.",Development of novel bioadhesive granisetron hydrochloride spanlastic gel and insert for brain targeting and study their effects on rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29228824/),%,199.3,146433,DB00145,Glycine
,29228824,brain targeting efficiency,"A high brain targeting efficiency (199.3%, 230%) for gel and insert, respectively and a direct nose to brain transport (49.8%, 56.95%) for gel and insert, respectively confirmed that there is a direct nose to brain transport of GH following nasal administration of GH spanlastic loaded in nasal gel and insert.",Development of novel bioadhesive granisetron hydrochloride spanlastic gel and insert for brain targeting and study their effects on rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29228824/),%,230,146434,DB00145,Glycine
,29228824,brain targeting efficiency,"A high brain targeting efficiency (199.3%, 230%) for gel and insert, respectively and a direct nose to brain transport (49.8%, 56.95%) for gel and insert, respectively confirmed that there is a direct nose to brain transport of GH following nasal administration of GH spanlastic loaded in nasal gel and insert.",Development of novel bioadhesive granisetron hydrochloride spanlastic gel and insert for brain targeting and study their effects on rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29228824/),%,49,146435,DB00145,Glycine
,29228824,brain targeting efficiency,"A high brain targeting efficiency (199.3%, 230%) for gel and insert, respectively and a direct nose to brain transport (49.8%, 56.95%) for gel and insert, respectively confirmed that there is a direct nose to brain transport of GH following nasal administration of GH spanlastic loaded in nasal gel and insert.",Development of novel bioadhesive granisetron hydrochloride spanlastic gel and insert for brain targeting and study their effects on rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29228824/),,56,146436,DB00145,Glycine
,28290121,terminal disposition phase half-life,"The geometric mean terminal disposition phase half-life was 9.5 days, steady-state volume of distribution was 543 L and systemic clearance was 1.86 L/h.","Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290121/),d,9.5,147189,DB00145,Glycine
,28290121,steady-state volume of distribution,"The geometric mean terminal disposition phase half-life was 9.5 days, steady-state volume of distribution was 543 L and systemic clearance was 1.86 L/h.","Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290121/),l,543,147190,DB00145,Glycine
,28290121,systemic clearance,"The geometric mean terminal disposition phase half-life was 9.5 days, steady-state volume of distribution was 543 L and systemic clearance was 1.86 L/h.","Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290121/),[l] / [h],1.86,147191,DB00145,Glycine
,28290121,absolute bioavailability,The absolute bioavailability of an oral dose was estimated to be 58%.,"Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290121/),%,58,147192,DB00145,Glycine
,12846596,elimination half-life (t1/2z),The maximum plasma concentration of melagatran (Cmax) was achieved 2-3 hours after administration; the mean elimination half-life (t1/2z) was 3.6 hours for hepatically impaired volunteers and 3.1 hours for the control volunteers.,"No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12846596/),h,3.6,148380,DB00145,Glycine
,12846596,elimination half-life (t1/2z),The maximum plasma concentration of melagatran (Cmax) was achieved 2-3 hours after administration; the mean elimination half-life (t1/2z) was 3.6 hours for hepatically impaired volunteers and 3.1 hours for the control volunteers.,"No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12846596/),h,3.1,148381,DB00145,Glycine
,33661566,elimination half-life,"Mean elimination half-life was 5.8 and 7.8 hours in the normal and hepatic impairment groups, respectively.","Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33661566/),h,5.8,149276,DB00145,Glycine
,33661566,elimination half-life,"Mean elimination half-life was 5.8 and 7.8 hours in the normal and hepatic impairment groups, respectively.","Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33661566/),h,7.8,149277,DB00145,Glycine
,20853464,flow rate,"Chromatographic separation was achieved with 0.2% formic acid-acetonitrile (25:75, v/v) at a flow rate of 0.50 mL/min on an X-Terra RP(18) column with a total run time of 2.5 min.","Validation and clinical application of an LC-ESI-MS/MS method for simultaneous determination of tolmetin and MED5, the metabolites of amtolmetin guacil in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853464/),[ml] / [min],0.50,149836,DB00145,Glycine
,20853464,total run time,"Chromatographic separation was achieved with 0.2% formic acid-acetonitrile (25:75, v/v) at a flow rate of 0.50 mL/min on an X-Terra RP(18) column with a total run time of 2.5 min.","Validation and clinical application of an LC-ESI-MS/MS method for simultaneous determination of tolmetin and MED5, the metabolites of amtolmetin guacil in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853464/),min,2.5,149837,DB00145,Glycine
,7647480,total serum clearance,"There was a 25% decrease in mean methotrexate total serum clearance in the GLN group compared with the control group (0.63 +/- 0.09 L.h-1.kg-1 and 0.47 +/- 0.13 L.h-1.kg-1, respectively, p = 0.01).",A significant methotrexate-glutamine pharmacokinetic interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7647480/),[l] / [h·kg],0.63,150291,DB00145,Glycine
,7647480,total serum clearance,"There was a 25% decrease in mean methotrexate total serum clearance in the GLN group compared with the control group (0.63 +/- 0.09 L.h-1.kg-1 and 0.47 +/- 0.13 L.h-1.kg-1, respectively, p = 0.01).",A significant methotrexate-glutamine pharmacokinetic interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7647480/),[l] / [h·kg],0.47,150292,DB00145,Glycine
,32305862,elimination half-life,The urinary data indicated the elimination half-life was 9 h.,Urine glyphosate level as a quantitative biomarker of oral exposure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32305862/),h,9,151059,DB00145,Glycine
,15671203,CL,"Estimated pharmacokinetic parameters were CL (41.2 to 27.4 l/h over the study), V (131 liters), Q (1.7 l/h), V(p) (36 liters), and k(a) (1.85 h(-1)).","Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671203/),[l] / [h],41.2 to 27.4,153609,DB00145,Glycine
,15671203,V,"Estimated pharmacokinetic parameters were CL (41.2 to 27.4 l/h over the study), V (131 liters), Q (1.7 l/h), V(p) (36 liters), and k(a) (1.85 h(-1)).","Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671203/),l,131,153610,DB00145,Glycine
,15671203,Q,"Estimated pharmacokinetic parameters were CL (41.2 to 27.4 l/h over the study), V (131 liters), Q (1.7 l/h), V(p) (36 liters), and k(a) (1.85 h(-1)).","Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671203/),[l] / [h],1.7,153611,DB00145,Glycine
,15671203,V(p),"Estimated pharmacokinetic parameters were CL (41.2 to 27.4 l/h over the study), V (131 liters), Q (1.7 l/h), V(p) (36 liters), and k(a) (1.85 h(-1)).","Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671203/),l,36,153612,DB00145,Glycine
,15671203,k(a),"Estimated pharmacokinetic parameters were CL (41.2 to 27.4 l/h over the study), V (131 liters), Q (1.7 l/h), V(p) (36 liters), and k(a) (1.85 h(-1)).","Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671203/),1/[h],1.85,153613,DB00145,Glycine
,15671203,production rate of DHPG (k(in)),"The production rate of DHPG (k(in)) was 2540 ng . h(-1), reduced by 63% at maximal CHF3381 concentrations.","Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671203/),[ng] / [h],2540,153614,DB00145,Glycine
,15671203,EC(50),"EC(50) was 1670 mug/l, not significantly different from the in vitro IC(50).","Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671203/),[μg] / [l],1670,153615,DB00145,Glycine
,15671203,heart rate,The increase in heart rate due to CHF3381 was 0.0055 bpm/micro(g l-1).,"Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671203/),[bpm] / [l·μ(g],0.0055,153616,DB00145,Glycine
,7261553,Plasma clearances,"3. Plasma clearances were significantly increased after the meal for both [14C]glycocholic acid (median 455 ml min--1 m--2, range 376--672 increased to 704, 528--1968; P less than 0.01) and indocyanine green (359, 227--473 increased to 435, 358--985; P less than 0.01).",Effects of a meal on plasma clearance of [14C]glycocholic acid and indocyanine green in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7261553/),[ml] / [(m-)^2·min-],455,154228,DB00145,Glycine
,7261553,Plasma clearances,"3. Plasma clearances were significantly increased after the meal for both [14C]glycocholic acid (median 455 ml min--1 m--2, range 376--672 increased to 704, 528--1968; P less than 0.01) and indocyanine green (359, 227--473 increased to 435, 358--985; P less than 0.01).",Effects of a meal on plasma clearance of [14C]glycocholic acid and indocyanine green in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7261553/),[ml] / [(m-)^2·min-],"704, 528",154229,DB00145,Glycine
,7261553,Plasma clearances,"3. Plasma clearances were significantly increased after the meal for both [14C]glycocholic acid (median 455 ml min--1 m--2, range 376--672 increased to 704, 528--1968; P less than 0.01) and indocyanine green (359, 227--473 increased to 435, 358--985; P less than 0.01).",Effects of a meal on plasma clearance of [14C]glycocholic acid and indocyanine green in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7261553/),[ml] / [(m-)^2·min-],"359, 227",154230,DB00145,Glycine
,7261553,Plasma clearances,"3. Plasma clearances were significantly increased after the meal for both [14C]glycocholic acid (median 455 ml min--1 m--2, range 376--672 increased to 704, 528--1968; P less than 0.01) and indocyanine green (359, 227--473 increased to 435, 358--985; P less than 0.01).",Effects of a meal on plasma clearance of [14C]glycocholic acid and indocyanine green in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7261553/),[ml] / [(m-)^2·min-],"435, 358",154231,DB00145,Glycine
,3783453,half-life,"Haloperidol (4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1- butanone), a reference compound used for model development, disappeared from the intestinal lumen with a half-life of 14 +/- 3 min.",Evaluation of drug absorption and presystemic metabolism using an in situ intestinal preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3783453/),min,14,155304,DB00145,Glycine
,3783453,t1/2,"When the antiarthritic agent, tolmetin sodium (sodium 1-methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetate dihydrate), was studied in the preparation, it was rapidly absorbed (t1/2 for disappearance from the intestinal lumen = 8 min), achieved plasma concentrations comparable to in vivo data, and underwent little presystemic elimination.",Evaluation of drug absorption and presystemic metabolism using an in situ intestinal preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3783453/),min,8,155305,DB00145,Glycine
,3783453,t1/2,"In contrast, fenoctimine sulfate (4-(diphenylmethyl)-1-[(octylimino)methyl]piperidine sulfate), an antisecretory compound, disappeared more slowly from the intestinal lumen (t1/2 = 60 min), was present in portal plasma, but was not detected in systemic plasma.",Evaluation of drug absorption and presystemic metabolism using an in situ intestinal preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3783453/),min,60,155306,DB00145,Glycine
,3783453,t1/2,"Tolmetin glycine amide (N-([1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetyl)glycine), a tolmetin prodrug, disappeared from the intestinal lumen very slowly (t1/2 approximately 3 h) compared with the other agents tested.",Evaluation of drug absorption and presystemic metabolism using an in situ intestinal preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3783453/),h,3,155307,DB00145,Glycine
,10411561,half-life,In serum the half-life of MRZ 2/576 (30 mg/kg) was also increased by coadministration of probenecid from 15.6 +/- 1.3 to 40.6 +/- 6.0 min.,The role of probenecid-sensitive organic acid transport in the pharmacokinetics of N-methyl-D-aspartate receptor antagonists acting at the glycine(B)-site: microdialysis and maximum electroshock seizures studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10411561/),min,15.6,156588,DB00145,Glycine
,10411561,half-life,In serum the half-life of MRZ 2/576 (30 mg/kg) was also increased by coadministration of probenecid from 15.6 +/- 1.3 to 40.6 +/- 6.0 min.,The role of probenecid-sensitive organic acid transport in the pharmacokinetics of N-methyl-D-aspartate receptor antagonists acting at the glycine(B)-site: microdialysis and maximum electroshock seizures studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10411561/),min,40.6,156589,DB00145,Glycine
,7945529,elimination of half-lives,Their elimination of half-lives from plasma were 11-13 days.,"Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. First communication: plasma concentration, distribution, metabolism and excretion of the new monoclonal antibody, regavirumab after intravenous administration in rats and rabbits. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945529/),d,11-13,157130,DB00145,Glycine
,10102460,mean plasma concentrations,"The mean plasma concentrations in the low, medium and high dose groups were 0.17, 0.31 and 0.53 micromol/l, respectively.","Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10102460/),[μM] / [l],0.17,158176,DB00145,Glycine
,10102460,mean plasma concentrations,"The mean plasma concentrations in the low, medium and high dose groups were 0.17, 0.31 and 0.53 micromol/l, respectively.","Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10102460/),[μM] / [l],0.31,158177,DB00145,Glycine
,10102460,mean plasma concentrations,"The mean plasma concentrations in the low, medium and high dose groups were 0.17, 0.31 and 0.53 micromol/l, respectively.","Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10102460/),[μM] / [l],0.53,158178,DB00145,Glycine
,10340917,area under FEV1,"Albuterol-evoked FEV1 was higher and the response was more rapid in Arg16 homozygotes compared with the cohort of carriers of the Gly16 variant: Maximal percentage increase in FEV1 (%deltaFEV1), 18% versus 4.9% (P < .03); area under FEV1 albuterol concentration curve, 194%.mL/ng versus 30%.mL/ng (P < .05); initial slope (dE/dC), 1.43%.mL/ng versus 0.55%.mL/ng (P < .003).",Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10340917/),[%·ml] / [ng],194,158440,DB00145,Glycine
,10340917,area under FEV1,"Albuterol-evoked FEV1 was higher and the response was more rapid in Arg16 homozygotes compared with the cohort of carriers of the Gly16 variant: Maximal percentage increase in FEV1 (%deltaFEV1), 18% versus 4.9% (P < .03); area under FEV1 albuterol concentration curve, 194%.mL/ng versus 30%.mL/ng (P < .05); initial slope (dE/dC), 1.43%.mL/ng versus 0.55%.mL/ng (P < .003).",Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10340917/),[%·ml] / [ng],30,158441,DB00145,Glycine
,10340917,initial slope (dE/dC),"Albuterol-evoked FEV1 was higher and the response was more rapid in Arg16 homozygotes compared with the cohort of carriers of the Gly16 variant: Maximal percentage increase in FEV1 (%deltaFEV1), 18% versus 4.9% (P < .03); area under FEV1 albuterol concentration curve, 194%.mL/ng versus 30%.mL/ng (P < .05); initial slope (dE/dC), 1.43%.mL/ng versus 0.55%.mL/ng (P < .003).",Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10340917/),[%·ml] / [ng],1,158442,DB00145,Glycine
,10340917,initial slope (dE/dC),"Albuterol-evoked FEV1 was higher and the response was more rapid in Arg16 homozygotes compared with the cohort of carriers of the Gly16 variant: Maximal percentage increase in FEV1 (%deltaFEV1), 18% versus 4.9% (P < .03); area under FEV1 albuterol concentration curve, 194%.mL/ng versus 30%.mL/ng (P < .05); initial slope (dE/dC), 1.43%.mL/ng versus 0.55%.mL/ng (P < .003).",Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10340917/),[%·ml] / [ng],0.55,158443,DB00145,Glycine
,25841105,Tmax,"Sarcosine exhibited linear kinetics, with a Tmax and t½ of ~1½- 2½ hr and ~1hr, respectively.","Safety, tolerability and pharmacokinetics of open label sarcosine added on to anti-psychotic treatment in schizophrenia - preliminary study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25841105/),h,1½- 2½,158896,DB00145,Glycine
,25841105,t½,"Sarcosine exhibited linear kinetics, with a Tmax and t½ of ~1½- 2½ hr and ~1hr, respectively.","Safety, tolerability and pharmacokinetics of open label sarcosine added on to anti-psychotic treatment in schizophrenia - preliminary study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25841105/),h,1,158897,DB00145,Glycine
,24136086,Terminal half-lives,Terminal half-lives were about 22 h for unchanged safinamide and 80 h for radioactivity.,"Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24136086/),h,22,160041,DB00145,Glycine
,24136086,Terminal half-lives,Terminal half-lives were about 22 h for unchanged safinamide and 80 h for radioactivity.,"Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24136086/),h,80,160042,DB00145,Glycine
,22020315,MTD,The MTD for GSK923295 was determined to be 190 mg/m(2).,"First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22020315/),[mg] / [m(2],190,162269,DB00145,Glycine
,22020315,terminal elimination half-life,The mean terminal elimination half-life of GSK923295 was 9-11 h.,"First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22020315/),h,9-11,162270,DB00145,Glycine
,2379536,terminal half-lives,The total and non-protein-bound concentrations versus time curves were best described by a three-exponential function with terminal half-lives of 55 and 59 h respectively.,Pharmacokinetics of intravenous 2-mercaptopropionylglycine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379536/),h,55,162453,DB00145,Glycine
,2379536,terminal half-lives,The total and non-protein-bound concentrations versus time curves were best described by a three-exponential function with terminal half-lives of 55 and 59 h respectively.,Pharmacokinetics of intravenous 2-mercaptopropionylglycine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379536/),h,59,162454,DB00145,Glycine
,2379536,Body clearance,Body clearance based upon the total concentration was estimated to be 105 and 231 ml/min based on the non-protein-bound 2-MPG.,Pharmacokinetics of intravenous 2-mercaptopropionylglycine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379536/),[ml] / [min],105,162455,DB00145,Glycine
,2379536,Body clearance,Body clearance based upon the total concentration was estimated to be 105 and 231 ml/min based on the non-protein-bound 2-MPG.,Pharmacokinetics of intravenous 2-mercaptopropionylglycine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379536/),[ml] / [min],231,162456,DB00145,Glycine
,2379536,Vss,"The corresponding values for Vss were 99 l and Vss,n 173 l, and for V gamma 485 l and V gamma,n 1121 l respectively.",Pharmacokinetics of intravenous 2-mercaptopropionylglycine in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379536/),l,99,162457,DB00145,Glycine
,2379536,"Vss,n","The corresponding values for Vss were 99 l and Vss,n 173 l, and for V gamma 485 l and V gamma,n 1121 l respectively.",Pharmacokinetics of intravenous 2-mercaptopropionylglycine in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379536/),l,173,162458,DB00145,Glycine
,2379536,V gamma,"The corresponding values for Vss were 99 l and Vss,n 173 l, and for V gamma 485 l and V gamma,n 1121 l respectively.",Pharmacokinetics of intravenous 2-mercaptopropionylglycine in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379536/),l,485,162459,DB00145,Glycine
,2379536,"V gamma,n","The corresponding values for Vss were 99 l and Vss,n 173 l, and for V gamma 485 l and V gamma,n 1121 l respectively.",Pharmacokinetics of intravenous 2-mercaptopropionylglycine in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379536/),l,1121,162460,DB00145,Glycine
,27178807,elimination half-life time,"The in vivo pharmacokinetics studies displayed that DOX-loaded cRGD20/PEG-SS-PCL micelles had a prolonged elimination half-life time of 3.51h, which was comparable to that of cRGD20/PEG-PCL counterparts, indicating that disulfide bonds in the PEG-SS-PCL micelles are stable in the circulation.",cRGD-functionalized reduction-sensitive shell-sheddable biodegradable micelles mediate enhanced doxorubicin delivery to human glioma xenografts in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27178807/),h,3.51,162980,DB00145,Glycine
,33788422,area under the plasma concentration-time curve from time 0 to infinity,"Hemodialysis did not significantly affect overall total concentrations with similar mean area under the plasma concentration-time curve from time 0 to infinity (coefficient of variation) of 3350 (26.4%) and 3640 (20.9%) ng · h/mL on days 1 and 8, respectively, and mean terminal half-life was 9.35 (11.9%) and 9.96 (18.7%) hours on the 2 occasions.","Hemodialysis Clearance of Enarodustat (JTZ-951), an Oral Erythropoiesis Stimulating Agent, in Patients with End-Stage Renal Disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33788422/),[h·ng] / [ml],3350,163667,DB00145,Glycine
,33788422,area under the plasma concentration-time curve from time 0 to infinity,"Hemodialysis did not significantly affect overall total concentrations with similar mean area under the plasma concentration-time curve from time 0 to infinity (coefficient of variation) of 3350 (26.4%) and 3640 (20.9%) ng · h/mL on days 1 and 8, respectively, and mean terminal half-life was 9.35 (11.9%) and 9.96 (18.7%) hours on the 2 occasions.","Hemodialysis Clearance of Enarodustat (JTZ-951), an Oral Erythropoiesis Stimulating Agent, in Patients with End-Stage Renal Disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33788422/),[h·ng] / [ml],3640,163668,DB00145,Glycine
,33788422,terminal half-life,"Hemodialysis did not significantly affect overall total concentrations with similar mean area under the plasma concentration-time curve from time 0 to infinity (coefficient of variation) of 3350 (26.4%) and 3640 (20.9%) ng · h/mL on days 1 and 8, respectively, and mean terminal half-life was 9.35 (11.9%) and 9.96 (18.7%) hours on the 2 occasions.","Hemodialysis Clearance of Enarodustat (JTZ-951), an Oral Erythropoiesis Stimulating Agent, in Patients with End-Stage Renal Disease. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33788422/),h,9.35,163669,DB00145,Glycine
,33788422,terminal half-life,"Hemodialysis did not significantly affect overall total concentrations with similar mean area under the plasma concentration-time curve from time 0 to infinity (coefficient of variation) of 3350 (26.4%) and 3640 (20.9%) ng · h/mL on days 1 and 8, respectively, and mean terminal half-life was 9.35 (11.9%) and 9.96 (18.7%) hours on the 2 occasions.","Hemodialysis Clearance of Enarodustat (JTZ-951), an Oral Erythropoiesis Stimulating Agent, in Patients with End-Stage Renal Disease. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33788422/),h,9.96,163670,DB00145,Glycine
,33788422,maximum concentration,Mean maximum concentration was somewhat lower on day 1 compared to day 8 (404 vs 559 ng/mL); the difference did not significantly affect total exposure (area under the plasma concentration-time curve from time 0 to infinity).,"Hemodialysis Clearance of Enarodustat (JTZ-951), an Oral Erythropoiesis Stimulating Agent, in Patients with End-Stage Renal Disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33788422/),[ng] / [ml],404,163671,DB00145,Glycine
,33788422,maximum concentration,Mean maximum concentration was somewhat lower on day 1 compared to day 8 (404 vs 559 ng/mL); the difference did not significantly affect total exposure (area under the plasma concentration-time curve from time 0 to infinity).,"Hemodialysis Clearance of Enarodustat (JTZ-951), an Oral Erythropoiesis Stimulating Agent, in Patients with End-Stage Renal Disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33788422/),[ng] / [ml],559,163672,DB00145,Glycine
,33788422,Di,"Dialysis clearance (0.415 L/h) was insignificant relative to dialyzer plasma flow (∼20 L/h), and the fraction of administered dose recovered in dialysate was small (6.74% of dose) with low intersubject variability (coefficient of variation, 14.7%).","Hemodialysis Clearance of Enarodustat (JTZ-951), an Oral Erythropoiesis Stimulating Agent, in Patients with End-Stage Renal Disease. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33788422/),[l] / [h],0.415,163673,DB00145,Glycine
,33788422,plasma flow,"Dialysis clearance (0.415 L/h) was insignificant relative to dialyzer plasma flow (∼20 L/h), and the fraction of administered dose recovered in dialysate was small (6.74% of dose) with low intersubject variability (coefficient of variation, 14.7%).","Hemodialysis Clearance of Enarodustat (JTZ-951), an Oral Erythropoiesis Stimulating Agent, in Patients with End-Stage Renal Disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33788422/),[l] / [h],∼20,163674,DB00145,Glycine
,26745345,Tm,"However, RFX001.D is unstable at physiological temperatures (Tm = 33 °C).","A Potent d-Protein Antagonist of VEGF-A is Nonimmunogenic, Metabolically Stable, and Longer-Circulating in Vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26745345/),°c,33,163747,DB00145,Glycine
>,26745345,Tm,"Here, we describe RFX037.D, a variant of RFX001.D with extreme thermal stability (Tm > 95 °C), high affinity for VEGF-A (Kd = 6 nM), and improved receptor blocking.","A Potent d-Protein Antagonist of VEGF-A is Nonimmunogenic, Metabolically Stable, and Longer-Circulating in Vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26745345/),°c,95,163748,DB00145,Glycine
,26745345,Kd,"Here, we describe RFX037.D, a variant of RFX001.D with extreme thermal stability (Tm > 95 °C), high affinity for VEGF-A (Kd = 6 nM), and improved receptor blocking.","A Potent d-Protein Antagonist of VEGF-A is Nonimmunogenic, Metabolically Stable, and Longer-Circulating in Vivo. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26745345/),nM,6,163749,DB00145,Glycine
,18271278,oral bioavailability,Bis-glycinate administration was safe and well tolerated and bis-glycinate significantly increased the oral bioavailability of zinc (+43.4%) compared with the gluconate.,A bioavailability study comparing two oral formulations containing zinc (Zn bis-glycinate vs. Zn gluconate) after a single administration to twelve healthy female volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18271278/),%,43.4,164009,DB00145,Glycine
,29938772,overall response rate,"In 62 evaluable patients, the confirmed overall response rate was 94% (68% ≥very good partial response; 24% complete response).",Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29938772/),%,94,164466,DB00145,Glycine
,29938772,progression-free survival,Median progression-free survival was 24·9 months.,Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29938772/),month,24·9,164467,DB00145,Glycine
,28000099,T max,"Ixazomib was rapidly absorbed with a median T max of approximately 1-2-h post-dose, and had a geometric mean terminal half-life of 5-6 days.",Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28000099/),h,1-2-,164685,DB00145,Glycine
,28000099,terminal half-life,"Ixazomib was rapidly absorbed with a median T max of approximately 1-2-h post-dose, and had a geometric mean terminal half-life of 5-6 days.",Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28000099/),d,5-6,164686,DB00145,Glycine
,12507569,distribution (t(1/2alpha)),"After i.v. NFLXGA administration, the distribution (t(1/2alpha)) and elimination half-life (t(1/2beta)) were 0.42 (0.05) and 5.44 (1.36)h.",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and intramuscular administration to horses. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507569/),h,0.42,166701,DB00145,Glycine
,12507569,elimination half-life (t(1/2beta)),"After i.v. NFLXGA administration, the distribution (t(1/2alpha)) and elimination half-life (t(1/2beta)) were 0.42 (0.05) and 5.44 (1.36)h.",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and intramuscular administration to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507569/),h,5.44,166702,DB00145,Glycine
,12507569,volume of distribution of NFLXGA at steady state (Vd(ss)),The volume of distribution of NFLXGA at steady state (Vd(ss)) was 2.19 (0.53) Lkg(-1).,Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and intramuscular administration to horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507569/),1/[lkg],2.19,166703,DB00145,Glycine
,12507569,maximal absorption concentration (C(max)),"After NFLXGA i.m. administration, the maximal absorption concentration (C(max)) was 0.44 (0.04) microgml(-1) at 0.86 (0.15)h (T(max)).",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and intramuscular administration to horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507569/),1/[μgml],0.44,166704,DB00145,Glycine
,12507569,T(max),"After NFLXGA i.m. administration, the maximal absorption concentration (C(max)) was 0.44 (0.04) microgml(-1) at 0.86 (0.15)h (T(max)).",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and intramuscular administration to horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507569/),,0,166705,DB00145,Glycine
,12507569,absorption (t(1/2ka)),"The mean absorption (t(1/2ka)) and elimination half-life (t(1/2beta)) of NFLXGA were 0.27 (0.07) and 9.47 (2.24)h, respectively.",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and intramuscular administration to horses. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507569/),h,0.27,166706,DB00145,Glycine
,12507569,elimination half-life (t(1/2beta)),"The mean absorption (t(1/2ka)) and elimination half-life (t(1/2beta)) of NFLXGA were 0.27 (0.07) and 9.47 (2.24)h, respectively.",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and intramuscular administration to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507569/),h,9.47,166707,DB00145,Glycine
,12507569,systemic bioavailability (F),The mean systemic bioavailability (F) following i.m. administration was 55 (12)%.,Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and intramuscular administration to horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507569/),%,55,166708,DB00145,Glycine
,7968592,clearances,"All dipeptides were cleared rapidly from the blood (clearances ranged from 42.9 +/- 3.28 mL/min/kg body weight for GlyGln to 278 +/- 70.7 for GlnAla, mean +/- SD).",The effect of dipeptide structure on dipeptide and amino acid clearance in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7968592/),[ml] / [body·kg·min·weight],42.9,167238,DB00145,Glycine
,7968592,clearances,"All dipeptides were cleared rapidly from the blood (clearances ranged from 42.9 +/- 3.28 mL/min/kg body weight for GlyGln to 278 +/- 70.7 for GlnAla, mean +/- SD).",The effect of dipeptide structure on dipeptide and amino acid clearance in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7968592/),,278,167239,DB00145,Glycine
,1438523,serum half-life (t1/2),The serum half-life (t1/2) of PZG was 1 h.,"Pharmacokinetics of pyrazinoyl-guanidine, 3-aminopyrazinoyl-guanidine and their corresponding pyrazinoic acid metabolites in humans and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438523/),h,1,168184,DB00145,Glycine
,1631793,catalytic efficiencies for p,"The specific fibrinolytic activities on fibrin plates were 160,000 +/- 17,000, 210,000 +/- 88,000 and 460,000 +/- 72,000 IU/mg (mean +/- SEM) for rt-PA P47G, K49N, rt-PA and alteplase, respectively, while the catalytic efficiencies for plasminogen activation (k2/Km) in the absence of fibrin were comparable (1.1 to 1.7 x 10(-3) microM-1s-1).","Biochemical, thrombolytic and pharmacokinetic properties of rt-PA P47G, K49N, a substitution variant of human tissue-type plasminogen activator. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1631793/),1/[μM],1.1,168218,DB00145,Glycine
,9637308,elimination half-life (T1/2beta),The elimination half-life (T1/2beta) of NFLX (3.37+/-1.37 hr) was not significant as compared with those of NFLXN (3.61+/-0.65 hr) and NFLXGA (3.93+/-1.54 hr).,Comparative pharmacokinetic profiles of two norfloxacin formulations after oral administration in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9637308/),h,3.37,169592,DB00145,Glycine
,9637308,elimination half-life (T1/2beta),The elimination half-life (T1/2beta) of NFLX (3.37+/-1.37 hr) was not significant as compared with those of NFLXN (3.61+/-0.65 hr) and NFLXGA (3.93+/-1.54 hr).,Comparative pharmacokinetic profiles of two norfloxacin formulations after oral administration in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9637308/),h,3.61,169593,DB00145,Glycine
,9637308,elimination half-life (T1/2beta),The elimination half-life (T1/2beta) of NFLX (3.37+/-1.37 hr) was not significant as compared with those of NFLXN (3.61+/-0.65 hr) and NFLXGA (3.93+/-1.54 hr).,Comparative pharmacokinetic profiles of two norfloxacin formulations after oral administration in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9637308/),h,3.93,169594,DB00145,Glycine
,9637308,absolute bioavailability (F),"The absolute bioavailability (F) of NFLX, NFLXN and NFLXGA was calculated as 29%, 45% and 40%.",Comparative pharmacokinetic profiles of two norfloxacin formulations after oral administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9637308/),%,29,169595,DB00145,Glycine
,9637308,absolute bioavailability (F),"The absolute bioavailability (F) of NFLX, NFLXN and NFLXGA was calculated as 29%, 45% and 40%.",Comparative pharmacokinetic profiles of two norfloxacin formulations after oral administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9637308/),%,45,169596,DB00145,Glycine
,9637308,absolute bioavailability (F),"The absolute bioavailability (F) of NFLX, NFLXN and NFLXGA was calculated as 29%, 45% and 40%.",Comparative pharmacokinetic profiles of two norfloxacin formulations after oral administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9637308/),%,40,169597,DB00145,Glycine
<,15205387,oral bioavailability,GV196771 has low oral bioavailability (<10%) and plasma clearance ( approximately 2 ml/min/kg) in rats.,The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15205387/),%,10,177719,DB00145,Glycine
,15205387,plasma clearance,GV196771 has low oral bioavailability (<10%) and plasma clearance ( approximately 2 ml/min/kg) in rats.,The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15205387/),[ml] / [kg·min],2,177720,DB00145,Glycine
,15205387,passive membrane permeability (P(app),"In vitro, GV196771 was a Bcrp substrate [basolateral-to-apical/apical-to-basolateral (B-->A/A-->B) ratio = 5.1] with high passive membrane permeability (P(app) = 64-170 nm/s); however, GV196771 was not an in vitro Mdr1a substrate (B-->A/A-->B ratio = 1.9; no effect of GF120918 on efflux ratio).",The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15205387/),[nm] / [s],64-170,177721,DB00145,Glycine
,32603526,elimination half-life,Maximum plasma concentration and area under the plasma concentration-time curve for patients receiving roxadustat were slightly more than dose proportional and elimination half-life ranged from 14.7 to 19.4 hours.,Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32603526/),h,14.7 to 19.4,178877,DB00145,Glycine
,31267867,V(L),"At the same time, the population pharmacokinetic model of methotrexate was obtained CL(L·h-1) =8.25× e0.167× SNP (SNP: SLCO1B1 388A/A=3; SLCO1B1 388A/G=2; SLCO1B1 388G/G=1); V(L)= 32.8; Ka(h- 1)=1.69.",Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31267867/),,32.8,179357,DB00145,Glycine
,31267867,Ka(,"At the same time, the population pharmacokinetic model of methotrexate was obtained CL(L·h-1) =8.25× e0.167× SNP (SNP: SLCO1B1 388A/A=3; SLCO1B1 388A/G=2; SLCO1B1 388G/G=1); V(L)= 32.8; Ka(h- 1)=1.69.",Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31267867/),1·h-,1.69,179358,DB00145,Glycine
,21866096,terminal half-life,GSK1018921 showed dose-proportional PK with a terminal half-life of ~17 h.,"First-time-in-human study with GSK1018921, a selective GlyT1 inhibitor: relationship between exposure and dizziness. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21866096/),h,17,180707,DB00145,Glycine
,19466411,t(1/2),Na exhibits extensive plasma protein binding and the compound displays rapid elimination from the circulation in all three animal species (t(1/2) range 0.404-0.870 h).,"Preclinical pharmacokinetics and in vitro activity of ON 01910. Na, a novel anti-cancer agent. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19466411/),h,0.404-0.870,181474,DB00145,Glycine
<,11472217,IC(50),Further elaboration in the P3'-P4' area using the cyclophane and cyclic carbamate templates led to the identification of a number of potent analogues with IC(50) values of </=0.2 microM in whole blood assay (WBA).,"Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11472217/),μM,0.2,182411,DB00145,Glycine
,11472217,IC(50),"With a glycine residue at P3', an N-methylamide at P4' provided the best cyclophane analogue, SL422 (WBA IC(50) = 0.22 microM, LPS-mouse ED(50) = 15 mg/kg, po), whereas a morpholinylamide at P4' afforded the most potent and most orally active cyclic carbamate analogue, SP057 (WBA IC(50) = 0.067 microM, LPS-mouse ED(50) = 2.3 mg/kg, po).","Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11472217/),μM,0.22,182412,DB00145,Glycine
,11472217,IC(50),"With a glycine residue at P3', an N-methylamide at P4' provided the best cyclophane analogue, SL422 (WBA IC(50) = 0.22 microM, LPS-mouse ED(50) = 15 mg/kg, po), whereas a morpholinylamide at P4' afforded the most potent and most orally active cyclic carbamate analogue, SP057 (WBA IC(50) = 0.067 microM, LPS-mouse ED(50) = 2.3 mg/kg, po).","Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11472217/),μM,0.067,182413,DB00145,Glycine
,11472217,K(i),"Further profiling for SL422 and SP057 showed that these macrocyclic compounds are potent TACE inhibitors, with K(i) values of 12 and 4.2 nM in the porcine TACE assay, and are broad-spectrum MMP inhibitors.","Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11472217/),nM,12,182414,DB00145,Glycine
,11472217,K(i),"Further profiling for SL422 and SP057 showed that these macrocyclic compounds are potent TACE inhibitors, with K(i) values of 12 and 4.2 nM in the porcine TACE assay, and are broad-spectrum MMP inhibitors.","Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11472217/),nM,4.2,182415,DB00145,Glycine
,11472217,oral bioavailabilities,"Pharmacokinetic studies in beagle dogs revealed that SL422 and SP057 are orally bioavailable, with oral bioavailabilities of 11% and 23%, respectively.","Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11472217/),%,11,182416,DB00145,Glycine
,11472217,oral bioavailabilities,"Pharmacokinetic studies in beagle dogs revealed that SL422 and SP057 are orally bioavailable, with oral bioavailabilities of 11% and 23%, respectively.","Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11472217/),%,23,182417,DB00145,Glycine
,30274288,LOD (limit of detection),The LOD (limit of detection) was 1.5 ng/mL.,Pharmacokinetic and Metabolism Studies of 12-Riboside-Pseudoginsengenin DQ by UPLC-MS/MS and UPLC-QTOF-MSE. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30274288/),[ng] / [ml],1.5,184012,DB00145,Glycine
,30274288,recoveries,The recoveries were in the range 85.66~92.90%.,Pharmacokinetic and Metabolism Studies of 12-Riboside-Pseudoginsengenin DQ by UPLC-MS/MS and UPLC-QTOF-MSE. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30274288/),%,85.66~92.90,184013,DB00145,Glycine
,30274288,Tmax,"The results showed that RPDQ exhibited slow oral absorption (Tmax = 7.0 h, 7.5 h, and 7.0 h, respectively), low elimination (t1/2 = 12.59 h, 12.83 h, and 13.74 h, respectively) and poor absolute bioavailability (5.55, 5.15, and 6.08%, respectively).",Pharmacokinetic and Metabolism Studies of 12-Riboside-Pseudoginsengenin DQ by UPLC-MS/MS and UPLC-QTOF-MSE. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30274288/),h,7.0,184014,DB00145,Glycine
,30274288,Tmax,"The results showed that RPDQ exhibited slow oral absorption (Tmax = 7.0 h, 7.5 h, and 7.0 h, respectively), low elimination (t1/2 = 12.59 h, 12.83 h, and 13.74 h, respectively) and poor absolute bioavailability (5.55, 5.15, and 6.08%, respectively).",Pharmacokinetic and Metabolism Studies of 12-Riboside-Pseudoginsengenin DQ by UPLC-MS/MS and UPLC-QTOF-MSE. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30274288/),h,7.5,184015,DB00145,Glycine
,30274288,elimination (t1/2,"The results showed that RPDQ exhibited slow oral absorption (Tmax = 7.0 h, 7.5 h, and 7.0 h, respectively), low elimination (t1/2 = 12.59 h, 12.83 h, and 13.74 h, respectively) and poor absolute bioavailability (5.55, 5.15, and 6.08%, respectively).",Pharmacokinetic and Metabolism Studies of 12-Riboside-Pseudoginsengenin DQ by UPLC-MS/MS and UPLC-QTOF-MSE. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30274288/),h,12.59,184016,DB00145,Glycine
,30274288,elimination (t1/2,"The results showed that RPDQ exhibited slow oral absorption (Tmax = 7.0 h, 7.5 h, and 7.0 h, respectively), low elimination (t1/2 = 12.59 h, 12.83 h, and 13.74 h, respectively) and poor absolute bioavailability (5.55, 5.15, and 6.08%, respectively).",Pharmacokinetic and Metabolism Studies of 12-Riboside-Pseudoginsengenin DQ by UPLC-MS/MS and UPLC-QTOF-MSE. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30274288/),h,12.83,184017,DB00145,Glycine
,30274288,elimination (t1/2,"The results showed that RPDQ exhibited slow oral absorption (Tmax = 7.0 h, 7.5 h, and 7.0 h, respectively), low elimination (t1/2 = 12.59 h, 12.83 h, and 13.74 h, respectively) and poor absolute bioavailability (5.55, 5.15, and 6.08%, respectively).",Pharmacokinetic and Metabolism Studies of 12-Riboside-Pseudoginsengenin DQ by UPLC-MS/MS and UPLC-QTOF-MSE. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30274288/),h,13.74,184018,DB00145,Glycine
,30274288,absolute bioavailability,"The results showed that RPDQ exhibited slow oral absorption (Tmax = 7.0 h, 7.5 h, and 7.0 h, respectively), low elimination (t1/2 = 12.59 h, 12.83 h, and 13.74 h, respectively) and poor absolute bioavailability (5.55, 5.15, and 6.08%, respectively).",Pharmacokinetic and Metabolism Studies of 12-Riboside-Pseudoginsengenin DQ by UPLC-MS/MS and UPLC-QTOF-MSE. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30274288/),%,5.55,184019,DB00145,Glycine
,30274288,absolute bioavailability,"The results showed that RPDQ exhibited slow oral absorption (Tmax = 7.0 h, 7.5 h, and 7.0 h, respectively), low elimination (t1/2 = 12.59 h, 12.83 h, and 13.74 h, respectively) and poor absolute bioavailability (5.55, 5.15, and 6.08%, respectively).",Pharmacokinetic and Metabolism Studies of 12-Riboside-Pseudoginsengenin DQ by UPLC-MS/MS and UPLC-QTOF-MSE. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30274288/),%,5.15,184020,DB00145,Glycine
,30274288,absolute bioavailability,"The results showed that RPDQ exhibited slow oral absorption (Tmax = 7.0 h, 7.5 h, and 7.0 h, respectively), low elimination (t1/2 = 12.59 h, 12.83 h, and 13.74 h, respectively) and poor absolute bioavailability (5.55, 5.15, and 6.08%, respectively).",Pharmacokinetic and Metabolism Studies of 12-Riboside-Pseudoginsengenin DQ by UPLC-MS/MS and UPLC-QTOF-MSE. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30274288/),%,6.08,184021,DB00145,Glycine
,22369880,oral bioavailability,"The highest oral bioavailability of approximately 8.5% and 11.0% could be observed with subcutaneous insulin as reference for SGC-liposomes in non-diabetic and diabetic rats, respectively.","Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369880/),%,8.5,184243,DB00145,Glycine
,22369880,oral bioavailability,"The highest oral bioavailability of approximately 8.5% and 11.0% could be observed with subcutaneous insulin as reference for SGC-liposomes in non-diabetic and diabetic rats, respectively.","Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369880/),%,11.0,184244,DB00145,Glycine
,10805066,clearance (CL),"The mean clearance (CL) and central (Vc) and steady-state (Vss) volumes of distribution across the dose groups were 0.31-0.40 l x h(-1), 3.3-3.9 l, and 9.8-17 l, respectively.",Pharmacokinetics of a glycine site antagonist (gavestinel) following multiple dosing in patients with acute stroke. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10805066/),[l] / [h],0.31-0.40,190071,DB00145,Glycine
,10805066,central (Vc),"The mean clearance (CL) and central (Vc) and steady-state (Vss) volumes of distribution across the dose groups were 0.31-0.40 l x h(-1), 3.3-3.9 l, and 9.8-17 l, respectively.",Pharmacokinetics of a glycine site antagonist (gavestinel) following multiple dosing in patients with acute stroke. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10805066/),[l] / [h],0.31-0.40,190072,DB00145,Glycine
,10805066,central (Vc),"The mean clearance (CL) and central (Vc) and steady-state (Vss) volumes of distribution across the dose groups were 0.31-0.40 l x h(-1), 3.3-3.9 l, and 9.8-17 l, respectively.",Pharmacokinetics of a glycine site antagonist (gavestinel) following multiple dosing in patients with acute stroke. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10805066/),l,3.3-3.9,190073,DB00145,Glycine
,10805066,steady-state (Vss),"The mean clearance (CL) and central (Vc) and steady-state (Vss) volumes of distribution across the dose groups were 0.31-0.40 l x h(-1), 3.3-3.9 l, and 9.8-17 l, respectively.",Pharmacokinetics of a glycine site antagonist (gavestinel) following multiple dosing in patients with acute stroke. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10805066/),l,3.3-3.9,190074,DB00145,Glycine
,10805066,volumes of distribution,"The mean clearance (CL) and central (Vc) and steady-state (Vss) volumes of distribution across the dose groups were 0.31-0.40 l x h(-1), 3.3-3.9 l, and 9.8-17 l, respectively.",Pharmacokinetics of a glycine site antagonist (gavestinel) following multiple dosing in patients with acute stroke. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10805066/),l,3.3-3.9,190075,DB00145,Glycine
,10805066,volumes of distribution,"The mean clearance (CL) and central (Vc) and steady-state (Vss) volumes of distribution across the dose groups were 0.31-0.40 l x h(-1), 3.3-3.9 l, and 9.8-17 l, respectively.",Pharmacokinetics of a glycine site antagonist (gavestinel) following multiple dosing in patients with acute stroke. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10805066/),l,9.8-17,190076,DB00145,Glycine
,10805066,terminal half-life,The mean terminal half-life ranged from 29 h to 56 h.,Pharmacokinetics of a glycine site antagonist (gavestinel) following multiple dosing in patients with acute stroke. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10805066/),h,29,190077,DB00145,Glycine
,10805066,terminal half-life,The mean terminal half-life ranged from 29 h to 56 h.,Pharmacokinetics of a glycine site antagonist (gavestinel) following multiple dosing in patients with acute stroke. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10805066/),h,56,190078,DB00145,Glycine
,16289574,pharmacological availability,The pharmacological availability was 5.5% and significantly different from the reference formulation.,Effects of absorption promoters on insulin absorption through colon-targeted delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16289574/),%,5.5,193496,DB00145,Glycine
,16289574,absolute bioavailability,"The absolute bioavailability for CDS was 0.25%, and for CDSP it was 0.42%.",Effects of absorption promoters on insulin absorption through colon-targeted delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16289574/),%,0.25,193497,DB00145,Glycine
,16289574,absolute bioavailability,"The absolute bioavailability for CDS was 0.25%, and for CDSP it was 0.42%.",Effects of absorption promoters on insulin absorption through colon-targeted delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16289574/),%,0.42,193498,DB00145,Glycine
,9453437,Half-life (T1/2 time),"Half-life (T1/2 time) for the first (t1/2 1st phase), second (t1/2 2nd phase) and third (t1/2 3rd phase) phases of elimination was 1.7+/-0.9 min, 6.7+/-1.6 min and 68+/-17 min, respectively.",Plasma clearance of cholyl-lysyl-fluorescein: a pilot study in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453437/),min,1.7,193926,DB00145,Glycine
,9453437,Half-life (T1/2 time),"Half-life (T1/2 time) for the first (t1/2 1st phase), second (t1/2 2nd phase) and third (t1/2 3rd phase) phases of elimination was 1.7+/-0.9 min, 6.7+/-1.6 min and 68+/-17 min, respectively.",Plasma clearance of cholyl-lysyl-fluorescein: a pilot study in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453437/),min,6.7,193927,DB00145,Glycine
,9453437,Half-life (T1/2 time),"Half-life (T1/2 time) for the first (t1/2 1st phase), second (t1/2 2nd phase) and third (t1/2 3rd phase) phases of elimination was 1.7+/-0.9 min, 6.7+/-1.6 min and 68+/-17 min, respectively.",Plasma clearance of cholyl-lysyl-fluorescein: a pilot study in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453437/),min,68,193928,DB00145,Glycine
,9453437,Ninety-minute plasma retention,Ninety-minute plasma retention (% dose/l plasma) was 2.2%.,Plasma clearance of cholyl-lysyl-fluorescein: a pilot study in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453437/),%,2.2,193929,DB00145,Glycine
,11457652,nasal bioavailability,"The nasal bioavailability of Peptide T in water (control formulation), 5% glycofurol, 5% glycofurol+1% sodium glycocholate and 1% sodium glycocholate was 5.9, 22, 29 and 59%, respectively.",Nasal bioavailability of peptide T in rabbits: absorption enhancement by sodium glycocholate and glycofurol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11457652/),%,5.9,195398,DB00145,Glycine
,11457652,nasal bioavailability,"The nasal bioavailability of Peptide T in water (control formulation), 5% glycofurol, 5% glycofurol+1% sodium glycocholate and 1% sodium glycocholate was 5.9, 22, 29 and 59%, respectively.",Nasal bioavailability of peptide T in rabbits: absorption enhancement by sodium glycocholate and glycofurol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11457652/),%,22,195399,DB00145,Glycine
,11457652,nasal bioavailability,"The nasal bioavailability of Peptide T in water (control formulation), 5% glycofurol, 5% glycofurol+1% sodium glycocholate and 1% sodium glycocholate was 5.9, 22, 29 and 59%, respectively.",Nasal bioavailability of peptide T in rabbits: absorption enhancement by sodium glycocholate and glycofurol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11457652/),%,29,195400,DB00145,Glycine
,11457652,nasal bioavailability,"The nasal bioavailability of Peptide T in water (control formulation), 5% glycofurol, 5% glycofurol+1% sodium glycocholate and 1% sodium glycocholate was 5.9, 22, 29 and 59%, respectively.",Nasal bioavailability of peptide T in rabbits: absorption enhancement by sodium glycocholate and glycofurol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11457652/),%,59,195401,DB00145,Glycine
,9193875,terminal disposition half-life,"The following pharmacokinetic parameter values were obtained (mean +/- SD): terminal disposition half-life, 17.7 +/- 0.08 min; apparent steady-state volume of distribution, 0.89 +/- 0.14 liters/kg; systemic body clearance, 68.9 +/- 10.0 ml/kg *min; and mean residence time, 13.1 +/- 2.2 min.","Oral and topical absorption, disposition kinetics, and the metabolic fate of trans-methyl styryl ketone in the male Fischer 344 rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193875/),min,17.7,195604,DB00145,Glycine
,9193875,apparent steady-state volume of distribution,"The following pharmacokinetic parameter values were obtained (mean +/- SD): terminal disposition half-life, 17.7 +/- 0.08 min; apparent steady-state volume of distribution, 0.89 +/- 0.14 liters/kg; systemic body clearance, 68.9 +/- 10.0 ml/kg *min; and mean residence time, 13.1 +/- 2.2 min.","Oral and topical absorption, disposition kinetics, and the metabolic fate of trans-methyl styryl ketone in the male Fischer 344 rat. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193875/),[l] / [kg],0.89,195605,DB00145,Glycine
,9193875,systemic body clearance,"The following pharmacokinetic parameter values were obtained (mean +/- SD): terminal disposition half-life, 17.7 +/- 0.08 min; apparent steady-state volume of distribution, 0.89 +/- 0.14 liters/kg; systemic body clearance, 68.9 +/- 10.0 ml/kg *min; and mean residence time, 13.1 +/- 2.2 min.","Oral and topical absorption, disposition kinetics, and the metabolic fate of trans-methyl styryl ketone in the male Fischer 344 rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193875/),[ml] / [kg·min],68.9,195606,DB00145,Glycine
,9193875,mean residence time,"The following pharmacokinetic parameter values were obtained (mean +/- SD): terminal disposition half-life, 17.7 +/- 0.08 min; apparent steady-state volume of distribution, 0.89 +/- 0.14 liters/kg; systemic body clearance, 68.9 +/- 10.0 ml/kg *min; and mean residence time, 13.1 +/- 2.2 min.","Oral and topical absorption, disposition kinetics, and the metabolic fate of trans-methyl styryl ketone in the male Fischer 344 rat. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193875/),min,13.1,195607,DB00145,Glycine
,16611415,blood half-life,"Three factors were identified: 1) tumor cell integrin expression (the alpha(V)beta3 integrin was expressed in BT-20 cells, but not in 9L cells); 2) nanoparticle pharmacokinetics (the cyclic RGD peptide cross-linked iron oxide had a blood half-life of 180 minutes and was able to escape from the vasculature over its long circulation time); and 3) tumor vascularization (the tumor had a dense capillary bed, with distances of <100 microm between capillaries).",Nanoparticle imaging of integrins on tumor cells. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16611415/),min,180,196054,DB00145,Glycine
,19607892,elimination half-lives (T(1/2beta)),"For glyphosate, the elimination half-lives (T(1/2beta)) from plasma were 9.99 h after i.v. and 14.38 h after oral administration.",Toxicokinetics of glyphosate and its metabolite aminomethyl phosphonic acid in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19607892/),h,9.99,198979,DB00145,Glycine
,19607892,elimination half-lives (T(1/2beta)),"For glyphosate, the elimination half-lives (T(1/2beta)) from plasma were 9.99 h after i.v. and 14.38 h after oral administration.",Toxicokinetics of glyphosate and its metabolite aminomethyl phosphonic acid in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19607892/),h,14.38,198980,DB00145,Glycine
,19607892,total plasma clearance,The total plasma clearance was not influenced by dose concentration or route and reached a value of 0.995 l h(-1)kg(-1).,Toxicokinetics of glyphosate and its metabolite aminomethyl phosphonic acid in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19607892/),[l] / [h],0.995,198981,DB00145,Glycine
,19607892,apparent volume of distribution in the second compartment (V(2)),"After i.v. administration, the apparent volume of distribution in the second compartment (V(2)) and volume of distribution at steady state (V(ss)) were 2.39 and 2.99 l kg(-1), respectively, suggesting a considerable diffusion of the herbicide into tissues.",Toxicokinetics of glyphosate and its metabolite aminomethyl phosphonic acid in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19607892/),[l] / [kg],2.39,198982,DB00145,Glycine
,19607892,volume of distribution at steady state (V(ss)),"After i.v. administration, the apparent volume of distribution in the second compartment (V(2)) and volume of distribution at steady state (V(ss)) were 2.39 and 2.99 l kg(-1), respectively, suggesting a considerable diffusion of the herbicide into tissues.",Toxicokinetics of glyphosate and its metabolite aminomethyl phosphonic acid in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19607892/),[l] / [kg],2.99,198983,DB00145,Glycine
,19607892,T(max),"After oral administration, glyphosate was partially and slowly absorbed with a T(max) of 5.16 h.",Toxicokinetics of glyphosate and its metabolite aminomethyl phosphonic acid in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19607892/),h,5.16,198984,DB00145,Glycine
,19607892,oral bioavailability,The oral bioavailability of glyphosate was found to be 23.21%.,Toxicokinetics of glyphosate and its metabolite aminomethyl phosphonic acid in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19607892/),%,23.21,198985,DB00145,Glycine
,19607892,maximum plasma concentrations,"The maximum plasma concentrations of glyphosate and AMPA were 4.62 and 0.416 microg ml(-1), respectively.",Toxicokinetics of glyphosate and its metabolite aminomethyl phosphonic acid in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19607892/),[μg] / [ml],4.62,198986,DB00145,Glycine
,19607892,maximum plasma concentrations,"The maximum plasma concentrations of glyphosate and AMPA were 4.62 and 0.416 microg ml(-1), respectively.",Toxicokinetics of glyphosate and its metabolite aminomethyl phosphonic acid in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19607892/),[μg] / [ml],0.416,198987,DB00145,Glycine
,19607892,elimination half-life (T(1/2beta)),"For AMPA, the elimination half-life (T(1/2beta)) was 15.08 h after oral administration of glyphosate parent compound.",Toxicokinetics of glyphosate and its metabolite aminomethyl phosphonic acid in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19607892/),h,15.08,198988,DB00145,Glycine
,7274310,terminal half-life,The plasma concentration/time curve displayed a biphasic profile and the terminal half-life of Ticlopidine was tentatively estimated to be 6-10 h in the rat.,"Metabolism of ticlopidine in rats: identification and quantitative determination of some its metabolites in plasma, urine and bile. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7274310/),h,6-10,199048,DB00145,Glycine
,29846887,time to maximum plasma concentration,Median time to maximum plasma concentration was 3.0-4.5 h with steady state being reached between days 6 and 10.,"Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29846887/),h,3.0-4.5,201684,DB00145,Glycine
,1874879,limit of detection,"The extraction procedures are simple with a limit of detection 2 and 0.5 micrograms/ml for milacemide in plasma and cerebrospinal fluid, respectively, and 0.5 micrograms/ml for glycinamide in plasma or cerebrospinal fluid.",Simple and rapid micro-analytical procedures for the estimation of milacemide and its metabolite glycinamide in rat plasma and cerebrospinal fluid by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874879/),[μg] / [ml],2,202184,DB00145,Glycine
,1874879,limit of detection,"The extraction procedures are simple with a limit of detection 2 and 0.5 micrograms/ml for milacemide in plasma and cerebrospinal fluid, respectively, and 0.5 micrograms/ml for glycinamide in plasma or cerebrospinal fluid.",Simple and rapid micro-analytical procedures for the estimation of milacemide and its metabolite glycinamide in rat plasma and cerebrospinal fluid by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874879/),[μg] / [ml],0.5,202185,DB00145,Glycine
,1685770,half-life of clearance,"After intravenous injection, the half-life of clearance of authentic FTCP from blood was 4.2 min in mice, 12 min in rats and 45 min in a rhesus monkey.","In vivo study of NMDA-sensitive glutamate receptor by fluorothienylcyclohexylpiperidine [correction of fluorothienylcycloexylpiperidine], a possible ligand for positron emission tomography. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685770/),min,4.2,208370,DB00145,Glycine
,1685770,half-life of clearance,"After intravenous injection, the half-life of clearance of authentic FTCP from blood was 4.2 min in mice, 12 min in rats and 45 min in a rhesus monkey.","In vivo study of NMDA-sensitive glutamate receptor by fluorothienylcyclohexylpiperidine [correction of fluorothienylcycloexylpiperidine], a possible ligand for positron emission tomography. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685770/),min,12,208371,DB00145,Glycine
,1685770,half-life of clearance,"After intravenous injection, the half-life of clearance of authentic FTCP from blood was 4.2 min in mice, 12 min in rats and 45 min in a rhesus monkey.","In vivo study of NMDA-sensitive glutamate receptor by fluorothienylcyclohexylpiperidine [correction of fluorothienylcycloexylpiperidine], a possible ligand for positron emission tomography. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685770/),min,45,208372,DB00145,Glycine
,8742934,absolute bioavailability,Coadministration of 10 mM GDC increased the absolute bioavailability of FD4 from 1.8 +/- 0.5% to 12.7 +/- 2.0%.,In-vivo buccal delivery of fluorescein isothiocyanate-dextran 4400 with glycodeoxycholate as an absorption enhancer in pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742934/),%,1.8,208754,DB00145,Glycine
,8742934,absolute bioavailability,Coadministration of 10 mM GDC increased the absolute bioavailability of FD4 from 1.8 +/- 0.5% to 12.7 +/- 2.0%.,In-vivo buccal delivery of fluorescein isothiocyanate-dextran 4400 with glycodeoxycholate as an absorption enhancer in pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742934/),%,12.7,208755,DB00145,Glycine
,31152925,particle size,"The mean particle size and zeta potential of the RGD-DOX-SLNs was 96.3 nm and 35.6 mV, respectively.","Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152925/),nm,96.3,208915,DB00145,Glycine
,31152925,zeta potential,"The mean particle size and zeta potential of the RGD-DOX-SLNs was 96.3 nm and 35.6 mV, respectively.","Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152925/),mv,35.6,208916,DB00145,Glycine
,31152925,Terminal half life (T1/2),Terminal half life (T1/2) and peak concentration (Cmax) of RGD-DOX-SLNs was 10.85 h and 39.12 ± 2.71 L/kg/h. in vitro and in vivo antitumor results indicate that RGD-DOX-SLNs might be a promising novel lipid carrier which could improve breast cancer therapy.,"Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152925/),h,10.85,208917,DB00145,Glycine
,31152925,peak concentration (Cmax),Terminal half life (T1/2) and peak concentration (Cmax) of RGD-DOX-SLNs was 10.85 h and 39.12 ± 2.71 L/kg/h. in vitro and in vivo antitumor results indicate that RGD-DOX-SLNs might be a promising novel lipid carrier which could improve breast cancer therapy.,"Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152925/),[l] / [h·kg],39.12,208918,DB00145,Glycine
,9330777,clearance (Cl),"Following i.v. administration (556 mg) to six dogs, VCGD had a clearance (Cl) value of 3.8 +/- 1.1 Lh-1 (mean +/- SD), a volume of distribution (Vss) of 15 +/- 2 L, and a half-life (t1/2) of 1.9 +/- 0.3 h.",Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),1/[lh],3.8,210911,DB00145,Glycine
,9330777,volume of distribution (Vss),"Following i.v. administration (556 mg) to six dogs, VCGD had a clearance (Cl) value of 3.8 +/- 1.1 Lh-1 (mean +/- SD), a volume of distribution (Vss) of 15 +/- 2 L, and a half-life (t1/2) of 1.9 +/- 0.3 h.",Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),l,15,210912,DB00145,Glycine
,9330777,half-life (t1/2),"Following i.v. administration (556 mg) to six dogs, VCGD had a clearance (Cl) value of 3.8 +/- 1.1 Lh-1 (mean +/- SD), a volume of distribution (Vss) of 15 +/- 2 L, and a half-life (t1/2) of 1.9 +/- 0.3 h.",Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),h,1.9,210913,DB00145,Glycine
,9330777,Cl,"DIGD had Cl, Vss, and t1/2 values of 10 +/- 0.8 Lh-1, 19 +/- 3 L, and 1.6 +/- 0.2 h, respectively.",Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),1/[lh],10,210914,DB00145,Glycine
,9330777,Vss,"DIGD had Cl, Vss, and t1/2 values of 10 +/- 0.8 Lh-1, 19 +/- 3 L, and 1.6 +/- 0.2 h, respectively.",Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),l,19,210915,DB00145,Glycine
,9330777,t1/2,"DIGD had Cl, Vss, and t1/2 values of 10 +/- 0.8 Lh-1, 19 +/- 3 L, and 1.6 +/- 0.2 h, respectively.",Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),h,1.6,210916,DB00145,Glycine
,9330777,fractions metabolized (fm),Both glycinamides were biotransformed to their glycine analogues with similar fractions metabolized (fm): 59 +/- 5% (VCGD) and 62 +/- 15% (DIGD).,Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),%,59,210917,DB00145,Glycine
,9330777,fractions metabolized (fm),Both glycinamides were biotransformed to their glycine analogues with similar fractions metabolized (fm): 59 +/- 5% (VCGD) and 62 +/- 15% (DIGD).,Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),%,62,210918,DB00145,Glycine
,9330777,t1/2,"Both VCGA and DIGA had higher Cl and lower Vss values than VCGD and DIGD and therefore their mean t1/2 values were 0.43 +/- 0.02 and 0.30 +/- 0.07 h, respectively.",Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),h,0.43,210919,DB00145,Glycine
,9330777,t1/2,"Both VCGA and DIGA had higher Cl and lower Vss values than VCGD and DIGD and therefore their mean t1/2 values were 0.43 +/- 0.02 and 0.30 +/- 0.07 h, respectively.",Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),h,0.30,210920,DB00145,Glycine
,9330777,fractions excreted unchanged (fe),"VCGA and DIGA were excreted mainly intact in the urine, with fractions excreted unchanged (fe) of 60 +/- 9 and 55 +/- 7%, respectively.",Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),%,60,210921,DB00145,Glycine
,9330777,fractions excreted unchanged (fe),"VCGA and DIGA were excreted mainly intact in the urine, with fractions excreted unchanged (fe) of 60 +/- 9 and 55 +/- 7%, respectively.",Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),%,55,210922,DB00145,Glycine
,28854403,runtime,"The analyte and internal standard were separated on a Shimadzu Shim-pack XR-ODS column (4.6×50mm, 2.2μm) using 0.1% formic acid-water-methanol as mobile phase, with a runtime of 5min.",An HPLC-MS/MS method for quantitation of Gly-MCA in mouse plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28854403/),min,5,212967,DB00145,Glycine
,12818629,bioavailability,"Ximelagatran is therefore much better than melagatran at penetrating the gastrointestinal barrier and, as a consequence, has sufficient bioavailability (20%) for oral administration.",The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818629/),%,20,213333,DB00145,Glycine
,7834163,terminal plasma t1/2,"Under acidic urine conditions, salicylic acid (SA) had a terminal plasma t1/2 value of 3.29 +/- 0.52 hours while under alkaline urine conditions this t1/2 was significantly reduced to 2.50 +/- 0.41 hours (p = 0.0156).","Effect of urinary pH on the pharmacokinetics of salicylic acid, with its glycine and glucuronide conjugates in human. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834163/),h,3.29,213740,DB00145,Glycine
,7834163,t1/2,"Under acidic urine conditions, salicylic acid (SA) had a terminal plasma t1/2 value of 3.29 +/- 0.52 hours while under alkaline urine conditions this t1/2 was significantly reduced to 2.50 +/- 0.41 hours (p = 0.0156).","Effect of urinary pH on the pharmacokinetics of salicylic acid, with its glycine and glucuronide conjugates in human. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834163/),h,2.50,213741,DB00145,Glycine
,7834163,total oral body clearance,The total oral body clearance of salicylic acid under acidic conditions (1.38 +/- 0.43 l/h) is significantly lower than under alkaline urine conditions (2.27 +/- 0.83 l/h; p = 0.0410).,"Effect of urinary pH on the pharmacokinetics of salicylic acid, with its glycine and glucuronide conjugates in human. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834163/),[l] / [h],1.38,213742,DB00145,Glycine
,7834163,total oral body clearance,The total oral body clearance of salicylic acid under acidic conditions (1.38 +/- 0.43 l/h) is significantly lower than under alkaline urine conditions (2.27 +/- 0.83 l/h; p = 0.0410).,"Effect of urinary pH on the pharmacokinetics of salicylic acid, with its glycine and glucuronide conjugates in human. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834163/),[l] / [h],2.27,213743,DB00145,Glycine
,7834163,protein binding,The protein binding of SA was 93.8 +/- 1.0% and that of SU was 89.7 +/- 2.2% in vivo and in vitro.,"Effect of urinary pH on the pharmacokinetics of salicylic acid, with its glycine and glucuronide conjugates in human. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834163/),%,93.8,213744,DB00145,Glycine
,7834163,protein binding,The protein binding of SA was 93.8 +/- 1.0% and that of SU was 89.7 +/- 2.2% in vivo and in vitro.,"Effect of urinary pH on the pharmacokinetics of salicylic acid, with its glycine and glucuronide conjugates in human. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834163/),%,89.7,213745,DB00145,Glycine
,7834163,protein binding,"SUPG had a protein binding of 84.8 +/- 1.8%, while SAPG showed no protein binding at all.","Effect of urinary pH on the pharmacokinetics of salicylic acid, with its glycine and glucuronide conjugates in human. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834163/),%,84.8,213746,DB00145,Glycine
,12029548,t(1/2),A rapid method for radiolabelling short peptides with 18F ( t(1/2)=109.7 min) for use in positron emission tomography (PET) was developed.,Rapid solid phase synthesis and biodistribution of 18F-labelled linear peptides. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12029548/),min,109.7,218640,DB00145,Glycine
,12029548,overall synthesis time,"The linear peptides were rapidly labelled with 4-[18F]fluorobenzoic acid with an overall radiochemical yield of 80%-90% (decay corrected), a radiochemical purity of >95% without HPLC purification and an overall synthesis time of 20 min.",Rapid solid phase synthesis and biodistribution of 18F-labelled linear peptides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12029548/),min,20,218641,DB00145,Glycine
,2148814,half-life,"The half-life of 125I-ANF (99-126) in mouse blood in vivo, evaluated after HPLC analysis, was approximately 0.5 min.",Degradation of atrial natriuretic factor in mouse blood in vitro and in vivo: role of enkephalinase (EC 3.4.24.11). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2148814/),min,0.5,218950,DB00145,Glycine
,31325170,total run time,"EDB, IDB, VDB and the IS eluted at 7.36, 8.60, 9.50 and 5.12 min, respectively, with a total run time of 10 min.","Validated HPLC method for simultaneous quantification of mutant IDH1/2 inhibitors (enasidenib, ivosidenib and vorasidenib) in mouse plasma: Application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325170/),min,10,220858,DB00145,Glycine
,9113346,"dissociation constant, Kd,1","The highest binding affinity for dansylsarcosine was observed with HSA (dissociation constant, Kd,1 = 0.5 microM), while it was lowest in the mouse (Kd,1 = 18 microM).",Determination of protein binding of troglitazone stereoisomers by fluorometric titration. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9113346/),μM,0.5,221049,DB00145,Glycine
,9113346,"Kd,1","The highest binding affinity for dansylsarcosine was observed with HSA (dissociation constant, Kd,1 = 0.5 microM), while it was lowest in the mouse (Kd,1 = 18 microM).",Determination of protein binding of troglitazone stereoisomers by fluorometric titration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9113346/),μM,18,221050,DB00145,Glycine
,9113346,Ki,"The Ki values for KK and ddY mouse plasma and mouse and rat albumin were in the range 2-15 microM, and there were no large variations among stereoisomers, the maximum differences being twofold.",Determination of protein binding of troglitazone stereoisomers by fluorometric titration. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9113346/),μM,2-15,221051,DB00145,Glycine
,9662600,extraction fraction,"After peripheral injection in dogs, there was an early arteriovenous concentration gradient across the liver indicating an hepatocyte extraction fraction in the three animals of 0.9, 0.8 and 0.6.",Bidirectional transport of iminodiacetic organic anion analogues between plasma and hepatocyte. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9662600/),,0.9,222012,DB00145,Glycine
,9662600,extraction fraction,"After peripheral injection in dogs, there was an early arteriovenous concentration gradient across the liver indicating an hepatocyte extraction fraction in the three animals of 0.9, 0.8 and 0.6.",Bidirectional transport of iminodiacetic organic anion analogues between plasma and hepatocyte. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9662600/),,0.8,222013,DB00145,Glycine
,9662600,extraction fraction,"After peripheral injection in dogs, there was an early arteriovenous concentration gradient across the liver indicating an hepatocyte extraction fraction in the three animals of 0.9, 0.8 and 0.6.",Bidirectional transport of iminodiacetic organic anion analogues between plasma and hepatocyte. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9662600/),,0.6,222014,DB00145,Glycine
,10206321,absorptive clearances,"The absorptive clearances of the tripeptoid and tetrapeptide were 6.7 and 4.8 x 10(-4) mL min(-1) cm(-1), respectively, and the corresponding octanol/water partition coefficients were 0.39 and 0.30.",Absorption and disposition of a tripeptoid and a tetrapeptide in the rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10206321/),[ml] / [cm·min],6.7,224094,DB00145,Glycine
,10206321,absorptive clearances,"The absorptive clearances of the tripeptoid and tetrapeptide were 6.7 and 4.8 x 10(-4) mL min(-1) cm(-1), respectively, and the corresponding octanol/water partition coefficients were 0.39 and 0.30.",Absorption and disposition of a tripeptoid and a tetrapeptide in the rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10206321/),[ml] / [cm·min],4.8 x 10(-4),224095,DB00145,Glycine
,10206321,octanol/water partition coefficients,"The absorptive clearances of the tripeptoid and tetrapeptide were 6.7 and 4.8 x 10(-4) mL min(-1) cm(-1), respectively, and the corresponding octanol/water partition coefficients were 0.39 and 0.30.",Absorption and disposition of a tripeptoid and a tetrapeptide in the rat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10206321/),,0.39,224096,DB00145,Glycine
,10206321,octanol/water partition coefficients,"The absorptive clearances of the tripeptoid and tetrapeptide were 6.7 and 4.8 x 10(-4) mL min(-1) cm(-1), respectively, and the corresponding octanol/water partition coefficients were 0.39 and 0.30.",Absorption and disposition of a tripeptoid and a tetrapeptide in the rat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10206321/),,0.30,224097,DB00145,Glycine
,10206321,oral absorption,"The extent of oral absorption of the tripeptoid was only 3-8%, consistent with its low absorptive clearance.",Absorption and disposition of a tripeptoid and a tetrapeptide in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10206321/),%,3-8,224098,DB00145,Glycine
,10386522,ED50,"After i.p. administration to mice in the maximal electroshock seizure test (MES), DE-VGD had an ED50 value comparable to that of VGD (145 and 152 mg/kg, respectively), whereas in the subcutaneous metrazol test (sc Met) model, M-VGD had a slightly lower ED50 than VGD (108 and 127 mg/kg, respectively).",Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10386522/),[mg] / [kg],145,224465,DB00145,Glycine
,10386522,ED50,"After i.p. administration to mice in the maximal electroshock seizure test (MES), DE-VGD had an ED50 value comparable to that of VGD (145 and 152 mg/kg, respectively), whereas in the subcutaneous metrazol test (sc Met) model, M-VGD had a slightly lower ED50 than VGD (108 and 127 mg/kg, respectively).",Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10386522/),[mg] / [kg],152,224466,DB00145,Glycine
,10386522,ED50,"After i.p. administration to mice in the maximal electroshock seizure test (MES), DE-VGD had an ED50 value comparable to that of VGD (145 and 152 mg/kg, respectively), whereas in the subcutaneous metrazol test (sc Met) model, M-VGD had a slightly lower ED50 than VGD (108 and 127 mg/kg, respectively).",Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10386522/),[mg] / [kg],108,224467,DB00145,Glycine
,10386522,ED50,"After i.p. administration to mice in the maximal electroshock seizure test (MES), DE-VGD had an ED50 value comparable to that of VGD (145 and 152 mg/kg, respectively), whereas in the subcutaneous metrazol test (sc Met) model, M-VGD had a slightly lower ED50 than VGD (108 and 127 mg/kg, respectively).",Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10386522/),[mg] / [kg],127,224468,DB00145,Glycine
,10386522,clearance,"Of the N-alkyl VGD derivatives studied, M-VGD had the best pharmacokinetic profile: the lowest clearance (5.4 L/h), the longest half-life (1.8 h), and the lowest liver-extraction ratio (14%).",Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10386522/),[l] / [h],5.4,224469,DB00145,Glycine
,10386522,half-life,"Of the N-alkyl VGD derivatives studied, M-VGD had the best pharmacokinetic profile: the lowest clearance (5.4 L/h), the longest half-life (1.8 h), and the lowest liver-extraction ratio (14%).",Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10386522/),h,1.8,224470,DB00145,Glycine
,10386522,liver-extraction ratio,"Of the N-alkyl VGD derivatives studied, M-VGD had the best pharmacokinetic profile: the lowest clearance (5.4 L/h), the longest half-life (1.8 h), and the lowest liver-extraction ratio (14%).",Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10386522/),%,14,224471,DB00145,Glycine
,11384240,IC50,"The most potent compound in this series, 6,7-dichloro-5-[1-(1,2,4-triazol-4-yl)propyl]-1,4-dihydro-(1H, 4H)-quinoxaline-2,3-dione (17) (binding IC50 = 2.6 nM; cortical wedge EC50 = 90 nM), inhibited NMDA-induced hyperlocomotion in mice (6/9 protected at 20 mg/kg iv).","Structure-activity relationships of 1,4-dihydro-(1H,4H)-quinoxaline-2,3-diones as N-methyl-D-aspartate (glycine site) receptor antagonists. 1. Heterocyclic substituted 5-alkyl derivatives. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11384240/),nM,2.6,226469,DB00145,Glycine
,11384240,EC50,"The most potent compound in this series, 6,7-dichloro-5-[1-(1,2,4-triazol-4-yl)propyl]-1,4-dihydro-(1H, 4H)-quinoxaline-2,3-dione (17) (binding IC50 = 2.6 nM; cortical wedge EC50 = 90 nM), inhibited NMDA-induced hyperlocomotion in mice (6/9 protected at 20 mg/kg iv).","Structure-activity relationships of 1,4-dihydro-(1H,4H)-quinoxaline-2,3-diones as N-methyl-D-aspartate (glycine site) receptor antagonists. 1. Heterocyclic substituted 5-alkyl derivatives. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11384240/),nM,90,226470,DB00145,Glycine
,3888490,absorption half-life,Aspirin absorption follows first-order kinetics with an absorption half-life ranging from 5 to 16 minutes.,Clinical pharmacokinetics of the salicylates. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3888490/),min,5 to 16,227085,DB00145,Glycine
,3888490,serum half-life,The serum half-life of aspirin is approximately 20 minutes.,Clinical pharmacokinetics of the salicylates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3888490/),min,20,227086,DB00145,Glycine
less,24970349,D50,An exploration of the sensitivity to the presence of larger particles within a polydisperse distribution showed that simulated Cmax is again more affected than AUC but is less than 20% reduced as long as D50 is less than 8 μm and D90 is smaller than 56 μm.,Physiologically based absorption modelling to predict the impact of drug properties on pharmacokinetics of bitopertin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24970349/),μ,8,228649,DB00145,Glycine
smaller,24970349,D90,An exploration of the sensitivity to the presence of larger particles within a polydisperse distribution showed that simulated Cmax is again more affected than AUC but is less than 20% reduced as long as D50 is less than 8 μm and D90 is smaller than 56 μm.,Physiologically based absorption modelling to predict the impact of drug properties on pharmacokinetics of bitopertin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24970349/),μ,56,228650,DB00145,Glycine
,8383742,IC50,"Inhibition of [3H]5,7-dichlorokynurenic acid (a high-affinity glycine receptor antagonist) binding by felbamate (IC50 = 374 microM) corresponded well with peak felbamate concentrations found in brain (683 and 759 microM) and plasma (679 and 807 microM) 8 hr after 300 (i.p.) or 500 mg/kg (p.o.) doses, respectively.",Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8383742/),μM,374,229428,DB00145,Glycine
,8383742,peak felbamate concentrations,"Inhibition of [3H]5,7-dichlorokynurenic acid (a high-affinity glycine receptor antagonist) binding by felbamate (IC50 = 374 microM) corresponded well with peak felbamate concentrations found in brain (683 and 759 microM) and plasma (679 and 807 microM) 8 hr after 300 (i.p.) or 500 mg/kg (p.o.) doses, respectively.",Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8383742/),μM,683,229429,DB00145,Glycine
,8383742,peak felbamate concentrations,"Inhibition of [3H]5,7-dichlorokynurenic acid (a high-affinity glycine receptor antagonist) binding by felbamate (IC50 = 374 microM) corresponded well with peak felbamate concentrations found in brain (683 and 759 microM) and plasma (679 and 807 microM) 8 hr after 300 (i.p.) or 500 mg/kg (p.o.) doses, respectively.",Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8383742/),μM,759,229430,DB00145,Glycine
,8383742,peak felbamate concentrations,"Inhibition of [3H]5,7-dichlorokynurenic acid (a high-affinity glycine receptor antagonist) binding by felbamate (IC50 = 374 microM) corresponded well with peak felbamate concentrations found in brain (683 and 759 microM) and plasma (679 and 807 microM) 8 hr after 300 (i.p.) or 500 mg/kg (p.o.) doses, respectively.",Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8383742/),μM,679,229431,DB00145,Glycine
,8383742,peak felbamate concentrations,"Inhibition of [3H]5,7-dichlorokynurenic acid (a high-affinity glycine receptor antagonist) binding by felbamate (IC50 = 374 microM) corresponded well with peak felbamate concentrations found in brain (683 and 759 microM) and plasma (679 and 807 microM) 8 hr after 300 (i.p.) or 500 mg/kg (p.o.) doses, respectively.",Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8383742/),μM,807,229432,DB00145,Glycine
,26872892,time to peak plasma concentration (Tmax ),"Under fed conditions, the median time to peak plasma concentration (Tmax ) of ixazomib was delayed by approximately 3 hours compared with administration in the fasted state (1.02 hours vs 4.0 hours), and there was a 28% reduction in total systemic exposure (area under the curve, AUC) and a 69% reduction in peak plasma concentration (Cmax ).","The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26872892/),h,1.02,229845,DB00145,Glycine
,26872892,time to peak plasma concentration (Tmax ),"Under fed conditions, the median time to peak plasma concentration (Tmax ) of ixazomib was delayed by approximately 3 hours compared with administration in the fasted state (1.02 hours vs 4.0 hours), and there was a 28% reduction in total systemic exposure (area under the curve, AUC) and a 69% reduction in peak plasma concentration (Cmax ).","The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26872892/),h,4.0,229846,DB00145,Glycine
,12974871,Oral bioavailability,"Oral bioavailability, measured as the plasma concentration of the active metabolite, seems to be higher for ximelagatran (20%) than for BIBR 1048 (estimated to 5%).",Oral direct thrombin inhibitors in clinical development. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12974871/),%,20,230458,DB00145,Glycine
,12974871,Oral bioavailability,"Oral bioavailability, measured as the plasma concentration of the active metabolite, seems to be higher for ximelagatran (20%) than for BIBR 1048 (estimated to 5%).",Oral direct thrombin inhibitors in clinical development. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12974871/),%,5,230459,DB00145,Glycine
,12974871,half-life,"BIBR 953 has a longer half-life (about 12 h) than does melagatran (3-5 h) after oral administration of BIBR 1048 and ximelagatran, respectively.",Oral direct thrombin inhibitors in clinical development. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12974871/),h,12,230460,DB00145,Glycine
,12974871,half-life,"BIBR 953 has a longer half-life (about 12 h) than does melagatran (3-5 h) after oral administration of BIBR 1048 and ximelagatran, respectively.",Oral direct thrombin inhibitors in clinical development. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12974871/),h,3-5,230461,DB00145,Glycine
,31005336,tmax,"In addition, median tmax was 3.5-4.0 h, with a geometric mean t½ of 29.0-41.2 h.",Pharmacokinetics of Single Doses of BI 425809 in Healthy Chinese and Japanese Subjects: A Randomized Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31005336/),h,3.5-4.0,231039,DB00145,Glycine
,31005336,t½,"In addition, median tmax was 3.5-4.0 h, with a geometric mean t½ of 29.0-41.2 h.",Pharmacokinetics of Single Doses of BI 425809 in Healthy Chinese and Japanese Subjects: A Randomized Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31005336/),h,29.0-41.2,231040,DB00145,Glycine
,31005336,Vz/F,Vz/F was 209-315 L and similar between the subgroups.,Pharmacokinetics of Single Doses of BI 425809 in Healthy Chinese and Japanese Subjects: A Randomized Study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31005336/),l,209-315,231041,DB00145,Glycine
,22352389,total recovery,"TH-302 was extensively metabolized with total recovery of 75.1%, with 47.5% and 25.3% excreted through the urine and through the bile into the feces, respectively.",Metabolism and excretion of TH-302 in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22352389/),%,75.1,231141,DB00145,Glycine
,22352389,total recovery,"TH-302 was extensively metabolized with total recovery of 75.1%, with 47.5% and 25.3% excreted through the urine and through the bile into the feces, respectively.",Metabolism and excretion of TH-302 in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22352389/),%,47.5,231142,DB00145,Glycine
,22352389,total recovery,"TH-302 was extensively metabolized with total recovery of 75.1%, with 47.5% and 25.3% excreted through the urine and through the bile into the feces, respectively.",Metabolism and excretion of TH-302 in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22352389/),%,25.3,231143,DB00145,Glycine
,21948240,maximal brain concentration,The maximal brain concentration (86.52 μg/g) was reached after 1 h post-dosing.,Pharmacokinetics of natural borneol after oral administration in mice brain and its effect on excitation ratio. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21948240/),[μg] / [g],86.52,231352,DB00145,Glycine
,6857680,alpha,"A linear two-compartment open model described the blood MeCl data: alpha and beta phase elimination half-times corresponded to approximately 4 and 15 min, respectively, in rats, and 8 and 40 min in dogs.",Pharmacokinetics and metabolism of inhaled methyl chloride in the rat and dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6857680/),min,4,234224,DB00145,Glycine
,6857680,alpha,"A linear two-compartment open model described the blood MeCl data: alpha and beta phase elimination half-times corresponded to approximately 4 and 15 min, respectively, in rats, and 8 and 40 min in dogs.",Pharmacokinetics and metabolism of inhaled methyl chloride in the rat and dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6857680/),min,15,234225,DB00145,Glycine
,6857680,alpha,"A linear two-compartment open model described the blood MeCl data: alpha and beta phase elimination half-times corresponded to approximately 4 and 15 min, respectively, in rats, and 8 and 40 min in dogs.",Pharmacokinetics and metabolism of inhaled methyl chloride in the rat and dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6857680/),min,8,234226,DB00145,Glycine
,6857680,beta phase elimination half-times,"A linear two-compartment open model described the blood MeCl data: alpha and beta phase elimination half-times corresponded to approximately 4 and 15 min, respectively, in rats, and 8 and 40 min in dogs.",Pharmacokinetics and metabolism of inhaled methyl chloride in the rat and dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6857680/),min,15,234227,DB00145,Glycine
,6857680,beta phase elimination half-times,"A linear two-compartment open model described the blood MeCl data: alpha and beta phase elimination half-times corresponded to approximately 4 and 15 min, respectively, in rats, and 8 and 40 min in dogs.",Pharmacokinetics and metabolism of inhaled methyl chloride in the rat and dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6857680/),min,8,234228,DB00145,Glycine
,6857680,beta phase elimination half-times,"A linear two-compartment open model described the blood MeCl data: alpha and beta phase elimination half-times corresponded to approximately 4 and 15 min, respectively, in rats, and 8 and 40 min in dogs.",Pharmacokinetics and metabolism of inhaled methyl chloride in the rat and dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6857680/),min,40,234229,DB00145,Glycine
,30136756,tmax,The peak plasma concentration (Cmax ) of BI 425809 was achieved earlier in plasma than in CSF (tmax 3-5 vs.,"Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30136756/),,3,234954,DB00145,Glycine
,30136756,tmax,The peak plasma concentration (Cmax ) of BI 425809 was achieved earlier in plasma than in CSF (tmax 3-5 vs.,"Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30136756/),,5,234955,DB00145,Glycine
,28440713,drug entrapment efficiency,The nanoconjugate with a drug entrapment efficiency of 82.71 ± 6.23% and a drug loading of 66.01 ± 4.98% was hemocompatibile with appreciable MCF-7 cytotoxicity.,Glycinated fullerenes for tamoxifen intracellular delivery with improved anticancer activity and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28440713/),%,82.71,235112,DB00145,Glycine
,28440713,drug loading,The nanoconjugate with a drug entrapment efficiency of 82.71 ± 6.23% and a drug loading of 66.01 ± 4.98% was hemocompatibile with appreciable MCF-7 cytotoxicity.,Glycinated fullerenes for tamoxifen intracellular delivery with improved anticancer activity and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28440713/),%,66.01,235113,DB00145,Glycine
,19638462,terminal half-life,The terminal half-life for CHR-2797 is approximately 1 to 3.5 hours and between 6 and 11 hours for CHR-79888.,"A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19638462/),h,1 to 3.5,236739,DB00145,Glycine
,19638462,terminal half-life,The terminal half-life for CHR-2797 is approximately 1 to 3.5 hours and between 6 and 11 hours for CHR-79888.,"A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19638462/),h,6 and 11,236740,DB00145,Glycine
,643124,urinary excretion,"Its urinary excretion is very low (2.5 per cent in 15 hours), 1.7 per cent being eliminated 3 hours after administration.",Pharmacokinetics of butocine. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/643124/),%,2.5,236953,DB00145,Glycine
,643124,urinary excretion,"Its urinary excretion is very low (2.5 per cent in 15 hours), 1.7 per cent being eliminated 3 hours after administration.",Pharmacokinetics of butocine. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/643124/),%,1.7,236954,DB00145,Glycine
,643124,renal clearance,"Its renal clearance is likwise very low, i.e. 1.5 ml/min compared with endogenous creatinine clearance of 81.2 ml/min.",Pharmacokinetics of butocine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/643124/),[ml] / [min],1.5,236955,DB00145,Glycine
,8095213,Aer,"After oral administration of a single dose of [14C]cefcanel daloxate hydrochloride to 7 healthy male volunteers (group A), plasma concentrations (t1/2 approximately 1 hr) and excretion of radioactivity, cefcanel (Aer = 38.2 +/- 3.8%, t1/2 approximately 1 hr), mandelic acid glycine conjugate (Aer = 3.7 +/- 0.5%, t1/2 approximately 15 hr) and N-mandelyl-2-aminoethanol (Aer = 7.5 +/- 3.0%) were evaluated.",Disposition of oral [14C]cefcanel daloxate hydrochloride in healthy male subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095213/),%,38.2,237385,DB00145,Glycine
,8095213,t1/2,"After oral administration of a single dose of [14C]cefcanel daloxate hydrochloride to 7 healthy male volunteers (group A), plasma concentrations (t1/2 approximately 1 hr) and excretion of radioactivity, cefcanel (Aer = 38.2 +/- 3.8%, t1/2 approximately 1 hr), mandelic acid glycine conjugate (Aer = 3.7 +/- 0.5%, t1/2 approximately 15 hr) and N-mandelyl-2-aminoethanol (Aer = 7.5 +/- 3.0%) were evaluated.",Disposition of oral [14C]cefcanel daloxate hydrochloride in healthy male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095213/),h,1,237386,DB00145,Glycine
,8095213,Aer,"After oral administration of a single dose of [14C]cefcanel daloxate hydrochloride to 7 healthy male volunteers (group A), plasma concentrations (t1/2 approximately 1 hr) and excretion of radioactivity, cefcanel (Aer = 38.2 +/- 3.8%, t1/2 approximately 1 hr), mandelic acid glycine conjugate (Aer = 3.7 +/- 0.5%, t1/2 approximately 15 hr) and N-mandelyl-2-aminoethanol (Aer = 7.5 +/- 3.0%) were evaluated.",Disposition of oral [14C]cefcanel daloxate hydrochloride in healthy male subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095213/),%,3.7,237387,DB00145,Glycine
,8095213,t1/2,"After oral administration of a single dose of [14C]cefcanel daloxate hydrochloride to 7 healthy male volunteers (group A), plasma concentrations (t1/2 approximately 1 hr) and excretion of radioactivity, cefcanel (Aer = 38.2 +/- 3.8%, t1/2 approximately 1 hr), mandelic acid glycine conjugate (Aer = 3.7 +/- 0.5%, t1/2 approximately 15 hr) and N-mandelyl-2-aminoethanol (Aer = 7.5 +/- 3.0%) were evaluated.",Disposition of oral [14C]cefcanel daloxate hydrochloride in healthy male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095213/),h,15,237388,DB00145,Glycine
,8095213,Aer,"After oral administration of a single dose of [14C]cefcanel daloxate hydrochloride to 7 healthy male volunteers (group A), plasma concentrations (t1/2 approximately 1 hr) and excretion of radioactivity, cefcanel (Aer = 38.2 +/- 3.8%, t1/2 approximately 1 hr), mandelic acid glycine conjugate (Aer = 3.7 +/- 0.5%, t1/2 approximately 15 hr) and N-mandelyl-2-aminoethanol (Aer = 7.5 +/- 3.0%) were evaluated.",Disposition of oral [14C]cefcanel daloxate hydrochloride in healthy male subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095213/),%,7.5,237389,DB00145,Glycine
,8095213,absolute oral bioavailability,"The absolute oral bioavailability of cefcanel was approximately 40% after administration of cefcanel daloxate hydrochloride and the extent of urinary excretion of cefcanel, mandelic acid glycine conjugate, and N-mandelyl-2-aminoethanol after an equimolar intravenous administration of cefcanel, were determined in a separate, similar group of volunteers (N = 12, group B).",Disposition of oral [14C]cefcanel daloxate hydrochloride in healthy male subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095213/),%,40,237390,DB00145,Glycine
,8095213,Total plasma clearance,Total plasma clearance of cefcanel was 179.1 +/- 22.4 ml/min/1.73 m2 after intravenous administration.,Disposition of oral [14C]cefcanel daloxate hydrochloride in healthy male subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095213/),[ml] / [1.73·m2·min],179.1,237391,DB00145,Glycine
,8095213,Renal clearances,"Renal clearances of cefcanel were 173.9 +/- 95.6 (po, group B), 166.6 +/- 31.9 (i.v., group B), and 136.3 +/- 16.1 ml/min/1.73 m2 (po, group A).",Disposition of oral [14C]cefcanel daloxate hydrochloride in healthy male subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095213/),[ml] / [1.73·m2·min],173.9,237392,DB00145,Glycine
,8095213,Renal clearances,"Renal clearances of cefcanel were 173.9 +/- 95.6 (po, group B), 166.6 +/- 31.9 (i.v., group B), and 136.3 +/- 16.1 ml/min/1.73 m2 (po, group A).",Disposition of oral [14C]cefcanel daloxate hydrochloride in healthy male subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095213/),[ml] / [1.73·m2·min],166.6,237393,DB00145,Glycine
,8095213,Renal clearances,"Renal clearances of cefcanel were 173.9 +/- 95.6 (po, group B), 166.6 +/- 31.9 (i.v., group B), and 136.3 +/- 16.1 ml/min/1.73 m2 (po, group A).",Disposition of oral [14C]cefcanel daloxate hydrochloride in healthy male subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095213/),[ml] / [1.73·m2·min],136.3,237394,DB00145,Glycine
,21880454,clearance,ON01910 exhibited a clearance of 3.61±0.85 l/h/kg and a half life of 8.66±3.30 h at 50 mg/kg dose given I.V.,Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21880454/),[l] / [h·kg],3.61,237492,DB00145,Glycine
,21880454,half life,ON01910 exhibited a clearance of 3.61±0.85 l/h/kg and a half life of 8.66±3.30 h at 50 mg/kg dose given I.V.,Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21880454/),h,8.66,237493,DB00145,Glycine
,28236703,diameter,"The mean diameter, zeta potential, entrapment efficiency and drug loading capacity for RGD/PEG-PUE-SLN were observed as 110.5nm, -26.2mV, 85.7% and 16.5% respectively.","RGD modified and PEGylated lipid nanoparticles loaded with puerarin: Formulation, characterization and protective effects on acute myocardial ischemia model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28236703/),nm,110.5,238868,DB00145,Glycine
,28236703,zeta potential,"The mean diameter, zeta potential, entrapment efficiency and drug loading capacity for RGD/PEG-PUE-SLN were observed as 110.5nm, -26.2mV, 85.7% and 16.5% respectively.","RGD modified and PEGylated lipid nanoparticles loaded with puerarin: Formulation, characterization and protective effects on acute myocardial ischemia model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28236703/),m,-,238869,DB00145,Glycine
,28236703,entrapment efficiency,"The mean diameter, zeta potential, entrapment efficiency and drug loading capacity for RGD/PEG-PUE-SLN were observed as 110.5nm, -26.2mV, 85.7% and 16.5% respectively.","RGD modified and PEGylated lipid nanoparticles loaded with puerarin: Formulation, characterization and protective effects on acute myocardial ischemia model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28236703/),m,-,238870,DB00145,Glycine
,28236703,entrapment efficiency,"The mean diameter, zeta potential, entrapment efficiency and drug loading capacity for RGD/PEG-PUE-SLN were observed as 110.5nm, -26.2mV, 85.7% and 16.5% respectively.","RGD modified and PEGylated lipid nanoparticles loaded with puerarin: Formulation, characterization and protective effects on acute myocardial ischemia model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28236703/),%,85.7,238871,DB00145,Glycine
,28236703,AUC,Pharmacokinetics results indicated that AUC increased from 52.93 (μg/mLh) for free PUE to 176.5 (μg/mLh) for RGD/PEG-PUE-SLN.,"RGD modified and PEGylated lipid nanoparticles loaded with puerarin: Formulation, characterization and protective effects on acute myocardial ischemia model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28236703/),[μg] / [mlh],52.93,238872,DB00145,Glycine
,28236703,AUC,Pharmacokinetics results indicated that AUC increased from 52.93 (μg/mLh) for free PUE to 176.5 (μg/mLh) for RGD/PEG-PUE-SLN.,"RGD modified and PEGylated lipid nanoparticles loaded with puerarin: Formulation, characterization and protective effects on acute myocardial ischemia model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28236703/),[μg] / [mlh],176.5,238873,DB00145,Glycine
,28236703,T1/2,"Similarly, T1/2 increased from 0.73h for free PUE to 2.62h for RGD/PEG-PUE-SLN.","RGD modified and PEGylated lipid nanoparticles loaded with puerarin: Formulation, characterization and protective effects on acute myocardial ischemia model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28236703/),h,0.73,238874,DB00145,Glycine
,28236703,T1/2,"Similarly, T1/2 increased from 0.73h for free PUE to 2.62h for RGD/PEG-PUE-SLN.","RGD modified and PEGylated lipid nanoparticles loaded with puerarin: Formulation, characterization and protective effects on acute myocardial ischemia model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28236703/),h,2.62,238875,DB00145,Glycine
,8894115,fe,"(E)-2-ene valproyl glycinamide was partially excreted unchanged in the urine (fe = 7.4%), while its urinary metabolite was (E)-2-ene valproyl glycine.",Pharmacokinetic and pharmacodynamic analysis of (E)-2-ene valproyl derivatives of glycine and valproyl derivatives of nipecotic acid. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894115/),%,7.4,240045,DB00145,Glycine
at,16080276,bioavailability,FSD has therefore documented a bioavailability of at least 11% from a single daily dose of 100 mg Fe and was effective in the treatment of the anaemia in almost all patients under study.,Bioavailability of oral iron drugs as judged by a 59Fe-whole-body counting technique in patients with iron deficiency anaemia. Therapeutic efficacy of iron(II)-glycine sulfate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080276/),%,11,240254,DB00145,Glycine
,3400930,maximal serum/plasma concentrations,"After oral administration of 15.6 to 31.3 of 2-MPG/kg of body weight, maximal serum/plasma concentrations were from 28.6 to 76.3/mumol/L after 1 to 3 hours in 6 cystinuric dogs.",Treatment of clinically normal and cystinuric dogs with 2-mercaptopropionylglycine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3400930/),1/[l·μM],28.6 to 76.3,240654,DB00145,Glycine
,3400930,urinary excretion,"The mean urinary excretion was 22% (range, 0.3 to 58.9%) of the dose.",Treatment of clinically normal and cystinuric dogs with 2-mercaptopropionylglycine. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3400930/),%,22,240655,DB00145,Glycine
,30268994,elimination t1/2,"After iv administration (0.1 mmol/kg body weight (bw)), plasma d-serine declined multiexponentially with an elimination t1/2 of 108 ± 16 min, and the total clearance was 7.9 ± 0.9 ml/min/kg bw.",Pharmacokinetics and toxicokinetics of d-serine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30268994/),min,108,242208,DB00145,Glycine
,30268994,total clearance,"After iv administration (0.1 mmol/kg body weight (bw)), plasma d-serine declined multiexponentially with an elimination t1/2 of 108 ± 16 min, and the total clearance was 7.9 ± 0.9 ml/min/kg bw.",Pharmacokinetics and toxicokinetics of d-serine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30268994/),[ml] / [bw·kg·min],7.9,242209,DB00145,Glycine
,30268994,oral bioavailability,The oral bioavailability of d-serine was estimated to be 94 ± 27%.,Pharmacokinetics and toxicokinetics of d-serine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30268994/),%,94,242210,DB00145,Glycine
>,30268994,Cmax,"When the Cmax value of d-serine was approximately >2 μmol/ml, the plasma creatinine increased remarkably 24 h after d-serine administration.",Pharmacokinetics and toxicokinetics of d-serine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30268994/),[μM] / [ml],2,242211,DB00145,Glycine
,24920586,maximum tolerated dose,"The maximum tolerated dose was 2.0 mg/m(2), which 40 patients received in 4 expansion cohorts.","Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24920586/),[mg] / [m(2],2.0,242784,DB00145,Glycine
,24920586,terminal half-life,The terminal half-life of ixazomib was 3.3 to 7.4 days; plasma exposure increased proportionally with dose (0.48-2.23 mg/m(2)).,"Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24920586/),d,3.3 to 7.4,242785,DB00145,Glycine
,1097636,half-lives of,"The half-lives of blood radioactivity, after the oral administration of I-9-14C, were about 18 and 12 hr in the rat and beagle hound, respectively.","Absorption, distribution, and metabolic fate of 7-chloro-3,3a-dihydro-2-methyl-2H,9H-isoxazolo-(3,2-b)(1,3)-benzoxazin-9-one in rats, dogs, and humans. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1097636/),h,18,243044,DB00145,Glycine
,1097636,half-lives of,"The half-lives of blood radioactivity, after the oral administration of I-9-14C, were about 18 and 12 hr in the rat and beagle hound, respectively.","Absorption, distribution, and metabolic fate of 7-chloro-3,3a-dihydro-2-methyl-2H,9H-isoxazolo-(3,2-b)(1,3)-benzoxazin-9-one in rats, dogs, and humans. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1097636/),h,12,243045,DB00145,Glycine
,1097636,half-life,"In human subjects, no intact I was detected in the bloodstream; however, the clearance of the metabolite, 5-chlorosalicylic acid, had a half-life of about 33 hr.","Absorption, distribution, and metabolic fate of 7-chloro-3,3a-dihydro-2-methyl-2H,9H-isoxazolo-(3,2-b)(1,3)-benzoxazin-9-one in rats, dogs, and humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1097636/),h,33,243046,DB00145,Glycine
,17094777,t(max),"Delayed gastric emptying was associated with a significantly longer MPA t(max)[1.0 (0.33-2.0) h vs. 0.5 (0.33-1.0) h; mean difference 0.39 h, 95% confidence interval (CI) 0.03, 0.75; P = 0.0289] and with a significant decrease in the maximum MPA concentration after dosing [10.6 (6.5-21.3) mg l(-1)vs. 20.1 (10.7-28.5) mg l(-1); mean difference 6.5 mg l(-1), 95% CI 2.1, 10.9; P = 0.0075].",Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17094777/),h,1.0,243590,DB00145,Glycine
,17094777,t(max),"Delayed gastric emptying was associated with a significantly longer MPA t(max)[1.0 (0.33-2.0) h vs. 0.5 (0.33-1.0) h; mean difference 0.39 h, 95% confidence interval (CI) 0.03, 0.75; P = 0.0289] and with a significant decrease in the maximum MPA concentration after dosing [10.6 (6.5-21.3) mg l(-1)vs. 20.1 (10.7-28.5) mg l(-1); mean difference 6.5 mg l(-1), 95% CI 2.1, 10.9; P = 0.0075].",Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17094777/),h,0.5,243591,DB00145,Glycine
,17094777,maximum MPA concentration,"Delayed gastric emptying was associated with a significantly longer MPA t(max)[1.0 (0.33-2.0) h vs. 0.5 (0.33-1.0) h; mean difference 0.39 h, 95% confidence interval (CI) 0.03, 0.75; P = 0.0289] and with a significant decrease in the maximum MPA concentration after dosing [10.6 (6.5-21.3) mg l(-1)vs. 20.1 (10.7-28.5) mg l(-1); mean difference 6.5 mg l(-1), 95% CI 2.1, 10.9; P = 0.0075].",Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17094777/),[mg] / [l],10.6,243592,DB00145,Glycine
,17094777,maximum MPA concentration,"Delayed gastric emptying was associated with a significantly longer MPA t(max)[1.0 (0.33-2.0) h vs. 0.5 (0.33-1.0) h; mean difference 0.39 h, 95% confidence interval (CI) 0.03, 0.75; P = 0.0289] and with a significant decrease in the maximum MPA concentration after dosing [10.6 (6.5-21.3) mg l(-1)vs. 20.1 (10.7-28.5) mg l(-1); mean difference 6.5 mg l(-1), 95% CI 2.1, 10.9; P = 0.0075].",Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17094777/),[mg] / [l],20.1,243593,DB00145,Glycine
,17094777,AUC(0-4),"Despite the substantial effect of delayed gastric emptying rates on MPA C(max) and t(max), total dose-interval exposure, measured by the MPA AUC(0-4), was not affected by the rate of gastric emptying [20.4 (13.9-43.0) mg h(-1) l(-1)vs. 22.4 (13.1-29.8) mg h(-1) l(-1)].",Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17094777/),[mg] / [h·l],20.4,243594,DB00145,Glycine
,17094777,rate of gastric emptying,"Despite the substantial effect of delayed gastric emptying rates on MPA C(max) and t(max), total dose-interval exposure, measured by the MPA AUC(0-4), was not affected by the rate of gastric emptying [20.4 (13.9-43.0) mg h(-1) l(-1)vs. 22.4 (13.1-29.8) mg h(-1) l(-1)].",Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17094777/),[mg] / [h·l],20.4,243595,DB00145,Glycine
,17094777,rate of gastric emptying,"Despite the substantial effect of delayed gastric emptying rates on MPA C(max) and t(max), total dose-interval exposure, measured by the MPA AUC(0-4), was not affected by the rate of gastric emptying [20.4 (13.9-43.0) mg h(-1) l(-1)vs. 22.4 (13.1-29.8) mg h(-1) l(-1)].",Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17094777/),[mg] / [h·l],22.4,243596,DB00145,Glycine
,932937,limit of sensitivity,"Following extraction of the sample at pH 5.5 with ether, radioimmunoassay of the residue from the ether extract allows for the determination of bumetanide with a limit of sensitivity of about 1 ng/ml using 0.1 ml of plasma or urine.",Bumetanide: radioimmunoassay and pharmacokinetic profile in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/932937/),[ng] / [ml],1,243768,DB00145,Glycine
,932937,peak plasma levels,The peak plasma levels ranged from 39 to 50 ng/ml at 1-4 hr after administration and declined with a mean apparent half-life of 1.17 hr.,Bumetanide: radioimmunoassay and pharmacokinetic profile in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/932937/),[ng] / [ml],39 to 50,243769,DB00145,Glycine
,932937,apparent half-life,The peak plasma levels ranged from 39 to 50 ng/ml at 1-4 hr after administration and declined with a mean apparent half-life of 1.17 hr.,Bumetanide: radioimmunoassay and pharmacokinetic profile in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/932937/),h,1.17,243770,DB00145,Glycine
,932937,plasma clearance rate,The mean plasma clearance rate was calculated to be 255 ml/min.,Bumetanide: radioimmunoassay and pharmacokinetic profile in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/932937/),[ml] / [min],255,243771,DB00145,Glycine
,12670369,half-lives (t1/2),"IGIV-C, 10% was bioequivalent to IGIV-SD, 10%, with half-lives (t1/2) of 35 and 34 days, respectively.","Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12670369/),d,35,244321,DB00145,Glycine
,12670369,half-lives (t1/2),"IGIV-C, 10% was bioequivalent to IGIV-SD, 10%, with half-lives (t1/2) of 35 and 34 days, respectively.","Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12670369/),d,34,244322,DB00145,Glycine
,12670369,t1/2,"IGIV-C, 5%, was bioequivalent to IGIV-C, 10%, with t1/2 of 35 and 36 days, respectively.","Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12670369/),d,35,244323,DB00145,Glycine
,12670369,t1/2,"IGIV-C, 5%, was bioequivalent to IGIV-C, 10%, with t1/2 of 35 and 36 days, respectively.","Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12670369/),d,36,244324,DB00145,Glycine
,12746109,elimination half-life,"3. UK-240,455 has a short elimination half-life in rats, dogs and man (0.4-1.4 h) and clearances of 12, 13 and 6 ml min(-1) kg(-1), respectively.","Pharmacokinetics and disposition of a novel NMDA glycine site antagonist (UK-240,455) in rats, dogs and man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12746109/),h,0.4-1.4,244461,DB00145,Glycine
,12746109,clearances,"3. UK-240,455 has a short elimination half-life in rats, dogs and man (0.4-1.4 h) and clearances of 12, 13 and 6 ml min(-1) kg(-1), respectively.","Pharmacokinetics and disposition of a novel NMDA glycine site antagonist (UK-240,455) in rats, dogs and man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12746109/),[ml] / [kg·min],12,244462,DB00145,Glycine
,12746109,clearances,"3. UK-240,455 has a short elimination half-life in rats, dogs and man (0.4-1.4 h) and clearances of 12, 13 and 6 ml min(-1) kg(-1), respectively.","Pharmacokinetics and disposition of a novel NMDA glycine site antagonist (UK-240,455) in rats, dogs and man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12746109/),[ml] / [kg·min],13,244463,DB00145,Glycine
,12746109,clearances,"3. UK-240,455 has a short elimination half-life in rats, dogs and man (0.4-1.4 h) and clearances of 12, 13 and 6 ml min(-1) kg(-1), respectively.","Pharmacokinetics and disposition of a novel NMDA glycine site antagonist (UK-240,455) in rats, dogs and man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12746109/),[ml] / [kg·min],6,244464,DB00145,Glycine
,12746109,volumes of distribution,"The compound shows limited tissue distribution with volumes of distribution of 0.4-0.8 l kg(-1) in rats, dogs and man.","Pharmacokinetics and disposition of a novel NMDA glycine site antagonist (UK-240,455) in rats, dogs and man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12746109/),[l] / [kg],0.4-0.8,244465,DB00145,Glycine
,12746109,cerebrospinal fluid/plasma concentration ratio,"The cerebrospinal fluid/plasma concentration ratio of UK-240,455 was 4.3%, which was similar to the plasma-free fraction of this compound (3%), indicating good blood-brain barrier permeability.","Pharmacokinetics and disposition of a novel NMDA glycine site antagonist (UK-240,455) in rats, dogs and man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12746109/),%,4.3,244466,DB00145,Glycine
,12746109,cerebrospinal fluid/plasma concentration ratio,"The cerebrospinal fluid/plasma concentration ratio of UK-240,455 was 4.3%, which was similar to the plasma-free fraction of this compound (3%), indicating good blood-brain barrier permeability.","Pharmacokinetics and disposition of a novel NMDA glycine site antagonist (UK-240,455) in rats, dogs and man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12746109/),%,3,244467,DB00145,Glycine
,9321522,terminal disposition half-life (t1/2),"After iv administration, [14C]MSK (20 mg/kg; 120 microCi/kg) was rapidly cleared from the blood as evidenced by the following pharmacokinetic values (mean +/- SD): terminal disposition half-life (t1/2), 7.98 +/- 1.72 min; mean residence time, 5.6 +/- 1.7 min; steady-state apparent volume of distribution (Vss), 3.33 +/- 0.75 liters/kg; and systemic body clearance (CLs), 0.53 +/- 0.05 liters/min/kg.","Absorption, disposition, and metabolism of trans-methyl styryl ketone in female B6C3F1 mice. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321522/),min,7.98,245033,DB00145,Glycine
,9321522,mean residence time,"After iv administration, [14C]MSK (20 mg/kg; 120 microCi/kg) was rapidly cleared from the blood as evidenced by the following pharmacokinetic values (mean +/- SD): terminal disposition half-life (t1/2), 7.98 +/- 1.72 min; mean residence time, 5.6 +/- 1.7 min; steady-state apparent volume of distribution (Vss), 3.33 +/- 0.75 liters/kg; and systemic body clearance (CLs), 0.53 +/- 0.05 liters/min/kg.","Absorption, disposition, and metabolism of trans-methyl styryl ketone in female B6C3F1 mice. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321522/),min,5.6,245034,DB00145,Glycine
,9321522,steady-state apparent volume of distribution (Vss),"After iv administration, [14C]MSK (20 mg/kg; 120 microCi/kg) was rapidly cleared from the blood as evidenced by the following pharmacokinetic values (mean +/- SD): terminal disposition half-life (t1/2), 7.98 +/- 1.72 min; mean residence time, 5.6 +/- 1.7 min; steady-state apparent volume of distribution (Vss), 3.33 +/- 0.75 liters/kg; and systemic body clearance (CLs), 0.53 +/- 0.05 liters/min/kg.","Absorption, disposition, and metabolism of trans-methyl styryl ketone in female B6C3F1 mice. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321522/),[l] / [kg],3.33,245035,DB00145,Glycine
,9321522,systemic body clearance (CLs),"After iv administration, [14C]MSK (20 mg/kg; 120 microCi/kg) was rapidly cleared from the blood as evidenced by the following pharmacokinetic values (mean +/- SD): terminal disposition half-life (t1/2), 7.98 +/- 1.72 min; mean residence time, 5.6 +/- 1.7 min; steady-state apparent volume of distribution (Vss), 3.33 +/- 0.75 liters/kg; and systemic body clearance (CLs), 0.53 +/- 0.05 liters/min/kg.","Absorption, disposition, and metabolism of trans-methyl styryl ketone in female B6C3F1 mice. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321522/),[l] / [kg·min],0.53,245036,DB00145,Glycine
,16123911,bioavailability,"The bioavailability of melagatran, the active form of ximelagatran, after oral administration of ximelagatran is approximately 20% with low inter- and intra-individual variability.",Pharmacokinetics and pharmacodynamics of ximelagatran. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123911/),%,20,245703,DB00145,Glycine
,16123911,half-life,"Peak plasma melagatran concentrations are reached approximately 2 hours after oral dosing of ximelagatran to healthy volunteers, and melagatran is eliminated with a half-life of approximately 3 hours with clearance predominantly by renal excretion.",Pharmacokinetics and pharmacodynamics of ximelagatran. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123911/),h,3,245704,DB00145,Glycine
,8801339,Plasma elimination half-lives,"Plasma elimination half-lives were 1.5, 2.5, 2.9, 20.3, and 5.9 h for the mouse, rat, monkey, dog, and human, respectively.",1-Aminocyclopropanecarboxylic acid: mouse to man interspecies pharmacokinetic comparisons and allometric relationships. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801339/),h,1.5,246661,DB00145,Glycine
,8801339,Plasma elimination half-lives,"Plasma elimination half-lives were 1.5, 2.5, 2.9, 20.3, and 5.9 h for the mouse, rat, monkey, dog, and human, respectively.",1-Aminocyclopropanecarboxylic acid: mouse to man interspecies pharmacokinetic comparisons and allometric relationships. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801339/),h,2.5,246662,DB00145,Glycine
,8801339,Plasma elimination half-lives,"Plasma elimination half-lives were 1.5, 2.5, 2.9, 20.3, and 5.9 h for the mouse, rat, monkey, dog, and human, respectively.",1-Aminocyclopropanecarboxylic acid: mouse to man interspecies pharmacokinetic comparisons and allometric relationships. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801339/),h,2.9,246663,DB00145,Glycine
,8801339,Plasma elimination half-lives,"Plasma elimination half-lives were 1.5, 2.5, 2.9, 20.3, and 5.9 h for the mouse, rat, monkey, dog, and human, respectively.",1-Aminocyclopropanecarboxylic acid: mouse to man interspecies pharmacokinetic comparisons and allometric relationships. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801339/),h,20.3,246664,DB00145,Glycine
,8801339,Plasma elimination half-lives,"Plasma elimination half-lives were 1.5, 2.5, 2.9, 20.3, and 5.9 h for the mouse, rat, monkey, dog, and human, respectively.",1-Aminocyclopropanecarboxylic acid: mouse to man interspecies pharmacokinetic comparisons and allometric relationships. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801339/),h,5.9,246665,DB00145,Glycine
,8801339,Volume of distribution at steady state,Volume of distribution at steady state (0.74 L/kg) was constant across all species.,1-Aminocyclopropanecarboxylic acid: mouse to man interspecies pharmacokinetic comparisons and allometric relationships. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801339/),[l] / [kg],0.74,246666,DB00145,Glycine
,1996632,whole body clearance (Ctot),"In CON, whole body clearance (Ctot) of Ala-Tyr (3,169 +/- 198 ml/min) was higher than Gly-Tyr (1,781 +/- 184, P less than 0.001), and both exceeded NAc-Tyr (284 +/- 24, P less than 0.001).",Utilization of tyrosine dipeptides and acetyltyrosine in normal and uremic humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1996632/),[ml] / [min],"3,169",248299,DB00145,Glycine
,1996632,whole body clearance (Ctot),"In CON, whole body clearance (Ctot) of Ala-Tyr (3,169 +/- 198 ml/min) was higher than Gly-Tyr (1,781 +/- 184, P less than 0.001), and both exceeded NAc-Tyr (284 +/- 24, P less than 0.001).",Utilization of tyrosine dipeptides and acetyltyrosine in normal and uremic humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1996632/),,"1,781",248300,DB00145,Glycine
,1996632,whole body clearance (Ctot),"In CON, whole body clearance (Ctot) of Ala-Tyr (3,169 +/- 198 ml/min) was higher than Gly-Tyr (1,781 +/- 184, P less than 0.001), and both exceeded NAc-Tyr (284 +/- 24, P less than 0.001).",Utilization of tyrosine dipeptides and acetyltyrosine in normal and uremic humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1996632/),,284,248301,DB00145,Glycine
,1996632,Ctot,"In HD, Ctot of Ala-Tyr was not different from CON, but Ctot of Gly-Tyr (858 +/- 73, P less than 0.001) and NAc-Tyr (129 +/- 30, P less than 0.02) was decreased.",Utilization of tyrosine dipeptides and acetyltyrosine in normal and uremic humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1996632/),,858,248302,DB00145,Glycine
,1996632,Ctot,"In HD, Ctot of Ala-Tyr was not different from CON, but Ctot of Gly-Tyr (858 +/- 73, P less than 0.001) and NAc-Tyr (129 +/- 30, P less than 0.02) was decreased.",Utilization of tyrosine dipeptides and acetyltyrosine in normal and uremic humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1996632/),,129,248303,DB00145,Glycine
,1996632,half-life,"The half-life of peptides incubated in CON and HD plasma was unchanged for Ala-Tyr (12.3 +/- 0.9 vs. 14.6 +/- 1.9 min) and prolonged for Gly-Tyr in HD (101.7 +/- 4.9 vs. 131.3 +/- 12, P less than 0.05).",Utilization of tyrosine dipeptides and acetyltyrosine in normal and uremic humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1996632/),min,12.3,248304,DB00145,Glycine
,1996632,half-life,"The half-life of peptides incubated in CON and HD plasma was unchanged for Ala-Tyr (12.3 +/- 0.9 vs. 14.6 +/- 1.9 min) and prolonged for Gly-Tyr in HD (101.7 +/- 4.9 vs. 131.3 +/- 12, P less than 0.05).",Utilization of tyrosine dipeptides and acetyltyrosine in normal and uremic humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1996632/),min,14.6,248305,DB00145,Glycine
,1996632,half-life,"The half-life of peptides incubated in CON and HD plasma was unchanged for Ala-Tyr (12.3 +/- 0.9 vs. 14.6 +/- 1.9 min) and prolonged for Gly-Tyr in HD (101.7 +/- 4.9 vs. 131.3 +/- 12, P less than 0.05).",Utilization of tyrosine dipeptides and acetyltyrosine in normal and uremic humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1996632/),,101.7,248306,DB00145,Glycine
,1996632,half-life,"The half-life of peptides incubated in CON and HD plasma was unchanged for Ala-Tyr (12.3 +/- 0.9 vs. 14.6 +/- 1.9 min) and prolonged for Gly-Tyr in HD (101.7 +/- 4.9 vs. 131.3 +/- 12, P less than 0.05).",Utilization of tyrosine dipeptides and acetyltyrosine in normal and uremic humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1996632/),,131.3,248307,DB00145,Glycine
,16231722,AUC,"Mean +/- SD AUC was 17,700 +/- 4,257, 18,616 +/- 8,078, and 16,168 +/- 6,031 counts per minute (cpm) at 0, 48, and 96 hours, respectively; mean +/- SD T1/2f was 2.80 +/- 0.38 minutes, 3.52 +/- 1.46 minutes, and 3.82 +/- 1.29 minutes at 0, 48, and 96 hours, respectively; median T1/2s was 63.9, 49.2, and 45.8 minutes at 0, 48, and 96 hours, respectively.",Quantitative assessment of hepatic function by means of 99mTc-mebrofenin in healthy horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231722/),[counts·min] / [cpm],"17,700",249641,DB00145,Glycine
,16231722,AUC,"Mean +/- SD AUC was 17,700 +/- 4,257, 18,616 +/- 8,078, and 16,168 +/- 6,031 counts per minute (cpm) at 0, 48, and 96 hours, respectively; mean +/- SD T1/2f was 2.80 +/- 0.38 minutes, 3.52 +/- 1.46 minutes, and 3.82 +/- 1.29 minutes at 0, 48, and 96 hours, respectively; median T1/2s was 63.9, 49.2, and 45.8 minutes at 0, 48, and 96 hours, respectively.",Quantitative assessment of hepatic function by means of 99mTc-mebrofenin in healthy horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231722/),[counts·min] / [cpm],"18,616",249642,DB00145,Glycine
,16231722,AUC,"Mean +/- SD AUC was 17,700 +/- 4,257, 18,616 +/- 8,078, and 16,168 +/- 6,031 counts per minute (cpm) at 0, 48, and 96 hours, respectively; mean +/- SD T1/2f was 2.80 +/- 0.38 minutes, 3.52 +/- 1.46 minutes, and 3.82 +/- 1.29 minutes at 0, 48, and 96 hours, respectively; median T1/2s was 63.9, 49.2, and 45.8 minutes at 0, 48, and 96 hours, respectively.",Quantitative assessment of hepatic function by means of 99mTc-mebrofenin in healthy horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231722/),[counts·min] / [cpm],"16,168",249643,DB00145,Glycine
,16231722,T1/2f,"Mean +/- SD AUC was 17,700 +/- 4,257, 18,616 +/- 8,078, and 16,168 +/- 6,031 counts per minute (cpm) at 0, 48, and 96 hours, respectively; mean +/- SD T1/2f was 2.80 +/- 0.38 minutes, 3.52 +/- 1.46 minutes, and 3.82 +/- 1.29 minutes at 0, 48, and 96 hours, respectively; median T1/2s was 63.9, 49.2, and 45.8 minutes at 0, 48, and 96 hours, respectively.",Quantitative assessment of hepatic function by means of 99mTc-mebrofenin in healthy horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231722/),min,2.80,249644,DB00145,Glycine
,16231722,T1/2f,"Mean +/- SD AUC was 17,700 +/- 4,257, 18,616 +/- 8,078, and 16,168 +/- 6,031 counts per minute (cpm) at 0, 48, and 96 hours, respectively; mean +/- SD T1/2f was 2.80 +/- 0.38 minutes, 3.52 +/- 1.46 minutes, and 3.82 +/- 1.29 minutes at 0, 48, and 96 hours, respectively; median T1/2s was 63.9, 49.2, and 45.8 minutes at 0, 48, and 96 hours, respectively.",Quantitative assessment of hepatic function by means of 99mTc-mebrofenin in healthy horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231722/),min,3.52,249645,DB00145,Glycine
,16231722,T1/2f,"Mean +/- SD AUC was 17,700 +/- 4,257, 18,616 +/- 8,078, and 16,168 +/- 6,031 counts per minute (cpm) at 0, 48, and 96 hours, respectively; mean +/- SD T1/2f was 2.80 +/- 0.38 minutes, 3.52 +/- 1.46 minutes, and 3.82 +/- 1.29 minutes at 0, 48, and 96 hours, respectively; median T1/2s was 63.9, 49.2, and 45.8 minutes at 0, 48, and 96 hours, respectively.",Quantitative assessment of hepatic function by means of 99mTc-mebrofenin in healthy horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231722/),min,3.82,249646,DB00145,Glycine
,16231722,T1/2s,"Mean +/- SD AUC was 17,700 +/- 4,257, 18,616 +/- 8,078, and 16,168 +/- 6,031 counts per minute (cpm) at 0, 48, and 96 hours, respectively; mean +/- SD T1/2f was 2.80 +/- 0.38 minutes, 3.52 +/- 1.46 minutes, and 3.82 +/- 1.29 minutes at 0, 48, and 96 hours, respectively; median T1/2s was 63.9, 49.2, and 45.8 minutes at 0, 48, and 96 hours, respectively.",Quantitative assessment of hepatic function by means of 99mTc-mebrofenin in healthy horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231722/),min,63.9,249647,DB00145,Glycine
,16231722,T1/2s,"Mean +/- SD AUC was 17,700 +/- 4,257, 18,616 +/- 8,078, and 16,168 +/- 6,031 counts per minute (cpm) at 0, 48, and 96 hours, respectively; mean +/- SD T1/2f was 2.80 +/- 0.38 minutes, 3.52 +/- 1.46 minutes, and 3.82 +/- 1.29 minutes at 0, 48, and 96 hours, respectively; median T1/2s was 63.9, 49.2, and 45.8 minutes at 0, 48, and 96 hours, respectively.",Quantitative assessment of hepatic function by means of 99mTc-mebrofenin in healthy horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231722/),min,49.2,249648,DB00145,Glycine
,16231722,T1/2s,"Mean +/- SD AUC was 17,700 +/- 4,257, 18,616 +/- 8,078, and 16,168 +/- 6,031 counts per minute (cpm) at 0, 48, and 96 hours, respectively; mean +/- SD T1/2f was 2.80 +/- 0.38 minutes, 3.52 +/- 1.46 minutes, and 3.82 +/- 1.29 minutes at 0, 48, and 96 hours, respectively; median T1/2s was 63.9, 49.2, and 45.8 minutes at 0, 48, and 96 hours, respectively.",Quantitative assessment of hepatic function by means of 99mTc-mebrofenin in healthy horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231722/),min,45.8,249649,DB00145,Glycine
,16231722,NEFAs,"NEFAs increased, reaching a plateau at 48 hours (650 +/- 152 micromol/L).",Quantitative assessment of hepatic function by means of 99mTc-mebrofenin in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231722/),[μM] / [l],650,249650,DB00145,Glycine
,20637614,IC(50),"Phenyl sulfonamides proved superior to alkyl and non-phenyl aromatic sulfonamides, while subsequent ortho substitution of the 2-(azepan-1-yl)-2-phenylethanamine aromatic ring yielded 39 (IC(50) 37 nM, solubility 14 microM), the most potent GlyT1 inhibitor in this series.",Identification of N-(2-(azepan-1-yl)-2-phenylethyl)-benzenesulfonamides as novel inhibitors of GlyT1. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637614/),nM,37,252371,DB00145,Glycine
,20637614,solubility,"Phenyl sulfonamides proved superior to alkyl and non-phenyl aromatic sulfonamides, while subsequent ortho substitution of the 2-(azepan-1-yl)-2-phenylethanamine aromatic ring yielded 39 (IC(50) 37 nM, solubility 14 microM), the most potent GlyT1 inhibitor in this series.",Identification of N-(2-(azepan-1-yl)-2-phenylethyl)-benzenesulfonamides as novel inhibitors of GlyT1. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637614/),μM,14,252372,DB00145,Glycine
,7519405,delta P,"Applying the changes along with a hydrodynamic isopore with shunt model, sinorphan significantly increased capillary pressure gradient (delta P; 39 +/- 1 vs. 34 +/- 1 mmHg; P < 0.01), whereas ultrafiltration coefficient was unchanged.",Acute renal effects of neutral endopeptidase inhibition in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7519405/),mmhg,39,252834,DB00145,Glycine
,7519405,delta P,"Applying the changes along with a hydrodynamic isopore with shunt model, sinorphan significantly increased capillary pressure gradient (delta P; 39 +/- 1 vs. 34 +/- 1 mmHg; P < 0.01), whereas ultrafiltration coefficient was unchanged.",Acute renal effects of neutral endopeptidase inhibition in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7519405/),mmhg,34,252835,DB00145,Glycine
,31028664,terminal half-life,"Results Ivosidenib demonstrated good oral exposure after single and multiple doses, was rapidly absorbed, and had a long terminal half-life (mean 40-102 h after single dose).","Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31028664/),h,40-102,253899,DB00145,Glycine
,28932928,plasma Tmax,"After oral administration, ixazomib was rapidly absorbed with a median plasma Tmax of 0.5 h and represented 70% of total drug-related material in plasma.","A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28932928/),h,0.5,256366,DB00145,Glycine
,28932928,total recovery,The mean total recovery of administered TRA was 83.9%; 62.1% in urine and 21.8% in feces.,"A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28932928/),%,83.9,256367,DB00145,Glycine
,28932928,total recovery,The mean total recovery of administered TRA was 83.9%; 62.1% in urine and 21.8% in feces.,"A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28932928/),%,62.1,256368,DB00145,Glycine
,28932928,total recovery,The mean total recovery of administered TRA was 83.9%; 62.1% in urine and 21.8% in feces.,"A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28932928/),%,21.8,256369,DB00145,Glycine
,7945531,elimination half-life,"1 h after single injection, 60.8 +/- 5.1 micrograms/ml of MCA C23 was detected in plasma, then the plasma level decreased with an elimination half-life of 20.5 +/- 6.2 days and the AUC value was 18.3 +/- 3.4 mg.h/ml.","Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. Third communication: correspondence of the idiotype activity and virus neutralization activity of the new monoclonal antibody, regavirumab in rat serum and its pharmacokinetics in rats and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945531/),d,20.5,256437,DB00145,Glycine
,7945531,AUC,"1 h after single injection, 60.8 +/- 5.1 micrograms/ml of MCA C23 was detected in plasma, then the plasma level decreased with an elimination half-life of 20.5 +/- 6.2 days and the AUC value was 18.3 +/- 3.4 mg.h/ml.","Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. Third communication: correspondence of the idiotype activity and virus neutralization activity of the new monoclonal antibody, regavirumab in rat serum and its pharmacokinetics in rats and monkeys. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945531/),[h·mg] / [ml],18.3,256438,DB00145,Glycine
,7945531,plasma concentration,"In the repeated administration experiment (2 mg/kg/week, 5 times), the MCA C23 plasma concentration reached a steady state (74.4 +/- 11.8 micrograms/ml) at 24 h after the fourth injection.","Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. Third communication: correspondence of the idiotype activity and virus neutralization activity of the new monoclonal antibody, regavirumab in rat serum and its pharmacokinetics in rats and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945531/),[μg] / [ml],74.4,256439,DB00145,Glycine
,7945531,steady state,"In the repeated administration experiment (2 mg/kg/week, 5 times), the MCA C23 plasma concentration reached a steady state (74.4 +/- 11.8 micrograms/ml) at 24 h after the fourth injection.","Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. Third communication: correspondence of the idiotype activity and virus neutralization activity of the new monoclonal antibody, regavirumab in rat serum and its pharmacokinetics in rats and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945531/),[μg] / [ml],74.4,256440,DB00145,Glycine
,22980315,terminal elimination t(½),The terminal elimination t(½) was ∼53 hours.,Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22980315/),h,∼53,256609,DB00145,Glycine
,23169299,Maximum-tolerated dose (MTD),"Maximum-tolerated dose (MTD) of NGR-hTNF was previously established at 45 μg m(-2) as 1-h infusion, with dose-limiting toxicity being grade 3 infusion-related reactions.",Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23169299/),μ,45,257171,DB00145,Glycine
,25262379,MTDs,"The MTDs were defined as 100mg/m(2) QOD and 67 mg/m(2) QD, respectively, with diarrhoea being dose-limiting on both 3 weeks on/1 week off schedules.","Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25262379/),,100,257239,DB00145,Glycine
,26451002,total recovery,"The total recovery of the administered radioactivity was 94.3% (±1.6%, S.D.) with 76.5% (±2.3%) in feces and 17.8% (±2.5%) in urine.","Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26451002/),%,94.3,257809,DB00145,Glycine
,26451002,total recovery,"The total recovery of the administered radioactivity was 94.3% (±1.6%, S.D.) with 76.5% (±2.3%) in feces and 17.8% (±2.5%) in urine.","Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26451002/),%,76.5,257810,DB00145,Glycine
,26451002,total recovery,"The total recovery of the administered radioactivity was 94.3% (±1.6%, S.D.) with 76.5% (±2.3%) in feces and 17.8% (±2.5%) in urine.","Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26451002/),%,17.8,257811,DB00145,Glycine
,26451002,"fraction absorbed, Fa","From this study, we concluded that cobimetinib had been well absorbed (fraction absorbed, Fa = 0.88).","Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26451002/),,0.88,257812,DB00145,Glycine
,26451002,"bioavailability, F","Given this good absorption and the previously determined low hepatic clearance, the systemic exposures were lower than expected (bioavailability, F = 0.28).","Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26451002/),,0.28,257813,DB00145,Glycine
,26451002,fraction escaping gut wall elimination (Fg),"Supporting this hypothesis, the fraction escaping gut wall elimination (Fg) was estimated to be 0.37 based on F and Fa from this study and the fraction escaping hepatic elimination (Fh) from the absolute bioavailability study (F = Fa × Fh × Fg).","Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26451002/),,0.37,257814,DB00145,Glycine
,25777468,MTD,"Five patients experienced DLTs (1.0 and 1.76 mg/m(2): grade 3 pruritic rash; 2.34 mg/m(2): grade 3 and 4 thrombocytopenia, and grade 3 acute renal failure); thus, the MTD was 1.76 mg/m(2).","Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25777468/),[mg] / [m(2],1.76,257922,DB00145,Glycine
,25777468,terminal half-life,Ixazomib terminal half-life was 3.8-7.2 days; plasma exposures increased dose-proportionally and drug was distributed to tumors.,"Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25777468/),d,3.8-7.2,257923,DB00145,Glycine
exceeded,30176059,Extraction recovery,Extraction recovery was reproducible within each matrix and exceeded 97%.,Simultaneous determination of tiopronin and its primary metabolite in plasma and ocular tissues by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30176059/),%,97,259383,DB00145,Glycine
,10100362,distribution half-lives,"The solutes had distribution half-lives of between 3 and 7 min; the elimination half-lives were 39 min (glycine), 97 min (mannitol) and 33 min (sorbitol).",Distribution and elimination of the solute and water components of urological irrigating fluids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100362/),min,3 and 7,259603,DB00145,Glycine
,10100362,elimination half-lives,"The solutes had distribution half-lives of between 3 and 7 min; the elimination half-lives were 39 min (glycine), 97 min (mannitol) and 33 min (sorbitol).",Distribution and elimination of the solute and water components of urological irrigating fluids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100362/),min,39,259604,DB00145,Glycine
,10100362,elimination half-lives,"The solutes had distribution half-lives of between 3 and 7 min; the elimination half-lives were 39 min (glycine), 97 min (mannitol) and 33 min (sorbitol).",Distribution and elimination of the solute and water components of urological irrigating fluids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100362/),min,97,259605,DB00145,Glycine
,10100362,elimination half-lives,"The solutes had distribution half-lives of between 3 and 7 min; the elimination half-lives were 39 min (glycine), 97 min (mannitol) and 33 min (sorbitol).",Distribution and elimination of the solute and water components of urological irrigating fluids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100362/),min,33,259606,DB00145,Glycine
,10100362,volume of distribution during steady state,"The volume of distribution during steady state was between 20 and 36 litres, while the volume of the body fluid space expanded by the water component of the irrigating fluids varied between 6 and 9 litres.",Distribution and elimination of the solute and water components of urological irrigating fluids. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100362/),l,20 and 36,259607,DB00145,Glycine
,10100362,volume of the body fluid space expanded,"The volume of distribution during steady state was between 20 and 36 litres, while the volume of the body fluid space expanded by the water component of the irrigating fluids varied between 6 and 9 litres.",Distribution and elimination of the solute and water components of urological irrigating fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100362/),l,6 and 9,259608,DB00145,Glycine
,31876104,recovery,"Fecal excretion was the major route of elimination of radioactivity, and urinary excretion a minor route, with mean (coefficient of variation [%CV]) recovery of 77.1 (16.2)% and 10.9 (92.0)% of the dose, respectively.","A Mass Balance Study of 14 C-Labeled JTZ-951 (Enarodustat), a Novel Orally Available Erythropoiesis-Stimulating Agent, in Patients With End-Stage Renal Disease on Hemodialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31876104/),%,77.1,259880,DB00145,Glycine
,31876104,recovery,"Fecal excretion was the major route of elimination of radioactivity, and urinary excretion a minor route, with mean (coefficient of variation [%CV]) recovery of 77.1 (16.2)% and 10.9 (92.0)% of the dose, respectively.","A Mass Balance Study of 14 C-Labeled JTZ-951 (Enarodustat), a Novel Orally Available Erythropoiesis-Stimulating Agent, in Patients With End-Stage Renal Disease on Hemodialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31876104/),%,10.9,259881,DB00145,Glycine
,31876104,total recovery,"Radioactivity was not detected in the dialysate, and mean (%CV) total recovery in excreta was 88.0 (14.9)%.","A Mass Balance Study of 14 C-Labeled JTZ-951 (Enarodustat), a Novel Orally Available Erythropoiesis-Stimulating Agent, in Patients With End-Stage Renal Disease on Hemodialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31876104/),%,88.0,259882,DB00145,Glycine
,31876104,effective half-life,"For parent JTZ-951 in plasma, the mean (%CV) effective half-life was 8.96 (7.7)% hours, and area under the curve over 24 hours comprised the majority (>80%) of total exposure, with relatively low variability in these pharmacokinetic variables.","A Mass Balance Study of 14 C-Labeled JTZ-951 (Enarodustat), a Novel Orally Available Erythropoiesis-Stimulating Agent, in Patients With End-Stage Renal Disease on Hemodialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31876104/),%·h,8.96,259883,DB00145,Glycine
,26640780,clearance,"PK was remarkably similar, with a clearance of 0.33 ± 0.03 L/h/m(2).",Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26640780/),[h·l] / [m(2],0.33,262546,DB00145,Glycine
,26640780,clearance,IMP288 PK was faster (clearance 1.4-3.3 L/h).,Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26640780/),[l] / [h],1.4-3.3,262547,DB00145,Glycine
,23224978,P eff (cm/s),"The P eff (cm/s) of cefadroxil in wild-type mice was 0.49 × 10(-4) in duodenum, 0.80 × 10(-4) in jejunum, 0.88 × 10(-4) in ileum and 0.064 × 10(-4) in colon.",Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23224978/),,0.49 × 10(-4),263590,DB00145,Glycine
,23224978,P eff (cm/s),"The P eff (cm/s) of cefadroxil in wild-type mice was 0.49 × 10(-4) in duodenum, 0.80 × 10(-4) in jejunum, 0.88 × 10(-4) in ileum and 0.064 × 10(-4) in colon.",Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23224978/),,0.80 × 10(-4),263591,DB00145,Glycine
,23224978,P eff (cm/s),"The P eff (cm/s) of cefadroxil in wild-type mice was 0.49 × 10(-4) in duodenum, 0.80 × 10(-4) in jejunum, 0.88 × 10(-4) in ileum and 0.064 × 10(-4) in colon.",Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23224978/),,0.88 × 10(-4),263592,DB00145,Glycine
,23224978,P eff (cm/s),"The P eff (cm/s) of cefadroxil in wild-type mice was 0.49 × 10(-4) in duodenum, 0.80 × 10(-4) in jejunum, 0.88 × 10(-4) in ileum and 0.064 × 10(-4) in colon.",Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23224978/),,0.064 × 10(-4),263593,DB00145,Glycine
,23224978,P eff (cm/s),"The P eff (cm/s) in PepT1 knockout mice was significantly reduced in small intestine, but not in colon, as shown by values of 0.003 × 10(-4), 0.090 × 10(-4), 0.042 × 10(-4) and 0.032 × 10(-4), respectively.",Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23224978/),,0.003 × 10(-4),263594,DB00145,Glycine
,23224978,P eff (cm/s),"The P eff (cm/s) in PepT1 knockout mice was significantly reduced in small intestine, but not in colon, as shown by values of 0.003 × 10(-4), 0.090 × 10(-4), 0.042 × 10(-4) and 0.032 × 10(-4), respectively.",Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23224978/),,0.090 × 10(-4),263595,DB00145,Glycine
,23224978,P eff (cm/s),"The P eff (cm/s) in PepT1 knockout mice was significantly reduced in small intestine, but not in colon, as shown by values of 0.003 × 10(-4), 0.090 × 10(-4), 0.042 × 10(-4) and 0.032 × 10(-4), respectively.",Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23224978/),,0.042 × 10(-4),263596,DB00145,Glycine
,23224978,P eff (cm/s),"The P eff (cm/s) in PepT1 knockout mice was significantly reduced in small intestine, but not in colon, as shown by values of 0.003 × 10(-4), 0.090 × 10(-4), 0.042 × 10(-4) and 0.032 × 10(-4), respectively.",Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23224978/),,0.032 × 10(-4),263597,DB00145,Glycine
,23224978,Km,"Jejunal uptake of cefadroxil was saturable (Km = 2-4 mM) and significantly attenuated by the sodium-proton exchange inhibitor 5-(N,N-dimethyl)amiloride.",Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23224978/),mM,2-4,263598,DB00145,Glycine
,11868971,oral no overall adverse effect level (NOAEL),The oral no overall adverse effect level (NOAEL) for chronic toxicity of 4-chloro-2-methylphenoxyacetic acid (MCPA) in rat is approximately 1.3 mg kg(-1) and in dog is 0.2 mg kg(-1).,"Absorption, metabolism and excretion of 4-chloro-2-methylphenoxyacetic acid (MCPA) in rat and dog. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868971/),[mg] / [kg],1.3,264263,DB00145,Glycine
,11868971,oral no overall adverse effect level (NOAEL),The oral no overall adverse effect level (NOAEL) for chronic toxicity of 4-chloro-2-methylphenoxyacetic acid (MCPA) in rat is approximately 1.3 mg kg(-1) and in dog is 0.2 mg kg(-1).,"Absorption, metabolism and excretion of 4-chloro-2-methylphenoxyacetic acid (MCPA) in rat and dog. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868971/),[mg] / [kg],0.2,264264,DB00145,Glycine
,11868971,t 1/2,"Rat eliminated radioactivity from plasma significantly faster than dog (approximate values biased on total radioactivity: 5 mg kg(-1) rat: t 1/2 dist 3.5 h, t 1/2 elim 17.2-36.2 h, AUC(0-infinity) 230 microg equiv hg(-1); 5 mg kg(-1) dog: t 1/2 47h, AUC(0-infinity) 2,500 microg equiv h g(-1); 100 mg kg(-1) rat: t 1/2 dist 10h, t 1/2 elim 10.27-25.4h, AUC(0-infinity) 5,400 microg equiv hg(-1); l00 mg kg(-1) dog: t 1/2 h, AUC(0-infinity) 20,500 microg eqiv h g(-1).","Absorption, metabolism and excretion of 4-chloro-2-methylphenoxyacetic acid (MCPA) in rat and dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868971/),h,3.5,264265,DB00145,Glycine
,11868971,t 1/2,"Rat eliminated radioactivity from plasma significantly faster than dog (approximate values biased on total radioactivity: 5 mg kg(-1) rat: t 1/2 dist 3.5 h, t 1/2 elim 17.2-36.2 h, AUC(0-infinity) 230 microg equiv hg(-1); 5 mg kg(-1) dog: t 1/2 47h, AUC(0-infinity) 2,500 microg equiv h g(-1); 100 mg kg(-1) rat: t 1/2 dist 10h, t 1/2 elim 10.27-25.4h, AUC(0-infinity) 5,400 microg equiv hg(-1); l00 mg kg(-1) dog: t 1/2 h, AUC(0-infinity) 20,500 microg eqiv h g(-1).","Absorption, metabolism and excretion of 4-chloro-2-methylphenoxyacetic acid (MCPA) in rat and dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868971/),h,17.2-36.2,264266,DB00145,Glycine
,11868971,AUC(0-infinity),"Rat eliminated radioactivity from plasma significantly faster than dog (approximate values biased on total radioactivity: 5 mg kg(-1) rat: t 1/2 dist 3.5 h, t 1/2 elim 17.2-36.2 h, AUC(0-infinity) 230 microg equiv hg(-1); 5 mg kg(-1) dog: t 1/2 47h, AUC(0-infinity) 2,500 microg equiv h g(-1); 100 mg kg(-1) rat: t 1/2 dist 10h, t 1/2 elim 10.27-25.4h, AUC(0-infinity) 5,400 microg equiv hg(-1); l00 mg kg(-1) dog: t 1/2 h, AUC(0-infinity) 20,500 microg eqiv h g(-1).","Absorption, metabolism and excretion of 4-chloro-2-methylphenoxyacetic acid (MCPA) in rat and dog. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868971/),[equiv·μg] / [hg],230,264267,DB00145,Glycine
,11868971,t 1/2,"Rat eliminated radioactivity from plasma significantly faster than dog (approximate values biased on total radioactivity: 5 mg kg(-1) rat: t 1/2 dist 3.5 h, t 1/2 elim 17.2-36.2 h, AUC(0-infinity) 230 microg equiv hg(-1); 5 mg kg(-1) dog: t 1/2 47h, AUC(0-infinity) 2,500 microg equiv h g(-1); 100 mg kg(-1) rat: t 1/2 dist 10h, t 1/2 elim 10.27-25.4h, AUC(0-infinity) 5,400 microg equiv hg(-1); l00 mg kg(-1) dog: t 1/2 h, AUC(0-infinity) 20,500 microg eqiv h g(-1).","Absorption, metabolism and excretion of 4-chloro-2-methylphenoxyacetic acid (MCPA) in rat and dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868971/),h,47,264268,DB00145,Glycine
,11868971,AUC(0-infinity),"Rat eliminated radioactivity from plasma significantly faster than dog (approximate values biased on total radioactivity: 5 mg kg(-1) rat: t 1/2 dist 3.5 h, t 1/2 elim 17.2-36.2 h, AUC(0-infinity) 230 microg equiv hg(-1); 5 mg kg(-1) dog: t 1/2 47h, AUC(0-infinity) 2,500 microg equiv h g(-1); 100 mg kg(-1) rat: t 1/2 dist 10h, t 1/2 elim 10.27-25.4h, AUC(0-infinity) 5,400 microg equiv hg(-1); l00 mg kg(-1) dog: t 1/2 h, AUC(0-infinity) 20,500 microg eqiv h g(-1).","Absorption, metabolism and excretion of 4-chloro-2-methylphenoxyacetic acid (MCPA) in rat and dog. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868971/),[equiv·h·μg] / [g],"2,500",264269,DB00145,Glycine
,11868971,t 1/2,"Rat eliminated radioactivity from plasma significantly faster than dog (approximate values biased on total radioactivity: 5 mg kg(-1) rat: t 1/2 dist 3.5 h, t 1/2 elim 17.2-36.2 h, AUC(0-infinity) 230 microg equiv hg(-1); 5 mg kg(-1) dog: t 1/2 47h, AUC(0-infinity) 2,500 microg equiv h g(-1); 100 mg kg(-1) rat: t 1/2 dist 10h, t 1/2 elim 10.27-25.4h, AUC(0-infinity) 5,400 microg equiv hg(-1); l00 mg kg(-1) dog: t 1/2 h, AUC(0-infinity) 20,500 microg eqiv h g(-1).","Absorption, metabolism and excretion of 4-chloro-2-methylphenoxyacetic acid (MCPA) in rat and dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868971/),h,10,264270,DB00145,Glycine
,11868971,t 1/2 elim,"Rat eliminated radioactivity from plasma significantly faster than dog (approximate values biased on total radioactivity: 5 mg kg(-1) rat: t 1/2 dist 3.5 h, t 1/2 elim 17.2-36.2 h, AUC(0-infinity) 230 microg equiv hg(-1); 5 mg kg(-1) dog: t 1/2 47h, AUC(0-infinity) 2,500 microg equiv h g(-1); 100 mg kg(-1) rat: t 1/2 dist 10h, t 1/2 elim 10.27-25.4h, AUC(0-infinity) 5,400 microg equiv hg(-1); l00 mg kg(-1) dog: t 1/2 h, AUC(0-infinity) 20,500 microg eqiv h g(-1).","Absorption, metabolism and excretion of 4-chloro-2-methylphenoxyacetic acid (MCPA) in rat and dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868971/),h,10.27-25.4,264271,DB00145,Glycine
,11868971,AUC(0-infinity),"Rat eliminated radioactivity from plasma significantly faster than dog (approximate values biased on total radioactivity: 5 mg kg(-1) rat: t 1/2 dist 3.5 h, t 1/2 elim 17.2-36.2 h, AUC(0-infinity) 230 microg equiv hg(-1); 5 mg kg(-1) dog: t 1/2 47h, AUC(0-infinity) 2,500 microg equiv h g(-1); 100 mg kg(-1) rat: t 1/2 dist 10h, t 1/2 elim 10.27-25.4h, AUC(0-infinity) 5,400 microg equiv hg(-1); l00 mg kg(-1) dog: t 1/2 h, AUC(0-infinity) 20,500 microg eqiv h g(-1).","Absorption, metabolism and excretion of 4-chloro-2-methylphenoxyacetic acid (MCPA) in rat and dog. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868971/),[equiv·μg] / [hg],"5,400",264272,DB00145,Glycine
,11868971,t 1/,"Rat eliminated radioactivity from plasma significantly faster than dog (approximate values biased on total radioactivity: 5 mg kg(-1) rat: t 1/2 dist 3.5 h, t 1/2 elim 17.2-36.2 h, AUC(0-infinity) 230 microg equiv hg(-1); 5 mg kg(-1) dog: t 1/2 47h, AUC(0-infinity) 2,500 microg equiv h g(-1); 100 mg kg(-1) rat: t 1/2 dist 10h, t 1/2 elim 10.27-25.4h, AUC(0-infinity) 5,400 microg equiv hg(-1); l00 mg kg(-1) dog: t 1/2 h, AUC(0-infinity) 20,500 microg eqiv h g(-1).","Absorption, metabolism and excretion of 4-chloro-2-methylphenoxyacetic acid (MCPA) in rat and dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868971/),h,2,264273,DB00145,Glycine
,11868971,AUC(0-infinity),"Rat eliminated radioactivity from plasma significantly faster than dog (approximate values biased on total radioactivity: 5 mg kg(-1) rat: t 1/2 dist 3.5 h, t 1/2 elim 17.2-36.2 h, AUC(0-infinity) 230 microg equiv hg(-1); 5 mg kg(-1) dog: t 1/2 47h, AUC(0-infinity) 2,500 microg equiv h g(-1); 100 mg kg(-1) rat: t 1/2 dist 10h, t 1/2 elim 10.27-25.4h, AUC(0-infinity) 5,400 microg equiv hg(-1); l00 mg kg(-1) dog: t 1/2 h, AUC(0-infinity) 20,500 microg eqiv h g(-1).","Absorption, metabolism and excretion of 4-chloro-2-methylphenoxyacetic acid (MCPA) in rat and dog. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868971/),[eqiv·h·μg] / [g],"20,500",264274,DB00145,Glycine
,12844328,population clearance,"The median population clearance (creatinine clearance 70 mL/min) was 5.3 and 22.9 L/h for the subcutaneous and oral formulations, respectively.",Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12844328/),[l] / [h],5.3,264579,DB00145,Glycine
,12844328,population clearance,"The median population clearance (creatinine clearance 70 mL/min) was 5.3 and 22.9 L/h for the subcutaneous and oral formulations, respectively.",Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12844328/),[l] / [h],22.9,264580,DB00145,Glycine
,12844328,bioavailability,The bioavailability of melagatran after oral ximelagatran relative to subcutaneous melagatran was 23%.,Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12844328/),%,23,264581,DB00145,Glycine
,1981701,elimination half-life,"The following pharmacokinetic values were estimated: elimination half-life, 5.9 hr; total body clearance, 61 ml/hr/kg; and volume of distribution (steady-state), 369 ml/kg.","Bioavailability, metabolism, and renal excretion of benzoic acid in the channel catfish (Ictalurus punctatus). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981701/),h,5.9,264980,DB00145,Glycine
,1981701,total body clearance,"The following pharmacokinetic values were estimated: elimination half-life, 5.9 hr; total body clearance, 61 ml/hr/kg; and volume of distribution (steady-state), 369 ml/kg.","Bioavailability, metabolism, and renal excretion of benzoic acid in the channel catfish (Ictalurus punctatus). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981701/),[ml] / [h·kg],61,264981,DB00145,Glycine
,1981701,volume of distribution (steady-state),"The following pharmacokinetic values were estimated: elimination half-life, 5.9 hr; total body clearance, 61 ml/hr/kg; and volume of distribution (steady-state), 369 ml/kg.","Bioavailability, metabolism, and renal excretion of benzoic acid in the channel catfish (Ictalurus punctatus). ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981701/),[ml] / [kg],369,264982,DB00145,Glycine
,1981701,Plasma protein binding,Plasma protein binding of [14C]benzoic acid was 18%.,"Bioavailability, metabolism, and renal excretion of benzoic acid in the channel catfish (Ictalurus punctatus). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981701/),%,18,264983,DB00145,Glycine
,1981701,absorption half-life,Benzoic acid was rapidly and extensively absorbed after po administration; absorption half-life was 0.8 hr and bioavailability was 95%.,"Bioavailability, metabolism, and renal excretion of benzoic acid in the channel catfish (Ictalurus punctatus). ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981701/),h,0.8,264984,DB00145,Glycine
,1981701,bioavailability,Benzoic acid was rapidly and extensively absorbed after po administration; absorption half-life was 0.8 hr and bioavailability was 95%.,"Bioavailability, metabolism, and renal excretion of benzoic acid in the channel catfish (Ictalurus punctatus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981701/),%,95,264985,DB00145,Glycine
,22542656,IC(50),ASP2535 potently inhibited rat GlyT1 (IC(50)=92 nM) with 50-fold selectivity over rat glycine transporter-2 (GlyT2).,"A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22542656/),nM,92,265111,DB00145,Glycine
,22542656,IC(50),It showed minimal affinity for many other receptors except for μ-opioid receptors (IC(50)=1.83 μM).,"A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22542656/),μM,1.83,265112,DB00145,Glycine
,12486679,K(m),"The K(m) value of the final model was 29.6 microg/mL, whereas V(m) was estimated to vary with time from 4.97 microg/h/kg at day 1 to a maximum mean value of 9.64 microg/h/kg at day 14.",An application of nonlinear mixed-effects modeling to pharmacokinetic data exhibiting nonlinear and time-dependent behavior. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12486679/),[μg] / [ml],29.6,265965,DB00145,Glycine
,12486679,V(m),"The K(m) value of the final model was 29.6 microg/mL, whereas V(m) was estimated to vary with time from 4.97 microg/h/kg at day 1 to a maximum mean value of 9.64 microg/h/kg at day 14.",An application of nonlinear mixed-effects modeling to pharmacokinetic data exhibiting nonlinear and time-dependent behavior. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12486679/),[μg] / [h·kg],4.97,265966,DB00145,Glycine
,12486679,maximum mean,"The K(m) value of the final model was 29.6 microg/mL, whereas V(m) was estimated to vary with time from 4.97 microg/h/kg at day 1 to a maximum mean value of 9.64 microg/h/kg at day 14.",An application of nonlinear mixed-effects modeling to pharmacokinetic data exhibiting nonlinear and time-dependent behavior. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12486679/),[μg] / [h·kg],9.64,265967,DB00145,Glycine
,30199708,IC50,"Antitumor activity screening assay indicated that BGC0222 exhibited better in vitro antiproliferation activity than irinotecan and NKTR-102 against HT29, MIA PaCa-2 and MCF-7 tumor cell lines, with IC50 of 1.83 ± 0.09 μM, 3.95 ± 0.16 μM and 0.68 ± 0.04 μM, respectively, while it displayed better in vivo antiproliferation activity than irinotecan and NKTR-102 in HT-29, MIA PaCa-2, NCI-H446, U-87 MG and MDA-MB-231 xenograft models.","Design, synthesis and pharmacological evaluation of a novel PEG-cRGD-conjugated irinotecan derivative as potential antitumor agent. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30199708/),μM,1.83,266037,DB00145,Glycine
,30199708,IC50,"Antitumor activity screening assay indicated that BGC0222 exhibited better in vitro antiproliferation activity than irinotecan and NKTR-102 against HT29, MIA PaCa-2 and MCF-7 tumor cell lines, with IC50 of 1.83 ± 0.09 μM, 3.95 ± 0.16 μM and 0.68 ± 0.04 μM, respectively, while it displayed better in vivo antiproliferation activity than irinotecan and NKTR-102 in HT-29, MIA PaCa-2, NCI-H446, U-87 MG and MDA-MB-231 xenograft models.","Design, synthesis and pharmacological evaluation of a novel PEG-cRGD-conjugated irinotecan derivative as potential antitumor agent. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30199708/),μM,3.95,266038,DB00145,Glycine
,30199708,IC50,"Antitumor activity screening assay indicated that BGC0222 exhibited better in vitro antiproliferation activity than irinotecan and NKTR-102 against HT29, MIA PaCa-2 and MCF-7 tumor cell lines, with IC50 of 1.83 ± 0.09 μM, 3.95 ± 0.16 μM and 0.68 ± 0.04 μM, respectively, while it displayed better in vivo antiproliferation activity than irinotecan and NKTR-102 in HT-29, MIA PaCa-2, NCI-H446, U-87 MG and MDA-MB-231 xenograft models.","Design, synthesis and pharmacological evaluation of a novel PEG-cRGD-conjugated irinotecan derivative as potential antitumor agent. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30199708/),μM,0.68,266039,DB00145,Glycine
,2158004,T1/2,"Following intravenous administration, 1-aminocyclobutane-1-carboxylate (ACBC, 100 mg/kg), a N-methyl-D-aspartate (NMDA)-associated glycine receptor antagonist, was eliminated with a T1/2 of 5 min in mouse brain and 4 min in rat cerebrospinal fluid (CSF).","Neuropharmacological characterization of 1-aminocyclopropane-1-carboxylate and 1-aminocyclobutane-1-carboxylate, ligands of the N-methyl-D-aspartate-associated glycine receptor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158004/),min,5,266512,DB00145,Glycine
,2158004,T1/2,"Following intravenous administration, 1-aminocyclobutane-1-carboxylate (ACBC, 100 mg/kg), a N-methyl-D-aspartate (NMDA)-associated glycine receptor antagonist, was eliminated with a T1/2 of 5 min in mouse brain and 4 min in rat cerebrospinal fluid (CSF).","Neuropharmacological characterization of 1-aminocyclopropane-1-carboxylate and 1-aminocyclobutane-1-carboxylate, ligands of the N-methyl-D-aspartate-associated glycine receptor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158004/),min,4,266513,DB00145,Glycine
less,2158004,T1/2,"1-Aminocyclopropane-1-carboxylate (ACC), a NMDA-associated glycine receptor agonist, was found to have a T1/2 of less than 5 min in mouse brain.","Neuropharmacological characterization of 1-aminocyclopropane-1-carboxylate and 1-aminocyclobutane-1-carboxylate, ligands of the N-methyl-D-aspartate-associated glycine receptor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158004/),min,5,266514,DB00145,Glycine
,8383813,half-life,"Following direct intracerebellar injection, SC-49648 was eliminated with a half-life of 12 min from the brain.","Indole-2-carboxylates, novel antagonists of the N-methyl-D-aspartate (NMDA)-associated glycine recognition sites: in vivo characterization. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8383813/),min,12,267035,DB00145,Glycine
,8383813,half-life,"Following intraperitoneal administration, SC-50132, the 3-ethylester analog of SC-49648, was eliminated from the brain with a half-life of 35 min and was found to be metabolized to SC-49648, in vivo.","Indole-2-carboxylates, novel antagonists of the N-methyl-D-aspartate (NMDA)-associated glycine recognition sites: in vivo characterization. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8383813/),min,35,267036,DB00145,Glycine
,15760098,Cl(total),"Total systemic clearance of Tc-99m mebrofenin approximated liver blood flow (Cl(total) 17.3 degrees 1.7 mL/min/kg), and 35% to 84% of the Tc-99m mebrofenin dose was recovered in bile.",A novel method for the determination of biliary clearance in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15760098/),[ml] / [kg·min],17.3,268577,DB00145,Glycine
,15760098,Cl(total),"Total systemic clearance of Tc-99m mebrofenin approximated liver blood flow (Cl(total) 17.3 degrees 1.7 mL/min/kg), and 35% to 84% of the Tc-99m mebrofenin dose was recovered in bile.",A novel method for the determination of biliary clearance in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15760098/),[ml] / [kg·min],1.7,268578,DB00145,Glycine
,6407991,corrected transfer,"(5) Analogously, the average corrected transfer was 56% and 113% of normal; the pool size was 67% and 139% of normal.",[Metabolism of parenterally administered amino acids in chronic kidney failure in childhood]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407991/),%,56,272010,DB00145,Glycine
,6407991,corrected transfer,"(5) Analogously, the average corrected transfer was 56% and 113% of normal; the pool size was 67% and 139% of normal.",[Metabolism of parenterally administered amino acids in chronic kidney failure in childhood]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407991/),%,113,272011,DB00145,Glycine
,6407991,pool size,"(5) Analogously, the average corrected transfer was 56% and 113% of normal; the pool size was 67% and 139% of normal.",[Metabolism of parenterally administered amino acids in chronic kidney failure in childhood]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407991/),%,67,272012,DB00145,Glycine
,6407991,pool size,"(5) Analogously, the average corrected transfer was 56% and 113% of normal; the pool size was 67% and 139% of normal.",[Metabolism of parenterally administered amino acids in chronic kidney failure in childhood]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407991/),%,139,272013,DB00145,Glycine
